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ABSTRACT 
Intravesical treatment for non-muscle invasive bladder cancer involves the direct instillation of 
immunotherapy or chemotherapy into the bladder. While this approach limits systemic 
absorption, patients undergoing this localised treatment frequently report significant urological 
side effects, including increased frequency and urgency of urination, haematuria and dysuria. A 
relatively new drug used for bladder cancer is gemcitabine, which has shown an improved 
efficacy and toxicity profile with comparison to the first -line chemotherapy mitomycin C in 
patients. Elucidating the effects of gemcitabine on the normal cells and changes in the normal 
function of the bladder may reveal possible targets for preventing, alleviating or treating the 
adverse urological effects associated with this treatment.  
The cytotoxic effect of gemcitabine alone and in combination with hyperthermia treatment was 
examined on cultured non-malignant and malignant human urothelial cells, and compared to 
mitomycin C. Luminal gemcitabine treatment on full thickness porcine bladder sections 
examined the immediate histological and functional effects on the urothelium and detrusor 
muscle. Finally, single and repeated intravesical instillations of gemcitabine in mice examined 
the changes in voiding behaviours and ex vivo bladder function. Chemical, mechanical and 
electrical stimuli were used to investigate and compare the responses of control and treated 
tissues.  
The potency of gemcitabine on malignant urothelial cells was >10,000 -fold greater than its 
potency on non-malignant cells. This effect is attributed in part to the enhanced reactive oxygen 
species production induced by gemcitabine, and the enhanced presence of the human 
equilabrative nucleoside transporters in malignant cells with comparison to non-malignant 
urothelial cells. Gemcitabine also induced increased release of inflammatory cytokines from 
cultured urothelial cells, and these effects were not potentiated by hyperthermia. Luminal 
gemcitabine sloughed urothelial cells from porcine tissue, resulting in decreased ATP but 
enhanced prostaglandin E2 release from the urothelium. Repeated intravesical gemcitabine 
treatment with subsequent recovery periods in mice increased voiding frequency, enhanced 
urothelial ATP and prostaglandin E2 release but depressed detrusor contractile responses 
mediated by efferent nerve stimulation. Taken together, these results suggest that intravesical 
gemcitabine induces a painful and overactive bladder phenotype in patients through a 
combination of enhanced urothelial and inflammatory mediators and altered efferent nerve 
activity, which may sensitise afferent nerves and reduce detrusor muscle contraction 
respectively.   
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α,β-mATP: alpha, beta methylene ATP 
ACh: acetylcholine 
AChE: acetylcholinesterase 
ADP: adenosine 5’-diphosphate 
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GENERAL INTRODUCTION 
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1.1 THE FUNCTION OF THE URINARY TRACT  
The urinary tract is the organ system that produces, stores and expels urine from the body. The 
kidneys and ureters comprise the upper urinary tract, while the lower urinary tract describes the 
bladder and urethra, and includes the prostate in males (Patel and Chapple, 2008). The kidneys 
function to filter the blood of toxins, metabolites and wastes, maintaining the homeostasis of 
fluid within the body. The wastes are transported by the ureters to the bladder, where it is stored 
until it can be expelled through the urethra. This process is called micturition, co-ordinated 
through the pelvic, hypogastric and pudendal nerves (de Groat and Yoshimura, 2001).  
 
GROSS ANATOMY OF THE BLADDER 
The urinary bladder is a hollow, spherical muscular organ that acts as a temporary reservoir for 
urine. The bladder, along with the urethra and urethral sphincters make up the lower urinary 
tract, and is positioned ret roperitoneally on the pelvic floor posterior to the pubic bone (Marieb 
and Hoehn, 2007). In males, the prostate surrounds the bladder neck where it empties to the 
urethra, while in females the bladder sits anterior to the vagina and uterus. There are specific 
regions of the bladder as seen in Figure 1.1, the apex, often termed the dome, a superior 
surface and two inferolateral walls, all covered in folded epithelia called rugae (Seeley et al., 
2007). The triangular area at the base of the bladder encompassed by the openings of the 
ureters and the urethra is called the trigone (Standring, 2008). At the apex of the trigone (also 
known as the bladder neck) lies the internal urethral sphincter, a band of smooth muscle under 
involuntary control, however, no well-defined internal urethral sphincter has been found in 
females (Colleselli et al., 1998, Seeley et al., 2007). 
There are three layers of the bladder wall (Figure 1.1): the outer adventitial layer, the muscular 
layer and an inner epithelial layer that is continuous with the ureters above and the urethra 
below. The inner epithelial layer, termed the urothelium, primarily acts as a barrier to water and 
solutes between the lumen and underlying muscle. Recent evidence supports the role of the 
urothelium in detecting and responding to mechanical, chemical and thermal stimuli, which will  
be discussed in detail further in this report (Birder, 2006). The urothelium can communicate with 
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underlying cells, including those found in the suburothelium and muscle layer, through the 
presence of receptors and secretion of mediators. The suburothelium is a collagen matrix 
containing blood vessels, myofibroblasts and afferent nerves.  
 
Figure 1.1: Gross anatomy of the urinary bladder (Mckinley, 2008)  
Below the suburothelium lies the bladder muscle, made up of an inner layer of longitudinal 
fibres, a middle layer of circular fibres and an outer layer in which the fibres run longitudinally 
and parallel to the inner layer (Stevens and Lowe, 2005). The muscle layers are collectively 
described as the detrusor and function in the contraction of the bladder during micturition.  The 
outer adventitial layer is a thick fibrous membrane that covers the blad der with the exception of 
the superior surface, where the peritoneum lies.  
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THE UROTHELIUM 
The urothelium is an epithelial lining that separates the suburothelium and bladder muscle from 
the contents of the bladder lumen. It is continuous with the distal portion of the urinary tract, 
including the ureters, upper urethra and glandular ducts of the prostate (Apodaca, 2004). Due to 
cyclical changes in volume and pressure of the bladder during the filling and micturition phases, 
the main role of the urothelium is to form a distensible barrier that regulates exchange of ions, 
solutes and water. However, the close proximity of the bladder nerves and bladder 
myofibroblasts, as well as the presence of receptors and ion channels on the urothelial cells 
similar to those found on afferent nerves, indicate that the urothelium plays an active role in 
sensory detection and communication, which will be discussed later in this report (Birder et al., 
2010a). There are three cell types in the urothelium, the umbrella, interme diate and basal cell  
layers, as seen in Figure 1.2. These cells are morphologically distinct, and play differing roles 
within the urothelium. 
 
UMBRELLA CELLS 
The inner most cell layer to the lumen of the bladder is the umbrella cell layer. They cast 
projections that reach the basement membrane of the urothelium, and are the largest cells, 
spanning 25-250µm in diameter (Apodaca, 2004). In the human, umbrella cells are mono- and 
multinucleate, and their morphology is reliant on the filling state of the bladder (Morrow et al., 
Figure 1.2: Schematic illustration of unstretched urothelium composed of three cell layers: umbrella, 
intermediate and basal cells (Birder, 2005)  
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2008). In the relaxed state, umbrella cells are cuboidal in shape, and become stretched and 
squamous during filling.  
The barrier function of the urothelium is dependent upon the presence of the apical membrane. 
This impermeable layer distinctly defines each cell, and is scalloped in appearance due to the 
presence of hinge areas and intervening transmembrane plaques (Apodaca, 2004). The 
membrane associated with the plaque regions is detergent insoluble, likely due to the rich lipid 
composition reported to be similar to myelin (Hicks et al., 1974). The arrangement of the 
membrane plaques is such that the outer leaflet is twice as thick as the inner, termed the 
asymmetric unit membrane (AUM) (Apodaca, 2004). The transmembrane proteins that make up 
the AUM are the family of uroplakins, which are also found in the cytoplasm of bladder umbrella 
cells within discoidal or fusiform vesicles (DFV) (Yu et al., 1990). Four types of uroplakins (UP) 
are arranged to form a heterotetramer, including UP Ia/UP II and UP Ib/ UP III (Lee, 2011), 
covering almost all of the mature DFV. These vesicles undergo exocytosis in response to 
stretch of the bladder during filling by fusing to the cell membrane to deliver uroplakins and 
other essential proteins (Truschel et al., 2002), which allow the umbrella cells to distend, 
preventing the AUM from rupturing (Lee, 2011). Uroplakins have been found to play a role in 
water and solutes transport, as studies into uroplakin knock-out mice have found increased 
permeability in the bladder to water and urea (Hu et al., 2002).  It is the release of ATP with 
stretch that initiates a signal cascade which begins the exocytosis process (Kreft et al., 2009a). 
The role of ATP as a signalling messenger in the bladder will  be discussed in detail later, along 
with other urothelial mediators. 
 The presence of the AUM, uroplakins and cytokeratins on the apical cells of the urothelium  
indicative of urothelial differentiation (Veranic et al., 2004). While the normal turnover rate for 
urothelial cells is up to 40 weeks (Jost, 1989), injury to the bladder such as urinary infections 
induce an immediate regeneration process. Production of new umbrella cells occurs through the 
maturation of the underlying intermediate cells, which increase their expression of uroplakins 
and develop tight junctions between stratum (Lavelle et al., 2002). The presence of multi-
nucleate umbrella cells has been proposed to be due to the fusing of two or more intermediate 
cells (Peter, 1978). The presence of surface glycosaminoglycans (GAGs) on the apical side of 
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the umbrella cells creates the principle barrier to permeability by modulating molecule and ion 
movement (Parsons et al., 1990, Lilly and Parsons, 1990). GAGs are strands of negatively 
charged polysaccharides, which attach to a core protein to form proteoglycans and attract 
cations and water molecules to form a mucus-like permeability barrier, as shown in Figure 1.3.  
 
GAGs are also thought to act as an anti-adherence factor, forming a defence barrier against 
bacteria, proteins and other small molecules (Parsons et al., 1979, Birder, 2011). Disruption of 
this GAG layer and the consequent loss/damage to the mucus barrier has been associated with 
infection, interstitial cystitis, radiation and chemical cystitis and cancer of the bladder (Parsons, 
2007).  
Umbrella cells are interconnected with gap junctions, and project transmembrane proteins that 
adhere to the basement membrane of the urothelium. Using atomic force microscopy, Kreplak 
and colleagues (2007) found that the membranes of aligning cells are fused to form a zipper, 
contributing to the barrier function of the urothelium. Desmosomes, complexes of cell adhesion 
proteins, connect the layer of intermediate cells to one another and to the overlying umbrella 
cells. Gap junctions within the layer of intermediate cells have been found to be distributed 
randomly, similarly to the basal cell layer of the urothelium (Peter, 1978). 
 
INTERMEDIATE AND BASAL CELLS 
The single-nuclei, pyriform shaped intermediate cells make up a transiently thick layer 
comprised of between one to several stratum, dependent on the state of the bladder (Jost et al., 
1989). It is thought that adjacent intermediate cells slide past each other during filling, however 
Figure 1.3: Urothelium with GAG layer, preventing irritants from contact w ith the bladder wall  
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whether this is due to reversible breakage of cell connections is unknown (Khandelwal et al., 
2009). The intermediate cells directly deep to the umbrella cell layer are partially differentiated 
and can express uroplakins and vesicles, similar to the superior layer (Wu et al., 2009, Apodaca,  
2004). The basal cells of the urothelium also have the ability to differentiate further to form 
intermediate cells (Mysorekar et al., 2002), as a result of infection or disruption to the superior 
urothelial layers. The single basal cell layer of the urothelium sits atop the basement membrane 
and beneath the intermediate cell layer, attached by hemidesmosomes and desmosomes 
respectively (Woldemeskel et al., 1998).  
 
SUBUROTHELIUM/LAMINA PROPRIA 
Beneath the urothelium lies the suburothelium, often termed the lamina propria. The 
suburothelium is a collagen matrix that contains afferent and efferent nerve terminals, blood 
vessels of the bladder, fibroblasts and a group of specialised cells, the interstitial cells (Fry et al., 
2007, Sui et al., 2002).  
 
INTERSTITIAL CELLS/MYOFIBROBLASTS 
Interstitial cells, also known as myofibroblasts, have structural characteristics of both smooth 
muscle cells and fibroblasts and resemble those found in the gut, where they are called 
interstitial cells of Cajal (McCloskey, 2010). Interstitial cells were first discovered within the 
bladder in 1996 (Smet et al.), and their presence in close proximity to nerve endings has since 
been confirmed through c-Kit antibody marking and vimentin immunolabelling (Davidson and 
McCloskey, 2005). Suburothelial interstitial cells are stellate shaped cells, connected by gap 
junctions (Fry et al., 2007). While these cells are also found within the detrusor layer of the 
bladder, they are comparatively different in distribution and morphology, the detrusor interstitial 
cells being elongated cells arranged in circular and longitudinal orientation (McCloskey, 2010, 
Wiseman et al., 2003).  
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Interstitial cells in other smooth muscle tissues such as the gastrointestinal tract act as 
pacemaker cells (Sui et al., 2002, Sanders, 1996), and generate phasic myogenic contractions 
without neural stimulation, however whether this is the case with bladder interstitial cells has not 
yet been elucidated (Thornbury et al., 2011, Birder et al., 2010a). Interstitial cells form a network 
through connexion 43-containing gap junctions, establishing cell -to-cell communication enabling 
these cells to act as a functional synticum (Sui et al., 2002).  It has been proposed that these 
cells in the bladder act as mediators of signal transduction between the urothelium and nerves, 
due their ability to respond to various neurotransmitters such as ATP, acetylcholine, and nit ric 
oxide (NO) (Birder et al., 2010b, Sanders, 1996, Wiseman et al., 2003). The ion channels and 
receptors present on interstitial cells of the bladder include calcium, sodium and potassium 
channels; transient receptor potential cation channel V1 (TRPV1), purinergic and cholinergic 
receptors (Grol et al., 2009, McCloskey, 2006, Fry et al., 2007, Hanna-Mitchell and Birder, 
2008). These receptors will be discussed in detail later on in this report.   
 
INNERVATION OF THE BLADDER 
The phases of storage and micturition of the bladder are mediated by a complex pattern of 
afferent and efferent signalling through the pelvic, hypogastric and pudendal nerves. During 
storage, afferent axons transmit signals regarding the volume and stretch of the bladder. The 
micturition reflex is stimulated by increased afferent firing to the sacral region of the spinal cord, 
which in turn stimulates efferent activity, mediated voluntarily by the cerebral cortex (de Groat 
and Yoshimura, 2001). Signals travelling through the sympathetic, parasympathetic and somatic 
neurons coordinate the contraction of the bladder and relaxation of the bladder out let (the 
bladder neck, urethra, internal and external sphincters).  
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AFFERENT NERVES 
The afferent nerves carry sensory information about the fullness of the bladder and bladder 
outlet through the pelvic, pudendal and hypogastric nerves through the dorsal root ganglia 
(DRG) to the upper lumbar and sacral regions of the spinal cord, as shown in Figure 1.4 
(Fowler et al., 2008, Jänig and Morrison, 1986). The main afferents involved in the micturition 
process are the small myelinated A- and unmyelinated C fibres, which are carried through the 
pelvic (majority) and hypogastric nerves, terminating in the bladder wall (Andersson et al., 1999, 
Ford et al., 2006).  
 
Figure 1.4: Innervation of the bladder and bladder outlet. The hypogastric (sympathetic), pelvic 
(parasympathetic) and pudendal (somatic) nerves coordinate the micturition process of the bladder and urethra. 
Primary cell bodies of A- and C-fibre afferents of the pelvic and pudendal nerves are contained in lower lumbar 
and sacral dorsal root ganglia (DRG), and afferent innervations in the hypogastric nerve arises in rostral lumbar 
DRG (reprinted with permission Kanai and Andersson, 2010)  
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These mechanosensitive afferents originating in the bladder wall convey information regarding 
the degree of stretch of the bladder, travelling through the pelvic nerve to the second order 
neurons in the spinal cord. The A - fibres have been found to instantly respond to very small 
changes in pressure through passive distension and active contraction of the bladder wall 
(Fowler et al., 2008, Wyndaele, 2010). Additionally, these afferents have chemosensitive 
properties, exhibiting a more sensitive response with exposure to irritants. In comparison, the 
slower unmyelinated C fibres that originate in the urothelium and underlying suburothelium have 
very high thresholds and thus have little contribution during normal bladder filling (de Groat, 
2006, Häbler et al., 1990, Abrams et al., 2001). C fibres are sensitive to neurotoxins, capsacin 
and resiniferatoxin, as well as tachykinins, NO, ATP, prostaglandins, endothelins and 
neurotrophic factors released in the bladder, shown in Figure 1.5, and are particularly active 
during periods of hypersensitivity due to inflammation or damage to the LUT (Abrams et al., 
2001, Habler et al., 1990, Maggi, 1990, de Groat, 2006).  
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Figure 1.5: Interactions of neurotransmitters and chemical factors on bladder afferent pathways (especially C-
fibre afferent nerves) originating in the bladder. During periods of bladder inflammation, bradykinins (BK), 
histamine (Hist) and protons act on their respective bradykinin receptor (B2), histamine receptor (H1) and 
vanilloid receptor (Caps) and induce an influx of calcium ions (Ca2+), triggering the production of 
neuropeptides including calcitonin gene-related peptide (CGRP), substance P (SP) and neurokinin A (NKA), 
which act on their respective CGRP and neurokinin 1 (NK1) and 2 (NK2) receptors on the bladder wall. 
Inflammation also initiates the production of prostaglandins (PG) by cyclooxygenase, which act in an autocrine 
manner on prostaglandin receptors to sensitize the afferent nerve terminals and stimulate the release of 
neurotransmitters (reprinted with permission from Yoshimura and de Groat, 1997)  
 
The sensory somatic nerves ending in the striated musc le of the external urethral sphincter 
travel through the pudendal nerve to the sacral region of the spinal cord, while the sensory 
information from the urethra is transmitted through the hypogastric nerve.  
Nocioceptors present in the bladder are unmyelinated afferent fibres that monitor 
mechanosensitivity during over distension of the bladder, and transmit signals of pain. These 
are activated by increased release of ATP, which will be discussed in detail later.  
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EFFERENT NERVES 
The efferent neural pathways are responsible for the voluntary control of micturition process, 
involving the somatic, parasympathetic and sympathetic nerve pathways. The somatic and 
parasympathetic innervations originate in the sacral part of the spinal cord, travelling through 
the pudendal and pelvic nerves respectively, while the sympathetic nerves to the bladder pass 
via the hypogastric nerve from the thoracolumbar segments, as seen in Figure 1.6 (Fowler et al., 
2008).  
 
  
Figure 1.6: Efferent neural pathways of the urinary bladder . a) Blue sympathetic fibres originate in the 
thoracolumbar spinal segments T10-L2 and run through the inferior mesenteric plexus (IMP) and hypogastric 
nerve (HGN) to the base of the bladder and the urethral neck. The green fibres represent the parasympathetic 
nerves that arise between the S2-S4 segments, travelling through the pelvic nerve (PEL) via the pelvic plexus 
(PP) to the bladder wall. Somatic nerves (yellow fibres) arise from the sacral spinal segments S2-S4 and pass 
through the pudendal nerve to the external urethral spincter. b) The post-ganglionic sympathethetic nerve 
fibres release noradrenaline, which acts of the β and α adrenoreceptors on the bladder and urethra respectively. 
The parasympathetic and somatic postganglionic axons release acetylcholine, which respectively stimulate the 
muscarinic receptors in the detrusor muscle and nicotinic receptors on the external urethral spincter (reprinted 
with permission from Fowler et al., 2008). 
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PARASYMPATHETIC SUPPLY 
The micturition reflex is initiated through afferent activity monitoring the stretch and fullness of 
the bladder, which is conveyed to the pontine storage centre via the brainstem and midbrain. 
With increasing afferent activity, the pontine micturition centre is excited, which in turn 
stimulates the parasympathetic pathway that leads to detrusor contraction (Drake et al., 2010). 
The parasympathetic bladder nerves originate in the spinal cord between the S2 -S4 sacral 
segments, with the post-ganglionic nerves sending excitatory stimulation t o the bladder detrusor 
muscle (Andersson et al., 1999, Birder et al., 2010a), as seen in Figure 1.6.  
The majority of the postganglionic parasympathetic fibres release acetylcholine, acting on the 
muscarinic receptors of the bladder muscle, inducing contraction. In addition to the release of 
acetylcholine, parasympathetic stimulation causes the release of non -adrenergic, non-
cholinergic (NANC) transmitters including ATP (Burnstock, 2009). The release of these 
transmitters leads to the activation of their respective receptors, initiating and maintaining 
detrusor contraction in the bladder, while relaxing the bladder outlet for the expulsion of urine 
(Sellers and Chess-Williams, 2012).  
Besides the excitatory effect on the detrusor muscle, parasympathetic stimulation plays a role in 
the inhibition of the urethral smooth muscle. Previous studies found that urethral tissue relaxed 
in response to neural stimulation, abolished by the addition of tetrotodoxin (TTX), implying the 
release of these transmitters is dependent on nerve activity (Andersson et al., 1992, Persson 
and Andersson, 1992, Andersson et al., 1983). Nitric oxide (NO), released with parasympathetic 
stimulation to the proximal urethra, is responsible for the relaxation of the urethral smooth 
muscle, in particular the internal urethral sphincter (Bennett et al., 1995, de Groat and 
Yoshimura, 2001). These transmitters and receptors will be discussed in further detail later on in 
this report. 
 
SYMPATHETIC SUPPLY 
The sympathetic innervation of the bladder begins with preganglionic axons originating from the 
thoracic spinal and extending to the upper lumbar segments (T10 - L2) (Kanai and Andersson, 
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2010), seen in Figure 1.6. These axons run through the inferior mesenteric plexus (ganglion) 
and hypogastric nerve to inhibit contraction of the detrusor wall allowing bladder filling, and the 
ganglia of the pelvic plexus via the pelvic nerve to induce contraction of the internal urethra 
(Lincoln and Burnstock, 1993). 
The bladder base has a denser sympathetic innervation than the detrusor muscle (Michel and 
Vrydag, 2006). Sympathetic nerves release noradrenaline that act upon -adrenoreceptors in 
the detrusor muscle, mediating relaxation and enhancing bladder compliance (Michel and 
Barendrecht, 2008). In the bladder outlet, noradrenaline acts upon -adrenoceptors, which 
increase muscle tone in the proximal urethra and the bladder base preventing any leakage of 
bladder contents (Ochodnicky et al., 2013). In males, the presence of -adrenoceptors on the 
prostate enhances bladder outlet resistance, particularly in men with enlarged prostates (Michel 
and Vrydag, 2006). A further role of the sympathetic nerves of the bladder is to inhibit the 
parasympathetic pathway at spinal and ganglionic levels (Chapple et al., 2011).  
Inhibition of detrusor tone by the sympathetic fibres of the bladder was first suggested by  Gjone 
(1966) and Edvardsen (1968) after investigations into transected sympathetic nerves in cats led 
to increased spontaneous and reflex contractions. During filling, the parasympathetic ganglia of 
the bladder are suggested to be inhibited by the sympathetic stimulation of 2-adrenoceptors 
(de Groat, 2006, De Groat and Saum, 1972).  
 
SOMATIC NERVES 
The somatic nerves of the bladder arise in Onuf’s nucleus in the sacral segments S2-S4 of the 
spinal cord, and travel through the pudendal nerve to supply the striated muscle of the external 
urethral sphincter (Fowler et al., 2008), as seen in Figure 1.6. These cholinergic nerves 
voluntarily contract the external urethral sphincter muscle via acetylcholine acting upon nicotinic 
receptors (de Groat, 2006, Michel and Barendrecht, 2008).  
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DETRUSOR MUSCLE 
The role of the bladder to transiently store and excrete urine is mediated through complex 
interactions between the sensory and muscular components of the urinary tract. Contraction of 
the bladder muscle, the detrusor, is responsible for the rapid expulsion of urine. During filling, 
the detrusor cells relax and elongate over an extended period to accommodate the gradual 
increase in bladder contents. In comparison, the micturition reflex involves a synergistic 
contraction of the muscle cells over a relatively short period (Andersson and Arner, 2004). 
The smooth muscle cells of the bladder are spindle shaped, single nucleated cel ls, organised 
into bundles of circular and longitudinal muscle called fascicles, surrounded by collagen -rich 
connective tissue (Andersson and Arner, 2004). John et al. (2003) discovered the presence of 
connexin 45 mRNA on human detrusor cells, suggesting the presence of electrically coupled 
gap junctions. They concluded that intercellular communications mediated through gap 
junctions might play a role in detrusor tone. Further investigations into connexin proteins in 
rodent bladders found a relationship between overactive detrusor and increased Cx-43 
expression, indicating a link between intercellular communication and spontaneous contractions 
of the detrusor (Christ et al., 2003).  
Like all other muscle types, the interaction of the contractile proteins act in and myosin are 
responsible for the tension development and shortening of the detrusor muscle (Gunst and 
Zhang, 2008). Compared to striated muscle, smooth muscle can maintain contractions more 
economically, using less ATP and contracting for longer periods (Mundy et al., 2000).  
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Figure 1.7: The intracellular signalling pathways in detrusor muscle contraction (reprinted with permission from 
Fry et al., 2010). 
The release of neurotransmitters acetylcholine and ATP from parasympathetic nerves initiates a 
signalling cascade for the activation of actin-myosin cross bridge cycling in detrusor muscle, as 
shown in Figure 1.7 (Fry et al., 2010). The G-coupled muscarinic M3 receptor binds 
acetylcholine released from the parasympathetic nerves, initiating the formation of initisol 
triphosphate (IP3) and diacyglycerol (DAG) from membrane phospholipids (PIP2) by the action 
of phospholipase-C (PLC). IP3 initiates Ca
2+
 release from intracellular Ca
2+
 stores (sarcoplasmic 
reticulum, SR). Ca
2+
 binds to calmodulum (CaM) to activate myosin light chain (MLC) kinase 
and phosphorylate and activate myosin to bind to actin. The binding of ATP to the purinergic 
P2X1 receptor opens the ion and the L-type Ca
2+
 channel, causing influx of Ca
2+
 and Na
+
 ions 
(Fry et al., 2010). Intrac ellular calcium from the sarcoplasmic reticulum and extracellular calcium 
bind to calmodulin, which in turn activates myosin, through the activation of the myosin light 
chain (MLC) kinase (See Figure 1.7). Cross bridge cycling between actin and myosin molecules 
occurs as long as myosin is activated and ATP is available for consumption.  
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NEUROTRANSMITTERS, UROTHELIAL MEDIATORS AND RECEPTORS 
The urothelium was previously thought to act solely as a barrier to water and solutes, protecting 
the underlying tissues of the bladder. The discovery by Hypolite and colleagues (1993) that the 
urothelium has a higher metabolic rate than the underlying detrusor muscle suggested a greater 
role for urothelial cells in bladder function than a barrier. The presence of muscarinic, purinergic 
and adrenergic receptors and the secretion of mediators including ATP, acetylcholine, 
prostaglandins and nitric oxide from urothelial cells indicate a role in coordinating responses to 
mechanical and chemical stimuli between the urothelium and underlying nerves, interstitial cells 
and detrusor muscle, as seen in Figure 1.8 (Birder, 2011).  
 
Figure 1.8: Release of mediators from the urothelium and the interactions with underlying nerves, interstitial 
cells (myofibroblasts) and detrusor muscle. Urothelial cells are stimulated by receptors or channels in a 
number of ways, including mechanical and osmotic stretch and via autocrine and paracrine neurotransmitter 
release. These neurotransmitters include adenosine triphosphate (ATP), nitric oxide (NO), prostaglandins (PG), 
substance P (SP), acetylcholine (ACh) and nerve growth factor (NGF). Receptors for these mediators include 
purinergic receptors (P2X, P2Y and P2R [purinergic 2 receptor unidentified subtype]), muscarinic receptors 
(MR), nictonic receptors (NicR), receptor tyrosine kinase A (Trk -A) and neurokinin receptors (NR). Other 
receptors and channels present on the urothelium include the bradykinin receptor (BR) which binds bradykinin, 
adrenergic receptors (AdR) for [noradrenaline] norepinephrine (NE) and transient receptor potential channel 
(TRPs) which a sensitive to capsaicin, temperature, H+ ions and stretch (reprinted with permission from Birder 
and de Groat, 2007). 
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ACETYLCHOLINE AND CHOLINERGIC RECEPTORS 
Increased parasympathetic activity during bladder emptying causes acetylcholine release, 
which in turn works in a paracrine and autocrine manner, acting on the bladder nerves and 
muscle and the urothelium respectively (Hanna-Mitchell et al., 2007, Chess-Williams, 2002). 
Acetylcholine is synthesised from the reversible reaction between choline and acetyl coenzyme 
A forming acetylcholine and coenzyme A, catalysed by the enzyme choline acetyltransferase.  
While acetylcholine released from storage vesicles in parasympathetic nerves stimulate the 
detrusor during voiding, studies have found that acetylcholine is also released during other 
phases of the bladder, from different sources (Apodaca, 2004). The release of acetylcholine 
from non-neuronal sources was confirmed when Yoshida and colleagues (2006) found that the 
basal release of acetylcholine was significantly decreased with the removal of the urothelial and 
suburothelial layer. Studies have since found urothelial cells possess the ability to synthesise, 
transport and metabolize acetylcholine in response to both chemical stimulation and mechanical 
stretch during bladder filling (Lips et al., 2007, Khandelwal et al., 2009, Hanna-Mitchell et al., 
2007). Hanna-Mitchell et al (2007) first reported that urothelial cells from the rat bladder express 
the acetylcholine synthesizing enzymes choline acetyltransferase and carnitine 
acetyltransferase. As in neuronal cells, the synthesis of acetylcholine in in urothelial cells 
requires uptake of choline from the extracellular compartment. However, it was  found that 
urothelial cells lack the vesicular acetylcholine transporter, and the addition of brefeldin (a 
substance that blocks vesicle formation) had no effect on the hypotonic -induced release of 
3
H-
acetylcholine from urothelial cells. Through the use o f reverse transcription-PCR, the presence 
of rat electrogenic polyspecific organic cation transporter 3 was confirmed, indicative that 
acetylcholine is released from urothelial cells mediated via this mechanism, as in other epithelial 
cells including bronchial and placental (Hanna-Mitchell et al., 2007, Wessler and Kirkpatrick, 
2001, Koepsell et al., 2003).  
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MUSCARINIC RECEPTORS 
Five types of muscarinic receptors have been pharmacologically defined, belonging to the 
family of G-protein coupled receptors classified as M1 – M5  (Giglio and Tobin, 2009, Caulfield 
and Birdsall, 1998). Within the bladder, the receptors are expressed in three locations; the 
detrusor smooth muscle, the urothelium and on autonomic nerve endings (Tyagi et al., 2006).  
The muscarinic receptors M1, M3 and M5 are coupled to the α subunit of the Gq/11 proteins, 
which as previously described, stimulate phospholipase C (PLC) when activated, leading to an 
up-regulation of the second messengers inositol triphosphate ( IP3) and diaglycerol (DAG) 
leading to the influx of extra- and intracellular Ca
2+
 ions and consequent contraction (Caulfield 
and Birdsall, 1998). In comparison, the M2 and M4 receptors cause contraction indirectly, by 
inhibiting the relaxation by noradrenaline released from sympathetic nerves. These rec eptors 
are coupled via the Gi and Go α subunits, and when stimulated, inhibit adenylate cyclase, 
reducing 3’ -5’-cyclic adenosine monophosphate (cAMP). This process is shown schematically in 
Figure 1.9. 
 
Figure 1.9: Stimulation of the M 2 and M3 receptors induce smooth muscle contraction by inhibition of cyclic 
AMP reversing relaxation and stimulation of second messengers IP3 and DAG (Uchiyama and Chess-Williams, 
2004).  
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In the detrusor muscle the M2 receptor is the most populous, however it is the M3 receptor that 
mediates the contractile response in all species examined, including human (Chess-Williams, 
2002). The M2 receptor has been proposed to regulate the detrusor muscle during conditions 
such as M3 dysfunction or desensitization (Braverman et al., 2006) or significant sympathetic 
activity, as well as mediating the acetylcholine induced release of prostaglandin E2 in the 
urothelium (Nile and Gillespie, 2012). Additionally, ATP is co-released with acetylcholine in the 
bladder, and binding to P2X1 receptors on the detrusor, it initiates a fast transient contraction 
through influx of calcium. In contrast, muscarinic receptor stimulation by acetylcholine released 
from the parasympathetic nerves induces prolonged contraction to maintain bladder emptying 
by opening initisol triphosphate channels (IP3) mediated channels, causing intracellular calcium 
release from the sarcoplasmic reticulum. 
Muscarinic receptors in the bladder have been found on both the parasympathetic and 
sympathetic nerve endings, and regulate the release of acetylcholine and noradrenaline 
respectively (Chess-Williams, 2002). The receptors present on the parasympathetic nerve are 
the excititory M1 and M3 receptors, compared to the inhibitory M2 and M4 receptors found on the 
sympathetic nerve endings.  
The bladder urothelium is estimated to have up to 40% greater muscarinic receptor density than 
the detrusor (Hawthorn et al., 2000). Consistent with animal species, the presence of the 
urothelium in isolated human bladder strip experiments was found to exert an inhibitory effect 
on cholinergic contractile responses of the underlying detrusor muscle (Chaiyaprasithi et al., 
2003). This inhibition has been attributed to the release of an unknown factor from the 
urothelium, termed urothelial -derived inhibitory factor (UDIF) (Hawthorn et al., 2000). UDIF will  
be discussed in more detail in later sections.  
Acetylcholine also influences sensory nerves. A study by Daly and colleagues (2010) found 
stimulating muscarinic receptors or inhibiting cholinesterase activity significantly attenuated 
meshanosensitivity in the bladder. While muscarinic receptor stimulation enhances contraction 
of the bladder, muscarinic antagonists have been used clinically with success to treat overactive 
bladder. Commonly termed anticholinergics or antimuscarinics, their mechanism of action is to 
competitively antagonise muscarinic receptors on the bladder and also potentially inhibit 
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urothelial sensory receptors and decrease afferent nerve activity (Marinkovic et al., 2012, 
Yamaguchi et al., 2009). 
NICOTINIC RECEPTORS 
Compared to muscarinic receptors, there is little known regarding the effect of acetylcholine on 
nicotinic receptors in the bladder. The urothelium expresses multiple nicotinic receptors, 
classified by either an α or  subunit, forming either neuronal or muscular nicotinic receptors 
(Beckel et al., 2006). Recent investigation into two subtypes of nicotinic receptors, α3 and α7, 
shows that with stimulation they aid to excite by influencing calcium influx and inhibit 
neurotransmitter release respectively (Beckel and Birder, 2012). 
The external urethral sphincter is comprised of striated muscle, which contracts  during bladder 
filling. This contraction is mediated through the release of acetylcholine from the somatic nerves 
acting upon the nicotinic receptors present in the urethral sphincter (Andersson and Michel, 
2011, Fowler et al., 2008).  
 
ATP AND PURINERGIC RECEPTORS 
Adenosine-5’-triphosphate (ATP) was first implicated as the mediator for the NANC contractions 
from the observation that parasympathetic nerves induce atropine -resistant contractions of the 
bladder (Burnstock et al., 1972). In addition to being co-released in vesicles with acetylcholine 
from parasympathetic nerves, ATP has shown to be released from the urothelium in response 
to stretch (Ferguson et al., 1997, de Groat and Yoshimura, 2001). Ferguson et al. (1997) 
suggested that the mechanism of ATP release is non-vesicular from three sources of evidence: 
that the absence of extracellular calcium potentiates ATP release, tetrodotoxin had no effect on 
electrically induced ATP release and urothelial cells do not possess secretory granules as in 
sensory nerves (Dixon and Gilpin, 1987). Furthermore, it appears that distension-induced ATP 
release is mediated by an increase in intracellular Ca
2+
. Firstly, the addition of capsacin to rabbit 
urothelium evokes ATP release without distension; stretch-induced ATP release is attenuated 
by the Ca
2+
-channel blocker nifedipine and finally, distension of urothelial cells with hypotonic 
solutions also increase intracellular Ca
2+
 (Dunning-Davies et al., 2013, Wu et al., 2011) 
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ATP acts on two groups of purinergic receptors, an ion channel family P2X and a G-protein-
coupled receptor family P2Y (Ralevic and Burnstock, 1998). Seven P2X (P2X1 – P2X7) and 
eight P2Y (P2Y1, P2Y2, P2Y4, P2Y6, P2Y8, P2Y11, P2Y12 and P2Y13) receptor subtypes have 
been identified and cloned (Burnstock, 2006, Shaver, 2001).   
Purinergic receptors are found in numerous locations of the bladder, and have been suggested 
to play an important role in regulating normal bladder function. In both the human and rat 
bladder, P2X1 receptors have been found in the detrusor muscle, while P2X3 receptors are 
found on the afferent nerves (Elneil et al., 2001, Birder et al., 2004, Wang et al., 2005). These 
receptors function respectively  to convey information regarding bladder filling and storage, and 
have been implicated in nociception from tissue damage and overfilling (Cook and McCleskey, 
2000). Furthermore, P2X3 receptor knockout mice exhibit decreased voiding frequency, pain 
response and increased bladder capacity with normal filling pressures, which indicate a role for 
this receptor in peripheral pain responses and afferent pathways controlling bladder reflexes 
(Cockayne et al., 2000) 
 In the urothelium, the entire P2X receptor family and the P2Y1, P2Y2, and P2Y4 subunits are 
expressed, however the functional role of these receptors are still under examination (Birder et 
al., 2004, Sun and Chai, 2004, Elneil et al., 2001). 
As previously mentioned, there is evidence that ATP is in part responsible for the NANC 
contractions of the detrusor muscle, mediated by the P2 X receptors (Burnstock, 2009). 
Bladders from patients with a range of lower urinary tract disorders have observed increases in 
P2X receptor subtypes and a consequent change in nerve mediated contractions, suggesting a 
role of ATP in the symptoms presented in these patients (Andersson and Arner, 2004, O'Reilly 
et al., 2002).  
ATP is also released from the urothelium in response to cellular stretch, electrical stimulation 
and osmotic stress (Ferguson et al., 1997, Vlaskovska et al., 2001, Knight et al., 2002). This 
urothelial-derived ATP acts on the surrounding structures in both an autocrine and paracrine 
manner. The ATP released from the urothelium acts as a t rigger for discoidal/ fusiform vesicle 
exocytosis through signalling at the P2X2, P2X3 and possibly P2Y receptors present on the 
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urothelial membrane (Truschel et al., 2002, Wang et al., 2005). Urothelial derived ATP release 
acts in a paracrine manner on the P2X3 receptors on bladder afferent nerves (Ferguson et al., 
1997, Vlaskovska et al., 2001). The stimulated nerve in turn conveys information regarding the 
degree of bladder fullness and distension to the CNS (Vlaskovska et al., 2001, Wang et al., 
2005). It has been suggested that myofibroblasts situated in the suburothelium may have a role 
in coupling urothelial-derived ATP to afferent excitation, due to the presence of P2Y receptors 
and their positioning between the urothelium and afferent nerves (Wu et al., 2004).  
After release from parasympathetic nerves or the urothelium, ATP is rapidly converted by  
endonucleotidases to adenosine diphosphate (ADP), adenosine monophosphate (AMP) and 
adenosine (Lazarowski et al., 2003). Dunning-Davies et al. (2013) found that adenosine acts as 
a potent inhibitor of stretch-induced ATP release, via stimulation of the adenosine-A1 receptor, 
suggested being due to a reduction in intracellular Ca
2+
 levels via activation of ion channels. 
The presence of the four adenosine receptors A1, A2a, A2b and A3 in the urothelium was 
confirmed by Yu et al (2006), who also proposed that adenosine is released from the urothelium 
and may play a role in exocytosis in the umbrella cells.   
 
NORADRENALINE AND ADRENERGIC RECEPTORS 
As previously described, the release of noradrenaline from sympathetic nerves induces bladder 
relaxation. An inhibitory response of bladder smooth muscle and parasympathetic ganglia was 
observed through catecholamines administered externally and when released endogenously by 
electrical stimulation of cat hypogastric nerve in 1972 (De Groat and Saum, 1972). Bladder 
filling is associated with the cyclical relaxation of the detrusor muscle, and the contraction of the 
bladder neck and urethra to prevent involuntary micturition, with these actions mediated through 
noradrenaline acting on the various adrenergic G-protein coupled receptors, namely the α- and 
β- subunits (Michel and Vrydag, 2006).  
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α-ADRENOCEPTORS 
The α-adrenoreceptor (AR) is further characterised by the α1- and α2- subtypes. The α1- AR 
(coupled with the Gq protein) is further subtyped into α1A-, α1B- and α1D-, while the α2-AR 
(coupled with the Gi protein) encompasses the α2A-, α2B- and α2C- family (Bylund, 1988).  
The presence of α1 receptors have been confirmed in the bladder of mice, rats, monkeys and 
humans (Michel and Vrydag, 2006). In the human bladder, it was found that stimulating these 
receptors produce a contractile effect, mediated by the phospholipase C complex ( Figure 1.10) 
(Goepel et al., 1997). The localisation of these receptor mRNAs, particularly the  α 1A and α1D   
(majority) subtypes, in the bladder trigone and base correlates with their function of preventing 
bladder content leakage (Malloy et al., 1998).  
 
Figure 1.10: Effects of noradrenaline on the α1-, α2- and β-adrenoceptors. α1-ARs initiate smooth muscle 
contraction coupled to the Gq protein, α2-ARs inhibit neurotransmitter release and initate smooth muscle 
contraction coupled to the Gi protein while the β-ARs initiate smooth muscle relaxation coupled to the Gs 
protein. 
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Radioligand binding studies have confirmed the presence of α2-AR coupled to the Gi protein in 
the urethra, detrusor and bladder base/neck of rabbits, pigs and humans (Goepel et al., 1997, 
Levin et al., 1988, Andersson et al., 1984). Despite their presence in the bladder, it has been 
confirmed that these receptors do not mediate contraction in the rabbit, guinea-pig and human 
detrusor (Ueda et al., 1984, Kunisawa et al., 1985, Gillespie, 2004). The prejunctional inhibition 
of post-ganglionic sympathetic and parasympathetic neurotransmitter release (Figure 1.10), 
and direct inhibition of parasympathetic nerve activity in the bladder as found in rabbits, appears 
to be the most significant function of these receptors.  
 
β-ADRENOCEPTORS 
Noradrenaline is released by sympathetic nerves during bladder filling. This acts upon the β-
ARs dispersed throughout the detrusor muscle, which relaxes to accommodate bladder filling.  
The presence of β-adrenoceptors has been confirmed within the rat and human bladder, with all  
three subtypes (β1, β2 and β3) present within both species (Takeda et al., 1999, Fujimura et al., 
1999, Igawa et al., 1999, Li et al., 2003). Through the application of selective β agonists, it has 
been found that the β3-AR mediates the relaxation of the detrusor muscle through the 
stimulation of adenylate cyclase, increasing cAMP and activating PKA (Figure 1.10) (Igawa et 
al., 1999, Igawa et al., 2001, Yamaguchi, 2002). 
 
NITRIC OXIDE 
Nitric oxide (NO) is an important signalling molecule released from the bladder in response to 
mechanical stretch, chemical stimulation including capsaicin, nicotine and calcium ionophores 
and neurotransmitters (acetylcholine, noradrenaline and substance P) (de Groat and Yoshimura,  
2001, Birder et al., 2002). NO is the neurogenic mediator that causes relaxation of the smooth 
muscle of the bladder neck and urethra during bladder micturition (Ehrén et al., 1994). 
Stimulation of the adrenoreceptors in the urinary bladder directly induces detrusor relaxation 
and causes NO release (Birder et al., 1998), however as the detrusor muscle cells lack soluble 
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guanylate cyclase (receptors for NO), it is likely that NO-induced relaxation of the detrusor is 
mediated by the localised myofibroblasts (Smet et al., 1996). NO is also released by the 
urothelium, proposed to play a role in regulating permeability, excites afferent nerve activity 
(particularly sensitizing nociceptors) and modulates efferent nerve neurotransmitter release 
(Mumtaz et al., 2000, Gold et al., 1996).  
Nitric oxide synthase (NOS) is the enzyme responsible for the catalysis of NO from L-arginine, 
localized in nerve fibres of the detrusor muscle in the trigone portion of the bladder and the 
urethra, as well as the urothelium (Andersson and Persson, 1995). Three isoforms of NO 
synthase (NOS) have been identified in the lower urinary tract, neuronal  NOS (nNOS), 
endothelial NOS (eNOS) and inducible NOS (iNOS), named after the cells in which they were 
first purified and isolated (de Groat and Yoshimura, 2001, Forstermann et al., 1994). The 
presence of NOS in preganglionic sympathetic and postganglionic  parasympathetic nerves in 
the lower urinary tract of the rat further indicate a role of NO in the inhibition of NANC induced 
contractions (McNeill et al., 1992, Mumtaz et al., 2000). 
Nitric oxide has been implicated in a range of bladder pathophysiology. nNOS knockout mice 
suffer from increased urinary frequency, and their bladders were found to be hypertrophic and 
resistant to relaxation by exogenous and neurogenic NO release  (Burnett et al., 1997). In 
comparison, NO production is upregulated  in inflamed and chronically infected (eg. due to 
bacterial cystitis) bladders, resulting in hyper-reflexivity (Nussler and Billiar, 1993). 
Measurement of bladder NO has also been used to differentiate urgency relating to 
inflammation from neurogenic disorders or bladder outlet obstructions (Ehren et al., 1999b).  
 
PROSTAGLANDINS 
Prostaglandins play a significant role in controlling urinary bladder motility. The release of 
eicosanoids by the urothelium, in particular prostaglandin E2, was first discovered by Jeremy 
and collegues (1987), using samples of human bladder obtained during cytoscopy. It was 
proposed that prostaglandin E2 play a role in modulating the tone and contractility of the bladder 
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detrusor muscle directly during the excitation-contaction coupling and indirectly by influencing 
neurotransmission (Jeremy et al., 1987).  
Prostaglandin E2 is formed through the metabolism of arachidonic acid to prostaglandin H2 
catalysed by cyclooxgenase enzymes, rapidly converting to prostaglandin E2. Both the detrusor 
muscle and urothelium have been found to release prostaglandin E2. The detrusor muscle 
releases prostaglandin E2 in response to bladder stretch and electrical field stimulation (Park et 
al., 1999, Park et al., 1997, Dveksler et al., 1989), while the urothelium releases it in response 
to stretch, potentiated by obstructive and overactive bladder disorders (Masunaga et al., 2006, 
Pinna et al., 2000).  
Early experiments on the bladder muscle observed that the detrusor muscle, but not the urethra,  
contracted with addition of prostaglandin E2 to the tissue (Abrams and Feneley, 1975). 
Prostaglandin E2 released from the detrusor and urothelium are thought to contribute to the 
detrusor basal tone and modulate afferent nerve activity and efferent neurotransmission 
(Anderson, 1993). It was proposed that prostaglandin E2 has an indirect effect on bladder 
emptying, through stimulating vanilloid receptors and the release of tachykinins, thus sensitizing 
afferent nerves (de Groat and Yoshimura, 2001, Morrison, 1999).  
Increased urinary prostaglandins have been linked to the pathophysiology of bladder disorders, 
including urinary tract infections/inflammation and particularly detrusor overactivity experienced 
in patients with bladder outlet obstruction and (Wheeler et al., 2002, Schroder et al., 2004).  
 
UROTHELIAL-DERIVED INHIBITORY FACTOR 
The presence of the urothelium has an inhibitory effect on contractions of the detrusor muscle. 
This was observed in experiments investigating the contractions of porcine detrusor with and 
without the urothelium to muscarinic agonists (Hawthorn et al., 2000). A significant difference in 
response to carbachol was observed between the intact and denuded tissues, with no change 
with the addition of inhibitors of the NO pathway, purinergic and adre nergic receptors and 
potassium channels. 
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It was concluded that a mediator released from the urothelium, termed the urothelial -derived 
inhibitory factor (UDIF), is responsible for the inhibition of detrusor muscle. At present, it is 
unclear what the UDIF is, however mediators including NO, eicosanoids, gamma aminobutyric 
acid, catecholamines and apamin-sensitive response to endothelium-derived hyperpolarizing 
factor have been ruled out (Hawthorn et al., 2000).  
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1.2 BLADDER CANCER 
Bladder cancer is the most common malignancy of the lower urinary tract, and is the seventh 
and seventeenth most common worldwide cancer in men and women respectively (Burger et al., 
2012).  This condition is more common in developed countries, and is predominantly a disease 
of the elderly, most common in the United States and Western Europe (Ferlay et al., 2010). 
Bladder cancer is approximately three times more common in males than in females, however it 
is interesting to note that women, particularly of African-American descent along with the elderly, 
experience higher mortality rates (Scosyrev et al., 2009).  
The prevalence of bladder cancer across the globe, as well as the high recurrence rate and 
necessity of continual monitoring result in this disease having the highest lifetime treatment 
costs per patient of all cancers, ranging from $97 000 - $187 000 per person in the US (Sievert 
et al., 2009, Racioppi et al., 2012, Botteman et al., 2003). These costs are attributed to the high 
rate of return of bladder cancer, and the associated long-term side effects from intravesical 
therapy accounting for approximately a third of all expenses (Avritscher et al., 2006). 
The risk factors for bladder cancer are differentiated into genetic and environmental exposures. 
As the urothelium lines the urinary tract, it is exposed to potential carcinogens and reactive 
oxygen species excreted in the urine. The most common and significant etiologic factor 
implicated in bladder cancer development is tobacco smoking (Hecht, 2006, Hartge et al., 1993, 
Ji et al., 2005). Patients with recurrent or chronic bladder infections and inflammations, such as 
the human papillomavirus infection, or iat rogenic effects from pelvic radiation or 
cyclophosphamide and thiazolidinedione treatment have a higher risk of bladder cancers 
(Groah et al., 2002, Kleinerman et al., 1995, Sandhu et al., 2006, Travis et al., 1995, Colmers et 
al., 2012). The risk of bladder cancer in a first-degree relative of a patient is increased two-fold, 
through the inheritance of a predisposition of oncogenes, epithelial growth factor receptors and 
susceptibility to potential carcinogens (Burger et al., 2012).  
Bladder tumours are either epithelial or non-epithelial in origin, approximately 90% being the 
former. These include transitional cell carcinoma (TCC) squamous cell carcinomas (SCCs), 
adenocarcinomas and small cell tumours, while the rarer nonepithelial tumours encompass 
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sarcomas, pheochromocytomas, melanomas and lymphomas. Transitional cell carcinoma (TCC) 
is the most common of histological neoplasms, representing over 90% of all bladder cancers 
(Griffiths, 2012). TCCs refer to malignancies originating from the urothelium and are often 
termed urothelial cancer. For the interests of this investigation, transitional cell carcinoma 
characteristics and treatment options will be discussed, being the majority of bladder cancer 
diagnoses. The majority of bladder cancer patients present with painless haematuria (Griffiths, 
2012, Kaufman et al., 2009). Other common presenting symptoms are unexplained uri nary 
frequency and urgency and dysuria during voiding. 
 
CLASSIFICATION OF BLADDER CANCER 
Classification of bladder tumours are determined by the degree of metastasis and level of 
invasion through the bladder wall, often termed the grade and stage. Tumour s tage and grade is 
useful in determining and monitoring patients’ risk of recurrence and disease progression. In 
2004, the World Health Organisation (WHO) in conjunction with the International Society of 
Urological Pathology (ISUP) proposed a two-tiered grading system as seen in Table 1.1 (Gorin 
et al., 2012, Montironi and Lopez-Beltran, 2005). This system delegates tumours to be of either 
low or high grade, as well as defining tumours to be either papillomas or papillary urothelial 
neoplasms of low malignant potential (PUNLMP). Previously, tumours were classified as 
papillomas or grades 1-3 according to the 1973 WHO classification (Montironi and Lopez-
Beltran, 2005). 
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Table 1.1: WHO/ISUP 2004 bladder tumour grading system (Montironi and Lopez-Beltran, 2005) 
Papilloma Delicate papillae with cellular organization and cytologic findings identical to 
normal urothelium 
PUNLMP Occasionally fused papillae, normal cell polarity, uniformly enlarged nuclei, fine 
chromatin, rare mitotic figures confined to the basal level (encompasses grade 1 
tumours from previous 1973 classification) 
Low 
Grade 
Fused and branching papillae, minimal cell crowding and loss of polarity, enlarged 
nuclei of variable size and slightly irregular shape, mild variation of chromatin,  
inconspicuous nucleoli, mitotic figures occasionally present at any level (includes 
grade 1 and 2 tumours) 
High 
Grade 
Fused and branching papillae, discohesive with loss of cell polarity, enlarged 
pleomorphic nuclei of variable size, moderate to marked variation of chromatin,  
multiple nucleoli, frequent mitotic figures at any level (consisting of grade 2 and 3 
tumours) 
 
Staging of bladder cancer tumours are based on the level of invasion through the bladder wall, 
adapted by the 2010 American Joint Commission on Cancer, seen in Table 1.2 and Figure 
1.11 (Edge and Compton, 2010, Gorin et al., 2012). Non-muscle invasive bladder cancer 
(NMIBC) encompass Tis (tumours in situ) to the level of T1 (tumours invading to the level of the 
suburothelium/lamina propria), while muscle invasive tumours (MIBC) include T2 tumours to T4 
(Gorin et al., 2012, Griffiths, 2012).  
Table 1.2: Adapted AJCC 2010 staging system of bladder cancer (Edge and Compton, 2010) 
Primary Tumour (T)  
 T0 No evidence of tumour 
 Ta Papillary tumour confined to the urothelium 
 Tis Carcinoma in situ 
 T1 Invades suburothelium/lamina propria 
 T2a Invades superficial muscularis propria 
 T2b Invades deep muscularis propria 
 T3a Microscopic invasion of perivesical fat 
 T3b Macroscopic invasion of perivesical fat 
 T4a Invades the prostate, seminal vesicles, uterus, or vagina 
 T4b Invades the pelvic or abdominal wall 
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Figure 1: Bladder cancer staging (Tis – T4b) 
 
Bladder cancer has a high propensity to return. Prognostic factors, including age, gender, 
tumour grade, stage and number must be taken in to account to determine the most appropriate 
adjuvant treatment.  Sylvester and colleagues (Sylvester et al., 2006) designed a number of 
nomograms from analysis of 2596 NMIBC patients included in seven European Organization for 
Research and Treatment of Cancer trials. These diagrams allow the determination of patient 
risk of recurrence and progression post one and five years transurethral resection (TUR), which 
in turn sheds light on the most appropriate adjuvant treatment and protocol. At present, it has 
been estimated that up to 90% of all patients will experience recurrence of tumours following 
transurethral resection over their lifetime (Herr, 2000). 
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DIAGNOSIS AND TREATMENT  
Bladder cancer is identified with a range of diagnostic tests. Urine cytology and molecular tests 
are used to investigate the presence of ex foliated cancer cells and soluble or cell -associated 
markers (Babjuk et al., 2008, Lokeshwar et al., 2005). Visualizing tumours is necessary for 
tumour diagnosis, performed by intravenous urography or the more commonly used cystoscopy. 
At presentation, between 70-80% of transitional cell carcinomas are diagnosed as superficial or 
non-muscle invasive bladder cancers (NMIBC), referring to carcinomas that are restricted to the 
bladder urothelium and suburothelium/lamina propria (Shelley et al., 2011b, Hendricksen and 
Witjes, 2007). Bladder tumours have a high predisposition to return, with 45% of patients having 
tumour recurrence within the first 12 months of diagnosis (van der Heijden and Witjes, 2009). 
10-20% of these recurring tumours will have progressed to be muscle invasive, significantly 
decreasing their probability of recurrence free survival (Kaufman et al., 2009, Rubben et al., 
1988).  
The first line of treatment for NMIBC is transurethral resection (dependent on tumour grade); 
followed by intravesical immunotherapy or chemotherapy, while MIBC patients undergo partial 
or full cystectomy. Figure 1.12 depicts an algorithm proposed by the International Bladder 
Cancer Group for the general treatment and management of non -muscle invasive bladder 
cancer. 
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Figure 1.12: Algorithm for the treatment and management of non-muscle invasive bladder cancer proposed by 
the International Bladder Cancer Group.  TURBT – transurethral resectionof the bladder tumour; BCG – bacillus 
Calmette-Guerin therapy; CIS: carcinoma (tumour) in situ (reprinted with permission from Lamm et al., 2008) 
 
TRANSURETHRAL RESECTION AND PARTIAL/FULL CYSTECTOMY  
Transurethral resection (TUR) of bladder tumours is used for both diagnostic and therapeutic 
purposes. A resectoscope is used to remove the tumour entirely or in fractions, dependent on 
the size and grade of tumours. Small tumours are removed in entirety with part of the underlying 
wall, while large tumours are resected in fractions, including the exophytic part of the tumour, 
the underlying detrusor muscle and edges of the resectioned area (Vaupel et al., 1989, Babjuk, 
2009). Succeeding transurethral resections are considered 2 -6 weeks following the initial 
procedure if the tumour was under-staged/graded or the procedure was incomplete.  
 For patients with muscle invasive tumours graded between T2 and T4, a partial or full 
cystectomy is considered to be the gold standard in treatment (Sternberg et al., 2007). The five-
year survival rate after cystectomy is up to 65% for patients with low graded tumours, and 
between 25-35% for T3 and T4 stage tumours (Stein et al., 2001, Ghoneim et al., 1997, Addeo 
36 
 
et al., 2010). For the purposes of this report, further discussion of bladder cancer treatment 
options will refer to the treatment of non-muscle invasive bladder cancer only. 
 
INTRAVESICAL IMMUNOTHERAPY 
Intravesical immunotherapy describes the direct instillation of agents to induce an immune 
response within the bladder. Since 1976, Bacillus Calmette-Guerin (BCG) therapy has been 
used for the management of bladder cancers as an adjuvant therapy post transurethral 
resection, after preliminary studies on the dog bladder produced marked inflammatory and 
immune reactions (Bloomberg et al., 1975, Schellhammer et al., 1975). BCG therapy involves 
direct instillation of tuberculosis bacteria, with a dose dependent on the strain of virus (Gontero 
et al., 2010). The most widely used strains in North American and Europe are the BCG 
Connaught and BCG Tice, with the Connaught strain having significantly improved recurrence-
free survival rate for patients with NMIBC compared to the Tice strain (Rentsch et al., 2014). 
The cytotoxic mechanism of BCG on cancer cells is still not fully understood, but it is thought 
that fibronectin-binding proteins on the surface of the BCG bacteria bind to urothelial receptors 
and initiate int racellular signalling to stimulate anti-tumour activity (Bohle and Brandau, 2003, 
Okeke et al., 2005). Limitations to this treatment are the systemic toxicity and local urological 
side effects including cystitis, increased frequency and haematuria (Babjuk et al., 2012). 
Systemic toxicity manifesting in side effects is less common in patients undergoing BCG therapy, 
but include fever, myalgia and nausea, as well as rare cases of BCG infection progressing to 
multiple organ failure and death.  
Numerous studies within the literature have confirmed that BCG post-TUR is superior in limiting 
tumour recurrences compared with TUR alone (Shelley et al., 2004). Conflicting evidence is 
reported in randomised trials comparing intravesical BCG with intravesical chemotherapy in 
terms of recurrence, disease progression and overall survival. When comparing to mitomycin C, 
the first line chemotherapeutic agent used in bladder cancer treatment, a meta-analysis by 
Shelley et al. (2004) suggested that BCG was the superior treatment in preventing tumour 
recurrence in high-risk patients, although Bohle and colleagues (2003) reported no significant 
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difference in intermediate risk patients. Other agents investigated included doxorubicin and 
epirubicin which are also commonly used in the treatment of NMIBC. In comparison to BCG, 
both agents were inferior in preventing or delaying tumour recurrence, however there is limited 
evidence to suggest that BCG improves the rate of tumour progression and overall survival 
(Shelley et al., 2010, Khanna et al., 1987, Lamm et al., 1991, Hinotsu et al., 2006, van der 
Meijden et al., 2001). 
While the evidence suggests intravesical BCG is the most favourable treatment, it is in some 
cases an inappropriate option. BCG for patients with tumours with a low risk of p rogression is 
considered to be an overtreatment, and the risk of systemic toxicity is significantly higher with 
BCG compared to intravesical chemotherapy. A dropout rate of 20.3% was seen in a cohort of 
487 patients in a 36-month treatment program using BCG, due to the local and/or systemic side 
effects (van der Meijden et al., 2003), thus requiring alternate treatment plans. Similarly, up to a 
third of patients with NMIBC will not respond to BCG therapy, and it has been observed that up 
to 40% of patients who initially respond to BCG therapy, fail with recurring tumours, thus 
evolving to being BCG-refractory (Herr and Dalbagni, 2003, Herr et al., 1989, Herr, 2005, Witjes, 
2006). 
Since July 2012 the worldwide production of BCG has struggled to meet demands, after mould 
compromised the BCG Connaught strain produced by Sanofi Pasteur (Lyon, France) after a 
flood in the manufacturing plant in Toronto, Canada (Mostafid et al., 2015). This facility was the 
sole producer of ImmuCyst (BCG Connaught), the market leader of BCG products in many 
countries, including the UK and United States. The consequent replacement market leader of 
BCG, OncoTICE (a Tice strain of BCG) manufactured by Merck Sharp & Dohme Ltd 
(Hertfordshire, UK), announced that it expected severely reduced OncoTICE supplies 
throughout 2015 due to a combination of increased demand and manufacturing issues 
(Mostafid et al., 2015). Furthermore, the doses of BCG used for NMIBC treatment are immense 
with comparison to the mount required for a BCG tuberculosis  vaccine, with a 6-instillation 
course for bladder cancer patients being sufficient to vaccinate 10,000-100,000 people. For this 
reason, alternative treatments and management plans for NMIBC patients are urgently needed.  
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INTRAVESICAL CHEMOTHERAPY 
Intravesical chemotherapy for non-muscle invasive bladder cancers involves direct instillation of 
the chemotherapeutic agents into the bladder. Frequently used drugs include doxorubicin, 
epirubicin, mitomycin C and gemcitabine. For patients with high risk NMIBC, there is a general 
consensus that intravesical chemotherapy remains the most favourable second -line treatment 
for BCG refractory patients. Intravesical chemotherapy for patients with low to intermediate risk 
features such as multifocal or low grade Ta tumours is often considered the most favourable 
first line treatment (Koya et al., 2006). Regimes for intravesical chemotherapy include 
immediate and adjuvant treatments, with an optimal protocol of duration and frequency post -
TUR yet to be determined (Sylvester et al., 2008).  
 
IMMEDIATE POST-TUR  CHEMOTHERAPY 
As non-muscle invasive tumours recur frequently and often progress to muscle invasive 
neoplasms even after TUR, adjuvant therapy is considered for all patients. A meta-analysis of 
seven-randomised trials showed that an instillation of chemotherapy (epirubicin or mitomycin C) 
within 24 hours of TUR for NMIBC significantly reduced the risk of recurrence of Ta/T1 tumours 
(Babjuk et al., 2012, Sylvester et al., 2004). This type of adjuvant therapy is thought to destroy 
residual and circulating tumour cells at the resection site. As chemotherapeutics generally have 
a high molecular weight and the presence of the protective GAG and uroplakin layer on the 
urothelium, there is little risk of absorption and thus systemic toxicity. Due to this, they can be 
instilled directly post-TUR.  
An initial randomised study in patients of Ta/T1 tumours comparing an immediate instillation of 
epirubicin to water post-TUR found that the interval to recurrence was significantly better and in 
a two-year follow up the recurrence rate was halved in the epirubicin group (Oosterlinck et al., 
1993). Similarly, a meta-analysis reported by Sylvester et al (2004) concurred with these results, 
finding a 39% decrease in the chance of recurrence with a single post-operative 
chemotherapeutic dose, with only mild and transient toxicity. From this data, a single instillation 
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of chemotherapuetic agent immediately post-TUR appears to be the best option for all patients 
with NMIBC, however further treatment is required for patients with high-risk tumours. 
 
ADJUNCT INTRAVESICAL CHEMOTHERAPY 
Intravesical chemotherapy is considered as an alternate treatment to Bacillus Calmette-Guerin 
immunotherapy for superficial bladder cancer, or as an adjunct therapy after refractory BCG. 
Chemotherapeutic drugs including mitomycin C, thiotepa, epirubicin and doxorubicin have been 
investigated in int ravesical therapy. As discussed previously, the literature suggests that none of 
these drugs are more effective compared to BCG in t reating NMIBC. However, as alternate 
treatments are required in refractory BCG or low risk NMIBC patients, investigation of 
chemotherapies is necessary to provide an appropriate second-line treatment. Significant 
adverse effects have been reported following intravesical instillation of the aforementioned 
drugs, including chemical cystitis, dysuria, increased frequency and urgency, as well as bladder 
toxicity (Koya et al., 2006, Thrasher and Crawford, 1992). 
These chemotherapeutics have been tried and tested on NMIBC and BCG-refractory patients, 
producing limited efficacy and poor toxicity profiles, which has led to the investigation of other 
chemotherapeutic agents. Gemcitabine, a prodrug chemotherapeutic, is FDA approved and 
used in the first line treatment in other cancers including, breast, ovarian, small cell lung cancer 
and pancreatic cancer (Lee, 2009). Although limited, reviews of the literature found that 
gemcitabine showed positive activity against metastatic bladder cancer, with an improved  
toxicity profile in comparison to commonly used MVAC (methotrexate, vinblastine, doxorubicin 
and cisplatin) treatment, mitomycin C and doxorubicin (Shelley et al., 2011a). Discussion of 
gemcitabine, its metabolism and methods of action will aim to describ e its pertinence as an 
ideal chemotherapeutic for non-muscle invasive bladder cancer.  
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1.3 GEMCITABINE 
Gemcitabine (GEM, 2’, 2’ -difluoro 2’ deoxycytidine, dFdC) is a pyrimidine analogue classified 
as a prodrug (Mini et al., 2006). It is commonly used both singularly and in combination with 
other anti-neoplasm therapies for the treatment of pancreatic, breast, ovarian, lung and bladder 
cancer, due to its lack of cross-resistance with other anti-cancer agents (Candelaria et al., 2010, 
Lee, 2009). Originally investigated as an anti-viral treatment, it was found to have potent anti-
cancer activity and a wide spectrum of antitumor properties in 1990 through the inhibition of 
human leukaemia cells (Hertel et al., 1990).  Gemcitabine has a low molecular weight of 299D, 
compared to that of mitomycin C and doxorubicin, being 389D and 589D respectively (Gontero 
and Frea, 2006). This may allow it to more effectively penetrate the urothelium, while limiting 
systemic absorption.  
 
STRUCTURE AND UPTAKE  
Gemcitabine is an analogue of cytosine arabinoside (Ara-C), differing structurally at position 2’ 
with a fluorine substitute in the furanose ring, as shown in Figure 1.13. Like Ara-C, gemcitabine 
requires uptake into the cell and consequent phosphorylation to form its act ive metabolites. 
While the intracellular phosphorylated form of Ara-C competes with deoxycytidine triphosphate 
(dCTP) in inhibiting DNA polymerase activity and acts as a substrate in DNA synthesis 
(Heinemann et al., 1988), gemcitabine has multiple intracellular targets reflective in its wide 
antitumour-spectrum (Mini et al., 2006, Candelaria et al., 2010, Hertel et al., 1990).  
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Figure 1.13: Structure of Cytosine arabinoside and Gemcitabine (reprinted with permission from Mini et al., 
2006). 
Gemcitabine moves through the cellular membrane via nucleoside transporters (NT) located in 
the plasma membrane. Human NTs are either concentrative (sodium dependent, hCNTs) or 
equilibrative (sodium independent, hENTs) type, both of which are involved in gemcitabine 
uptake. Specifically, gemcitabine acts as a substrate for five of the hNTs, including hENT1, 
hENT2, hCNT1, hCNT2 and hCNT3 (Mackey et al., 1998, Mabel W. L. Ritzel, 2001). While 
equilabrative NTs appear to be widely distributed between cell and tissue types, concentrative 
NTs are limited to cells including intestinal and renal epithelia, liver and leukemic cells (Mackey 
et al., 1998, Belt et al., 1993). It has been reported that hENT1s have the greatest affinity for 
gemcitabine, and hENT1 deficient cells are highly resistant to this pyramidine analogue 
(Mackey et al., 1998).  
 
METABOLISM AND MECHANISM OF ACTION 
Once inside the cell, gemcitabine is phosphorylated by deoxycytidine kinase or thymidine 
kinase 2 to gemcitabine monophosphate (dFdCMP) (Mackey et al., 1998, Mini et al., 2006). 
This substrate is then converted to its active forms of gemcitabine 5’ -diphosphate (dFdCDP) 
and t riphosphate (dFdCTP), or deaminated to form 2’2’-difluorodeoxyuridine monophosphate 
(dFUMP) by doxycytidine monophosphate deaminase (dCMPDA), as shown in Figure 1.14 (van 
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der Wilt et al., 2000, Cerqueira et al., 2007, Giovannetti et al., 2007, Heinemann et al., 1992). 
These metabolites are therapeutically active agents that act by differing mechanisms to induce 
cell apoptosis and inhibit normal cellular processes. dFdCDP acts by inhibiting ribonucleotide 
reductase (RR) (Cerqueira et al., 2007), thus hindering the reaction that forms DNA monomers 
required for eventual cellular synthesis and repair (Baker et al., 1991). Inhibition of this enzyme 
by dFdCDP depletes intracellular deoxycytidine triphosphate (dCTP), a nucleoside triphosphate 
used in DNA synthesis, which in turn inhibits dCK, resulting in a more efficient phosphorylation 
of gemcitabine (Heinemann et al., 1990, Mini et al., 2006). 
 
 
Figure 1.14: Intracellular transport, metabolism and mechanism of action of gemcitabine. Gemcitabine (dFdC) is 
transported into the cell (1) via human nucleoside transporters (hNT) where it is either phosphorylated (2) by 
deoxycytidine kinase or thymidine kinase 2 (dCK/TK2) to form gemcitabine monophosphate (dFdCMP), or 
deaminated (3) to form dFdU. Gemcitabine monophosphate is either deaminated (4) to dFdUMP, 
dephosphorylated (5) by 5’-nucleotidase, or phosphorylated to its active forms of gemcitabine diphosphate and 
gemcitabine triphosphate (6). This triphosphorylated form of gemcitabine is incorporated into the cell’s DNA (7), 
RNA (8) and inhibits CTP-synthetase (10), and acts as a self-potentiator by inhibiting the enzyme dCMPDA (12). 
The diphosphate form of gemcitabine acts to inhibit ribonucleotide reductase (RR) (9). Finally, the presence of 
dFdUMP acts to inhibit thymidylate synthase (11) (reprinted with permission from Mini et al., 2006). 
 
In comparison, dFdCTP has multiple intracellular effects,  as seen in Figure 1.14. It is 
responsible for the self-potentiating characteristic of gemcitabine, as its presence inhibits the 
action of dCMP deaminase in deactivating dFdCMP, allowing for increased formation of the 
active phosphorylated forms of gemcitabine (Mini et al., 2006). In the hamster ovary, exposure 
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to gemcitabine was found to reduce cellular CTP and dCTP concentrations, indicating a block to 
CTP-synthetase by dFdCTP (Heinemann et al., 1995). The active form of gemcitabine also 
works to inhibit DNA polymerase, the enzyme that synthesises DNA strands from their 
nucleotide composites, as well as being incorporated into DNA (Cerqueira et al., 2007, Gandhi 
and Plunkett, 1990).  
Using in vitro models, (Huang et al., 1991) found that dFdCTP competed directly with dCTP for 
incorporation into the C sites of the growing DNA chain. The placement of this active metabolite 
at a non-terminal position on the forming strand leads to the termination of chain lengthening, as 
well as preventing detection and repair by DNA repair enzymes (Gandhi et al., 1996, Candelaria 
et al., 2010). Inhibition of RNR by dFdCDP works in synergy with the incorporation of dFdCTP 
into DNA by reducing the competing deoxyribonucleotide molecule availability.  
It is unclear as to how the incorporation of gemcitabine into DNA leads to bladder cancer cell 
death. The presence of dFdCTP in DNA strands has been suggested to promote cell apoptosis 
in breast and lung cancer by increasing the frequency of collisions of topoisomerase cleavage 
complexes causing strand breakages (Pourquier et al., 2002). In human lung-cancer cell lines, 
the apoptotic-inducing gene p53 was upregulated in a concentration -dependent manner after 
treatment with gemcitabine (Tolis et al., 1999), while accumulation of capsase-3, the apoptotic 
regulatory cell protein, was measured within pancreatic cancer cell lines (Chandler et al., 2004). 
It appears in bladder cancer cell lines that gemcitabine induces cell cycle arrest in the G1 phase,  
and that cell lines with the gene p53 are inherently more sensitive to the cytotoxic effects of 
gemcitabine (da Silva et al., 2010). It has been reported that dFdCTP is also incorporated into 
RNA in a concentration-dependent manner, however the effect on cell function is unknown 
(Ruiz van Haperen et al., 1993).  
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GEMCITABINE ROLE IN NON-MUSCLE INVASIVE BLADDER CANCER 
Phase I studies investigated gemcitabine treatment in patients with superficial TCC refractory to 
BCG with doses between 500-2000mg in saline, with instillation times of one hour (Dalbagni et 
al., 2002). Minimal urinary symptoms and systemic absorption was observed, similarly in 
consequent Phase II studies, resulting in a recommended regime of a 2000mg dose weekly for 
four to six weeks as an initial treatment (Campodonico et al., 2005, Bartoletti et al., 2005). 
Refractory BCG patients in Phase II trials had excellent tolerability to gemcitabine, with 50% 
and 23% achieving a complete and partial response respectively with a 1-year recurrence-free 
survival at 21% (Dalbagni et al., 2006). The low molecular weight, high lipid solubility and high 
plasma clearance of gemcitabine, as well as its excellent safety and toxicology profile make it 
an ideal intravesical chemotherapeutic for NMIBC (Laufer et al., 2003).   
Within the literature, there are limited comparisons of efficacy between gemcitabine and other 
intravesical agents commonly used in NMIBC treatment. A summary of these can be seen in 
Table 1.3, adapted from a Cochrane Review as published in 2012 (Jones et al., 2012). An 
immediate, single post-TUR instillation of gemcitabine was found to have no significant 
superiority to placebo, with overall recurrence rates of 35.5% and 36.3% respectively (Bohle et 
al., 2009). In comparison, intravesical gemcitabine therapy shows a favourable efficacy and 
toxicity profile against mitomycin C (Addeo et al., 2010). Notably, the recurrence rate post initial 
and maintenance therapy was 28% for gemcitabine and 39% for mitomycin C, with a smaller 
proportion of patients experiencing adverse effects in the gemcitabine group (38.8% compared 
to 72.2% for mitomycin C). BCG therapy had a superior recurrence rate to that of gemcitabine 
treatment post TUR, (28.1% to 53.1%), however in BCG-refractory patients, gemcitabine 
showed a significantly (p<0.05) improved recurrence profile (52.5% vs 87.5%) (Porena et al., 
2010, Di Lorenzo et al., 2010). 
It appears from the literature that gemcitabine is a viable treatment option for NMIBC when BCG 
is not an appropriate option, or for BCG refractory patients. Initial comparisons to mitomycin C 
display superior efficacy and toxicity profile of gemcitabine, however further investigation is 
required against other commonly used chemotherapeutics including doxorubicin and epirubicin.  
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Table 1.3: Summary of Randomised Trials w ith Intravesical Gemcitabine (NR – not reported) 
Study Patients/ 
Tumour 
Grade 
Interventions Recurrence 
Rate 
Recurrence 
Free Survival 
(months) 
% Patient 
Progression 
by stage 
Incidence 
of Adverse 
Effects 
Bohle et 
al. 2009 
248 
eligible 
primary or 
recurrent 
Ta-T1, 
G1-3 
Single 
gemcitabine 
instillation post  
TUR 
vs 
Placebo 
38.7% 
 
 
 
37.1% 
37.2 
(median) 
 
 
40.2 
2.4% 
 
 
 
0.8% 
NR 
Addeo et 
al. 2010 
109 
eligible 
recurrent 
Ta-T1, 
G1-3 
Gemcitabine 
vs 
Mitomycin C 
28% 
 
39% 
NR 
 
15 
11.1% 
 
18.2% 
38.8% 
 
72.2% 
Porena 
et al. 
2010 
64 Ta-T1, 
G1-3 
and/or 
CIS 
Gemcitabine 
vs 
BCG 
53.1% 
 
28.1% 
25.6 (mean) 
 
39.4 
0% 
 
0% 
NR 
 
NR 
Lorenzo 
et al. 
2010 
80 eligible 
Ta-T1, 
low-high 
grade 
BCG-
refractory 
Gemcitabine 
vs 
BCG 
52.5% 
 
87.5% 
3.9 
 
3.1 
33% 
 
37.5% 
37.5% 
(grade2-3) 
40% 
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LIMITING FACTORS OF INTRAVESICAL TREATMENT 
The adverse effects that are commonly associated with immuno - and chemotherapy singularly 
and in combination with hyperthermia therapy are a significant limiting factor in intravesical 
treatment for NMIBC. Approximately 20% of patients cease BCG immunotherapy due to the 
local and systemic side effects, while urological side effects are commonly reported in 
intravesical chemotherapy patients (van der Meijden et al., 2003). While there are numerous 
studies investigating the toxicity profiles of various treatments on the cancer cells, the effects of 
these intravesical agents on the normal bladder tissue function remain poorly explored within 
the literature. 
Intravesical immunotherapy using Bacillus Calmette-Guerin has been proven to be superior to 
chemotherapy in reducing the risk of recurrence of bladder cancer (Koya et al., 2006, Shelley et 
al., 2004). However, BCG therapy is associated with more local and systemic side effects 
compared to other intravesical agents (Sylvester, 2011). Dysuria and increased frequency and 
urgency are common local side effects, with systemic absorption manifesting as flu-like fevers to 
fatal sepsis (in rare cases) (Koya et al., 2006). A study of 2602 patients who underwent BCG 
therapy reported that 95% of all patients exhibited some form of irrative lower urinary tract 
symptoms (Lamm et al., 1992). As described in a recent Cochrane review (Shang et al., 2011), 
BCG is associated with significantly more drug-induced cystitis in patients compared to 
epirubicin treatment, at 54.1% and 31.7% respectively. Additionally, it was reported that 34.1% 
of patients suffered systemic adverse effects with BCG therapy, including, fever, influenza-like 
syndrome, nausea, vomiting, BCG lung infection, skin rash and general malaise (Shang et al., 
2011) 
Intravesical chemotherapy is a commonly used treatment in patients with low to intermediate 
risk and grade tumours, and as a second line therapy in BCG refractory patients. Due to the 
high molecular weight of commonly used chemotherapeutics, there is little risk of absorption 
and consequent systemic toxicity. However, there are often reports of local toxicity including 
increased frequency and urgency, suprapubic pain and cystitis (Bolenz et al., 2006, Thrasher 
and Crawford, 1992). 
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Mitomycin C has potent antitumour activity due to its alkylating properties inhibiting DNA 
synthesis, and is the first line chemotherapy used for bladder cancer treatment (Rockwell et al., 
1982). Commonly reported side effects from int ravesical mitomycin C treatment include 
chemical cystitis, increased frequency and urgency of urination, general discomfort and in some 
cases contact dermatitis. Chemical cystitis has been reported in up to 40% of patients, in 
addition to approximately 50% of patients describing dysuria post mitomycin C therapy (Bolenz 
et al., 2006, Thrasher and Crawford, 1992, Bohle et al., 2003, Au et al., 2001). Allergic reactions 
have been reported in 5-10% of patients, caused by either direct contact of the drug with or 
dermatitis due to a delayed hypersensitivity response (Witjes et al., 1998, de Groot and 
Conemans, 1991, Koya et al., 2006). Another rare side effect is decreased bladder volume and 
increased contracture of the detrusor muscle post-treatment (Duque and Loughlin, 2000). 
These changes were observed in rats treated intravesically with mitomycin C, where a 
significant difference between the bladder volume and compliance of treated and control rats 
was found, the effects lasting 3-weeks post cessation of therapy (Michielsen et al., 2005). 
Doxorubicin and epirubicin are anthracycline antibiotics that act to crosslink tumour DNA, 
commonly used for treatment of NMIBC (Koya et al., 2006). Epirubicin is a derivative of 
doxorubicin, both having a molecular mass of 580 kDa, which limits systemic absorption and 
complications when used for NMIBC treatment. Similarly to mitomycin C, intravesical therapy 
with these drugs causes local side effects, manifesting as dysuria, increased frequency, 
urgency and subpubic pain. A study by (Ali-el-Dein et al., 1997) compared instillations of 50mg 
and 80mg of epirubicin to 50mg of doxorubicin, reported that side effects, namely cystitis and 
haematuria developed in 15%, 23.5% and 41.7% of patients respectively. A further study 
reported that 7% of patients out of 829 receiving 50mg of epirubicin in various treatment 
schedules had to stop treatment due to the severity of cystitis and haematuria, among other 
local and systemic side effects (Hendricksen et al., 2008). An in vitro mouse study comparing 
doxorubicin and mitomycin C therapy and subsequent tolerance to radiation found that the 
treated mice exhibited a three-fold increase in micturition frequency, recovering 2-3 weeks post 
treatment (Post et al., 1995).  
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In comparison to the aforementioned therapies, gemcitabine treatment for NMIBC appears to 
have a better toxicity profile and fewer reported side effects (Shelley et al., 2012). A randomized 
Phase III trial of gemcitabine and mitomycin C reported the incidence of chemical cystitis and 
dysuria frequency being statistically lower in the gemcitabine group compared to the mitomycin 
C arm (Addeo et al., 2010). A Phase II trial found 81.3% of patients undergoing weekly 
40mg/mL gemcitabine treatment reported no local side effects (Bartoletti et al., 2005). 12% of 
patients reported urgency during the first instillations, while 2 patients (out of 116) ceased 
treatment due to ulcerative lesions on the bladder and parosmia. However, a further Phase II 
trial with the same treatment schedule described 38% of patients reporting Grade 1 dysuria, 
with two patients (out of 39) requiring antibiotic treatment for a positive urine culture (Gontero et 
al., 2004).  
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1.4 SUMMARY 
Extensive research has focused on investigating the effects of immunotherapy and 
chemotherapeutic agents on bladder cancer progression, recurrence and effects at a cellular 
level on the tumour cells. These studies often report local and systemic side effects, however no 
studies to date have assessed at a cellular or physiological level the effect of these d rugs on the 
function of normal bladder tissue.  
Due to the high recurrence rate and the long-term side effects associated with intravesical 
therapy, bladder cancer patients have the highest lifetime treatment costs of all cancer patients 
(Racioppi et al., 2012). Management of the side effects caused by intravesical therapy accounts 
for approximately a third of all expenses (Avritscher et al., 2006).  
These highlight the need for an understanding of the mechanisms of the commonly reported 
local side effects and thus identify approaches that reduce the incidence and severity of 
adverse effects. Comprehensive studies of this subject will provide potential mechanisms to 
treat or prevent the commonly reported side effects, thus improving patient quality of life and 
minimizing costs.  
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1.5 RESEARCH QUESTIONS AND HYPOTHESIS 
The overall objective of this study was to investigate the changes in bladder function following 
gemcitabine treatment. Specifically, this study aims to address the following research questions:  
1. Does gemcitabine treatment affect the responses of the urinary bladder urothelium, 
detrusor muscle and intact tissue to purinergic, cholinergic and adrenergic stimulation? 
2. Does gemcitabine treatment affect the immediate response to neurogenic stimulation of 
the detrusor muscle? 
3. Does gemcitabine treatment affect basal and stretch induced urothelial mediator 
release? 
4. Does gemcitabine treatment induce the release of inflammatory cytokines? 
5. Does gemcitabine treatment affect voiding pattern in mice? 
The hypothesis for this study is that gemcitabine treatment will alter the response of the urinary 
bladder in the aforementioned scenarios. 
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2.1 ASSAYS FOR UROTHELIAL MEDIATOR RELEASE 
The urothelial mediators ATP, ACh and prostaglandin E2 collected across all experiments were 
measured using respective assay kits, according to the product protocols.  
ACETYLCHOLINE ASSAYS 
Acetylcholine release was determined using Molecular Probes Amplex Red 
Acetylcholine/Acetylcholinesterase Assay Kit (A12217). This assay works through 
acetylcholinesterase (AChE) converting the ACh present in the sample to choline, which is in 
turn oxidized by choline oxidase to betaine and H2O2. The presence of horseradish peroxide 
allows the reaction between H2O2 and the Amplex Red reagent, causing the production of 
resorufin. This fluorescent product can then be measured using a Modulus Microplate 
Multimode Reader (Turner Biosystems, California, USA) with little interference from 
autoflourescence in samples, due to its close absorption and fluorescence emission maxima 
(approximately 571nm and 585nm respectively). A standard curve using known acetylcholine 
concentrations was produced for every plate and used to determine the ACh content in samples, 
as seen in Figure 2.1. 
0 1 2 3
0
10000
20000
30000
40000
[Acetylcholine] M
F
lo
u
re
s
c
e
n
c
e
(5
1
0
n
m
)
 
Figure 2.1: Standard linear regression of fluorescence of samples of known acetylcholine concentrations 
As this assay is based upon choline oxidisation, any acetylcholine degraded during sample 
collection was still measured.  
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ADENOSINE TRIPHOSPHATE ASSAYS 
ATP release was quantified using the Molecular Probes ATP Determination Kit (A22066). This 
kit is a bioluminescence assay using recombinant firefly luciferase and its substrate D-luciferin 
to determine ATP concentrations. The presence of ATP allows the conversion of luciferin to 
oxyluciferin, producing light as a by-product (emission maximum ~560nm at pH 7.8).  
 
 
The luminescence of this reaction is measured with a Modulus Microplate Multimode Reader 
(Turner Biosystems, California, USA), and ATP from unknown samples are determined from a 
standard curve using known ATP standards, such as in Figure 2.2. 
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Figure 2.2: Standard linear regression of luminescence readings of known ATP concentrations 
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PROSTAGLANDIN E2 ASSAYS 
Prostaglandin E2 sample quantification was determined using the R&D Systems Parameter™ 
prostaglandin E2 Assay (KGE004B). This assay is based on the sequential compet itive binding 
technique where prostaglandin E2 in samples compete with horseradish peroxide-labelled 
prostaglandin E2 for a limited number of binding sites on a mouse monoclonal antibody. 
Sampled prostaglandin E2 binds to the antibody in the first incubation, and with the addition of 
horseradish peroxide-labelled prostaglandin E2, any remaining binding sites are taken. Removal 
of unbound materials is followed by the addition of a substrate solution to quantify the bound 
enzyme activity. The intensity of colour of samples, which is inversely proportional to the 
concentration of prostaglandin E2, is measured by a Modulus Microplate Multimode Reader 
(Turner Biosystems, California, USA) with the absorbance of colour read at 450nm. The 
concentration of unknown samples was determined by a standard curve using samples of 
known prostaglandin E2 concentrations, as shown in Figure 2.3. 
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Figure 2.3: Standard curve of absorbance readings of prostaglandin E2 samples of known concentration 
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2.2 CHEMICALS AND DRUGS  
KREBS SOLUTION 
Krebs solution was used for all tissue experiments. The ingredients of this solution are below. 
Table 2.1: Krebs solution ingredients  
Compound Compoun
d Formula 
Supplier Catalogue 
Number 
Molarity (µM) 
(in 5L dH2O) 
Weight  
(for 5L) 
Sodium chloride   NaCl Sigma Aldrich  S7653 118.41 34.6g 
Glucose   C6H12O6 Sigma Aldrich  G0350500 11.65 10.5g 
Sodium 
bicarbonate 
NaHCO3 Sigma Aldrich  S5761 25.00 10.5g 
Potassium 
chloride 
KCl Sigma Aldrich  P9333 4.56 1.7g 
Magnesium 
sulphate 
MgSO4 Sigma Aldrich  M7506 2.41 1.45g 
Potassium 
dihydrogen 
orthophosphate 
KH2PO4 Sigma Aldrich  RES20760-A7 1.18 0.8g 
Calcium 
chloride 
CaCl2 Sigma Aldrich  21115 1900 9.5mL (1M) 
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DRUGS 
The drugs used within this project are listed in the table below. Stock solutions were made up in 
dH2O where possible, or in DMSO (Sigma Aldrich), and diluted in either Krebs solution or dH2O. 
Where appropriate, a vehicle control was used to account for any effects of the solvent. 
Concentrations of each pharmacological agent used within specific experiments are described 
in the corresponding chapters. 
Table 2.2: Drug compounds, mechanism of action and suppliers 
Compound 
Name 
Compound 
Formula 
Main Action Supplier Catalogue 
Number 
α,β-
Methyleneadeno
sine 5’-
triphosphate  
C11H18N5O12P3 P2X-purinergic agonist Sigma 
Aldrich 
M6517 
Adenosine 5’-
triphosphate 
salt 
C10H14N5Na2O13
P3 
Purinergic agonist Sigma 
Aldrich 
A2383 
Carbachol NH2COOOCH2
CH2N(Cl)(CH3)3 
Muscarinic agonist Sigma 
Aldrich 
C4382 
Isoprenaline HCl C11H17NO3-HCl β-adrenoceptor agonist Sigma 
Aldrich 
I5627 
Atropine C17H23NO3 Competitive muscarinic  
antagonist 
Sigma 
Aldrich 
A0132 
N-Nitro-L-
arginine (L-NNA) 
C6H13N5O4 Inhibitor of nitric oxide 
synthase 
Sigma 
Aldrich 
N5501 
S-(4-
Nitrobenzyl)-6-
thioinosine  
(NBMPR) 
C17H17N506S Inhibitor of equilibrative 
nucleoside transporters  
(ENTs) 
Sigma 
Aldrich 
N2255 
Gemcitabine 
HCl 
C9H11F2N3O4-
HCl 
Chemotherapeutic Sapphire 
BioScience 
A10423 
Mitomycin C C15H18N4O5 Chemotherapeutic Sapphire 
BioScience 
A11435 
Tetrodotoxin C11H17N3O8 Selective blocker of Na
+ 
channels 
Sigma 
Aldrich 
T8024 
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2.3 HISTOLOGY 
Histological chemistry was performed on various tissues including porcine and murine bladder 
tissues.  Porcine tissues were dissected to an approximate size of 5mm long, 3mm wide and 
3mm thick.  Murine bladders were approximately 1-2mm thick.  All histology processes were 
performed according to the following protocol.  
1. Fixing: Tissues were placed into neutral buffered formalin (10%) and left for 24 hours at 
4°C.  For whole mouse bladder a catheter was secured in the urethra and formalin was 
injected into the bladder to gently distend the bladder and then placed in formalin to fix 
the tissue in a distended state.  
2. Processing: The tissues were removed from the formalin and placed in the following 
solutions: 
a. 50% ethanol (15 minutes for murine tissue, 30 minutes for porcine tissue), 
b. 75% ethanol (15 minutes for murine tissue, 30 minutes for porcine tissue),  
c. 90% ethanol (15 minutes for murine tissue, 30 minutes for porcine tissue),  
d. 100% ethanol (15 minutes for murine tissue, 30 minutes for porcine tissue),  
e. 1:1 xylene:ethanol (7 minutes for murine tissue, 15 minutes for porcine tissue),  
f. 100% xylene (7 minutes for murine tissue, 15 minutes for porcine tissue),  
g. Fresh 100% xylene (7 minutes for murine tissue, 15 minutes for porcine tissue),  
h. 1:1 xylene:paraplast at 57°C (15 minutes for murine tissue, 30 minutes for 
porcine tissue), 
i. Liquid paraplast at 57°C (15 minutes for murine tissue, 30 minutes for porcine 
tissue),  
j. Change paraplast at 57°C (15 minutes for murine tissue, 30 minutes for porcine 
tissue). 
Tissues were positioned in aluminium moulds and completely covered with liquid 
paraplast.  A plastic cassette was placed in the paraplast and left for 12 hours to set.  
3. Mounting: Tissue sections were cut at 4-5µm using an Accu-Cut
®
 SRM™ 200 Rotary 
Microtome (Sakura Finetek Europe B.V., The Netherlands).  Sections were placed in a 
61 
 
small water bath at 48°C and then gently positioned on a glass microscope slide and 
left until dry.  
4. Rehydrating: Slides were placed in a heat box for 5-10 minutes and then placed in the 
following solutions:  
a. 100% xylene for 1 minute, 
b. Fresh 100% xylene for 1 minute, 
c. 1:1 ethanol:xylene for 3 minutes, 
d. 100% ethanol for 3 minutes, 
e. 90% ethanol for 3 minutes, 
f. 75% ethanol for 3 minutes, 
g. 50% ethanol for 3 minutes, and 
h. Distilled water for 3 minutes. 
5. Staining: Slides were placed in the following solutions:  
a. Haematoxylin stain (mayers) for 4 minutes 
b. Distilled water for 30 seconds 
c. Acid alcohol (0.5 or 1%) for 30 seconds 
d. Distilled water for 30 seconds 
e. Scott’s Blue for 30 seconds 
f. Distilled water for 30 seconds 
g. Eosin stain for 2 minutes 
h. Distilled water for 30 seconds 
6. Dehydrating: Stained slides were then placed in the following solutions:  
a. 50% ethanol for 3 minutes 
b. 75% ethanol for 3 minutes 
c. 90% ethanol for 3 minutes 
d. 100 % ethanol for 3 minutes 
e. Fresh 100% xylene for 1 minute 
7. Visualisation: Slides were allowed to dry and then visualised under a microscope 
(Infinity 2, Olympus, Tokyo).  Photographs were taken using an Infinity 2 miscroscope 
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camera (Olympus, Japan) attached to a computer using Infinity Capture s oftware 
(version 5.0.2 Lumenera Corporation, Canada). 
8. Urothelial thickness was measured using Image J software and were compared 
between treated and control to evaluate changes. At least seven urothelial 
measurements were obtained from each bladder section, using a blinded analysis. 
All histology solutions and chemicals were Fronine Pathology products obtained from Thermo 
Fisher Scientific, Taren Point, Australia.  
Further methodology specific to studies will be described in the methods sections of the 
corresponding chapters. 
2.4 ANALYSIS  
Various statistical tests were used where appropriate and details of analysis are stated in the 
relevant sections of each Chapter.   Statistical differences were considered significant at p<0.05.  
All graphical analyses used in this thesis were performed using GraphPad Prism (Version 5.04 
for Windows, Graph Pad Software, San Diego, USA) and all statistical analyses were performed 
using GraphPad InStat (version 3.06 for Windows, GraphPad Software, San Diego, USA). 
Specific tests used are described in each of the experimental chapters.  
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CHAPTER 3: 
EFFECTS OF GEMCITABINE ON CULTURED HUMAN 
UROTHELIAL CELLS 
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3.1 INTRODUCTION 
As discussed in Chapter 1, the urothelium plays a significant role in coordinating bladd er 
function. While the urothelium was previously thought to act solely as a distensible barrier 
protecting underlying tissues from the contents of urine, recent studies have suggested a role in 
sensory responses to mechanical and chemical stimuli (Birder, 2011). The urothelium responds 
to stretch during bladder filling by releasing a number of mediators that influence sensory 
mechanisms and contraction of the underlying detrusor muscle, including ATP, acetylcholine 
and prostaglandins (Ferguson et al., 1997, Hanna-Mitchell et al., 2007, Tanaka et al., 2011). 
Given that this layer is in immediate contact with cytotoxic drugs during intravesical treatment, 
urothelial function is likely affected following treatment and it is the focus of this chapter.  
 
GEMCITABINE PENETRATION THROUGH THE UROTHELIUM 
Intravesical gemcitabine treatment for bladder cancer is localised, in that it sits in direct contact 
with the urothelium and the tumour. As discussed previously, the urothelium is protected from 
bacteria, proteins and other small molecules through the presence of the GAG layer (Parsons et 
al., 1979, Birder, 2011). The low molecular weight of gemcitabine (299D) with comparison to 
other chemotherapeutics like mitomycin C (389D) and doxorubicin (589D) may enable 
penetration of the urothelium, but is high enough to prevent significant systemic absorption 
(Gontero and Frea, 2006). The systemic elimination half-li fe of gemcitabine is extremely short, 
within the range of 10-30 minutes. Gemcitabine is extensively deaminated systemically by 
cytidine deaminase in the liver, kidney and plama to the uracil metabolite 2’,2’ -
diflurodeoxyuridine (dFdU), which has significantly lower cytotoxicity profiles than its parent 
compound (Plunkett et al., 1995).  
One of the cytotoxic mechanisms of gemcitabine on cancer cells is the induction of enhanced 
reactive oxygen species (ROS) formation (Donadelli et al., 2011). ROS are produced as by -
products of cellular metabolism principally from the mitochondria, but also in response to 
cytokines, noxious stimuli and bacterial invasion (Ray et al., 2012). Paradoxically, ROS play a 
role in normal cellular proli feration, can promote carcinogensis due to oxidative stress, and can 
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also induce apoptosis of tumour cells (Laurent et al., 2005). Elevated ROS have been detected 
in almost all cancers, and represent a specific susceptibility of malignant cells to be selectively 
targeted by pro-oxidant drugs (Laurent et al., 2005, Szatrowski and Nathan, 1991). The 
enhanced production of ROS can inflict damage to a range of cellular components, including 
DNA strand breaks or crosslinks, protein damage to amino acid side chains and peptide 
cleavage and damage to lipid membranes (Halliwell, 2006, Randerath et al., 1996, Stadtman, 
1990). Furthermore, it is well reported that excessive production of cellular ROS can induce cell 
death through apoptosis or necrosis (Sastre et al., 2000, Pelicano et al., 2003, Higuchi, 2003).  
Donadelli et al. (2007) found that growth inhibition of pancreatic adenocarcinoma cell s by 
gemcitabine was dependent on ROS production, as there was significantly reduced growth 
inhibition with the addition of the free radical scavenger N-acetyl-L-cysteine. Additionally, a 
positive correlation was observed between intrinsic cellular ROS stress and sensitivity to 
cytotoxicity of gemcitabine in cancer cell lines (Donadelli et al., 2007). Furthermore, it was 
recently shown by Dalla Pozza et al. (2012) that gemcitabine-induced apoptosis of bladder 
cancer cell line RT112 is correlated with increased mitochondrial superoxide production, further 
enhanced by the inhibition of mitochondrial antioxidant properties.  
Both pre-clinical and clinical studies have determined that intravesical gemcitabine treatment 
limits bladder specific toxicity as well as systemic absorption. A study investigating weekly 
intravesical administration of gemcitabine in rabbits at 25mg/kg and 50mg/kg doses found no 
significant systemic drug absorption or organ-specific toxicity (Matera et al., 2004). Clinical 
investigations treating patients with a range of 500-2000mg/50mL have all reported very little to 
no gemcitabine present within the plasma, with small concentrations of the deaminated  
metabolite dFdU (0.5-2.7µmol/L) (Dalbagni et al., 2006, De Berardinis et al., 2004, Laufer et al., 
2003). The penetration of chemotherapeutics doxorubicin and mitomycin C through the bladder 
urothelium is reduced 32- and 35-fold respectively from the intravesical dosage (Wientjes et al., 
1993, Wientjes et al., 1996). The bladder pharmacokinetics of intravesical gemcitabine have not 
yet been elucidated, and for this reason, a range of concentrations of gemcitabine was used for 
treatment on urothelial cells within this study. As superficial bladder cancer has a high 
propensity to return and progress to invasive tumours, penetration to the sub -layers of the 
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urothelium is a desirable attribute of chemotherapies. Adjunct therapies such as localised 
hyperthermia (heat) in combination with chemotherapy have benn suggested to increase 
cellular membrane permeability, alter blood perfusion and enhance the cytotoxicity of 
chemotherapeutics (Lammers et al., 2011).  
 
ADJUNCT THERAPY – HYPERTHERMIA TREATMENT 
The therapeutic benefit of local hyperthermia (temperatures above 37C) on cancer cells was 
first recognised in 1952 (Barth et al.). Selawry et al (1957) observed that temporary interruption 
to the mitotic cycle occurred in cells incubated between 39 -40C, while irreversible heat damage 
occurred at temperatures above 40.5C (Rampersaud et al., 2010). Localised hyperthermia 
therapy for neoplasms has since evolved, and is currently used in conjunction with other 
therapies, such as chemotherapeutics. One of the challenges in hyperthermia treatment is its 
ability to effectively deliver localised treatment. The location and structure of the bladder and its 
constitute cells, and the improved chemosensitivity of urothelial carcinomas with heat makes it 
an ideal organ for chemohyperthermia treatment.  
 
EFFECTS OF HYPERTHERMIA ON THE CANCER CELL  
Tumour cells respond to hyperthermia treatment in multiple ways, promoting tumour necrosis 
and apoptosis. The effects of hyperthermia on cancer cells are multi factorial, including cytotox ic 
damage, injury to the surrounding vasculature and an increase in the immune response and 
thermosensitivity when used in conjunction with chemotherapeutics (Rampersaud et al., 2010). 
While there is no intrinsic difference in thermal sensitivity between n ormal and tumour cells, in 
vivo models have found temperatures between 40-44C to exhibit a tumour cell killing effect 
(van der Zee, 2002). In comparison, most normal body tissues, including the bladder, are 
undamaged by one-hour hyperthermia treatment up to temperatures of 44C (van der Zee, 
2002, Fajardo, 1984).  
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CYTOTOXIC EFFECTS  
Hyperthermia causes cytotoxicity in cancer cells in phases. Direct heat exposure causes initial 
reversible metabolic arrest, followed by irreversible cytotoxicity caused by pr otein denaturation 
and cell membrane disruption (Dewey et al., 1971, Westra and Dewey, 1971, Rampersaud et 
al., 2010). Additionally, at temperatures above 42C, RNA and DNA synthesis are diminished, 
the latter remaining inhibited after treatment due to the heat-induced unfolding of protein 
segments, rendering them insoluble (Hildebrandt et al., 2002). 
 
VASCULAR DAMAGE 
Localised hyperthermia significantly alters blood flow through the vasculature surrounding 
tumours, resulting in endothelial swelling, increased plasma in the interstitium, microthrombosis 
and change in viscosity of blood cell membranes (Hildebrandt et al., 2002, Song, 1984, Vaupel 
et al., 1989). Tumour vasculature is chaotic, often resulting in poorly perfused and low pH areas 
that exhibit increased sensitivity to hyperthermia (Reinhold and Endrich, 1986). The 
morphological changes caused by hyperthermia in the surrounding vessels promote reduction 
in oxygen and nutrient supply, as well as acidosis within the tumour thus leading to increased 
apoptotic activity.  
 
IMMUNE RESPONSE 
Hyperthermia is a natural response of the body to combat a wide range of infectious and 
immunologic attacks. The principle mediator of the immune effects seen post -hyperthermia 
treatment is due to the heat -induced expression of heat shock proteins (Rampersaud et al., 
2010). HSPs are released by heat from both normal and cancerous cells, protecting cellular 
proteins by binding to exposed hydrophobic segments. As heat shock proteins released from 
dying cancerous cells contain tumour antigens, the immune system produces a surplus of CD8+ 
T-cells, which in turn have an anti-tumour response (Binder and Srivastava, 2005). Total body 
hyperthermia upregulates the production of natural killer cells. These cells act on natural killer 
activating ligands MICA (MHC-class-I-chain related gene A), expressed on tumour cells, which 
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leads to improved natural killer-mediated anti -tumour properties (Skitzki et al., 2009, Dayanc et 
al., 2008, Ostberg et al., 2007).   
 
CHEMOHYPERTHERMIA TREATMENT 
When used in conjunction to chemotherapy, hyperthermia treatment enhances the cytotoxicity 
of many commonly used anti-neoplastic drugs, commonly termed thermal chemosensitization. 
There are several hypothesized reasons for the improved efficacy of neoplastic therapies when 
combined with heat. Firstly, due to the increased cellular membrane permeability and altered 
blood perfusion the chemotherapeutic agent more readily penetrates the tumour (Lammers et 
al., 2011). As discussed previously, hyperthermia therapy is directly cytotoxic, alters cell 
morphology and induces cell apoptosis. Finally, it has been shown that hyperthermia improves 
the cytotoxicity and consequent efficacy of mitomycin C, hypothesized to be the case for all  
chemotherapeutics (Paroni et al., 2001, Lammers et al., 2011).   
A review of 22 studies aimed to assess the efficacy of chemohyperthermia (Lammers et al., 
2011). The published data suggests a 59% reduction in recurrence of NMIBC and an improved 
bladder preservation profile in combined mitomycin C and hyperthermia therapy compared to 
mitomycin C alone. Local toxicity was reported to be higher in combined hyperthermia and 
mitomycin C therapy, however there was no major complications and patients appeared to self-
heal (Colombo et al., 1996, Colombo et al., 2001). Hyperthermia (at 43
o
C) combined with 
mitomycin C, epirubicin, apaziquone (an analogue of mitomycin C) and gemcitabine have all  
shown synergism in decreasing cell proli feration in transitional cell carcinoma lines RT4, RT112, 
253J and T24 (van der Heijden et al., 2005).  
Apart from the above reported studies, there is limited published data on the efficacy, 
recurrence and progression of NMIBC treated with chemotherapy and hyperthermia treatment, 
and none that could be found involving gemcitabine. Further investigation into the cellular 
changes of combined chemotherapy and hyperthermia treatment may elucidate the benefits of 
this treatment for patients.  
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PATHOLOGICAL UROTHELIAL FUNCTIONING 
Extensive studies have focused on enhancing the toxicity of int ravesical chemotherapies, with 
little regard to the effects of these treatments on the normal function of the bladder. As 
previously discussed, intravesical gemcitabine t reatment for bladder cancer is associated with 
local side effects including chemical cystitis, dysuria and increased frequency and urgency of 
urination in a significant patient population. Little is known about the mechanism causing the 
reported urological side effects following intravesical treatment with this agent.  
Changes in urothelial mediator release from the bladder have been reported in many 
pathological conditions of the bladder with symptoms similar to those reported by patients 
undergoing intravesical gemcitabine treatment. Significant increases in ATP release from the 
urothelium have been found in patients with painful bladder syndrome and with both idiopathic 
and neurogenic detrusor overactivity (Kumar et al., 2010, Kumar et al., 2007). In a feline 
interstitial cystitis model, the upregulated ATP release observed from the urothelium was 
partially mediated through a calcium-dependent vesicular exocytotic process (Birder et al., 
2003). As the IP3 pathway mediates in part the int racellular calcium component, this suggests a 
putative role of the muscarinic receptors of the bladder in this pathological condition. Urine 
levels of prostaglandin E2 are increased in patients with overactive bladder syndrome (Kim et al., 
2006).  Urothelial prostaglandin E2 has also been suggested to modulate afferent nerve activity 
during urinary bladder inflammation via the EP1 receptor (Ikeda et al., 2006).  
Interstitial cystitis is characterised by suprapubic pain and irritative voiding symptoms, which are 
similar to those reported by patients undergoing intravesical chemotherapy. The pathological 
process of interstitial cystitis is multifactorial, however it is often characterised by an 
inflammatory response and an increased release of mediators including histamines, substance 
P and cytokines (Theoharides et al., 2001, Sant, 2002). 
No studies to date have investigated the effect of gemcitabine treatment alone or in combination 
with increased temperature on urothelial mediator release. A recent investigation of the first -line 
chemotherapy for NMIBC, mitomycin C, found enhanced release of the urothelial mediator 
prostaglandin E2 and the pro-inflammatory cytokine IL-8 after 24 hours recovery from treatment, 
with levels still elevated with 1- and 2-weeks of recovery (Kang et al., 2015). Furthermore, 
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doxorubicin treatment also induced release of the cytokines interleukin -8 and -1β 24hours after 
treatment and enhanced stimulated (stretched) release of prostaglandin E2 (Kang et al., 2013a).  
 
CELL CULTURE AS A MODEL OF UROTHELIAL FUNCTION 
Urothelial, myofibroblast and detrusor muscle cells of the bladder have b een shown to release 
mediators such as ATP with stretch (Cheng et al., 2011). Therefore, to assess urothelial cell 
specific effects, urothelial cell cultures were used as an in vitro model for investigating the 
effects of gemcitabine on the urothelium of the bladder. To investigate the cytotoxicity of 
gemcitabine on the normal cells of the bladder, malignant and non -malignant urothelial cells 
were treated with this drug. For comparative purposes, this protocol was repeated with 
mitomycin C, the first-line intravesical chemotherapy for superficial bladder cancer (Witjes and 
Hendricksen, 2008). The UROtsa cell line was used as the non-malignant urothelial cell line, 
with the RT4 and T24 malignant bladder cell lines used as models of superficial and invasive 
cancer respectively. Further descriptions of these cell lines will be outlined within the Materials 
and Methods section. 
Mechanisms of gemcitabine cytotoxicity were examined between the malignant and non-
malignant urothelial cell lines. The metabolism and mechanism of gemcitabine cytotoxicity has 
been reviewed within Chapter 1.0. Briefly, gemcitabine is up-taken into the cells via nucleoside 
transporters, with the human equilabrative nucleoside transporter (hENT1) having the greatest 
affinity for gemcitabine (Mackey et al., 1998). The int racellular effects of gemcitabine are 
multifactorial, including being incorporated into DNA and RNA, and the inhibition of 
ribonucleotide reductase and CTP -synthetase (Mini et al., 2006). The production of reactive 
oxygen species (ROS) has also been linked to the cytotoxicity of gemcitabine (Donadelli et al., 
2011), and this was measured in this study.  
RT4 cells have been shown to release ATP during basal conditions, enhanced with hypotonic 
simulation (McDermott et al., 2012, Mansfield and Hughes, 2014a, Kang et al., 2013a). These 
cells also release measureable levels of acetylcholine and prostaglandin E 2 during basal and 
stretched conditions (Kang et al., 2013a, McDermott et al., 2012). However, as these cells are 
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derived from malignant urothelial cells, the present study used the UROtsa cell line, cultured 
from normal human urothelial cells.  
UROtsa cells have been shown to release ATP under basal and osmotic -stretch conditions, 
using isotonic and hypotonic solutions (Ochodnický et al., 2013, Mansfield and Hughes, 2014b). 
However, to the best of my knowledge, there have been no reports of basal and stimulated 
acetylcholine or prostaglandin E2 release from UROtsa cells. 
Rossi et al. (2001) proposed the UROtsa cell line as a useful cell culture model of human 
urothelium, reporting that these cells grow as an unstratified, undifferentiated monolayer with 
identical expression of methallothionien and heat shock gene expression to that of the basal cell  
layer of the urothelium. Furthermore, muscarinic receptor mRNA expression in the UROtsa cell 
line parallels expression in human urothelium (Tyagi et al., 2006), and it has recently been 
shown that UROtsa cells express functional purinergic receptors (Bakali et al., 2014). 
Additionally, mRNA for factors involved in the production or action of prostaglandins including 
COX-2, PTGES-1, EP2, EP4 and PGDH are expressed by UROtsa cells (Taylor et al., 2009).  
The ability of UROtsa cells to imitate the release of mediators from the stretched urothelium was 
investigated in the present study, before examining the effect of gemcitabine treatment alone 
and in combination with hyperthermia on these mediators as a model to investigate the 
urothelial cell-specific effects.  
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3.2 AIMS  
The aim of the present study was to investigate the cytotoxicity of gemcitabine and its effects on 
urothelial function. The specific aims of this experiment were separated into three arms:  
 
AIM 1: INVESTIGATION OF THE CYTOTOXICITY OF GEMCITABINE 
o To determine the potency of gemcitabine on non-malignant vs malignant urothelial 
cells and compare to the current standard chemotherapeutic mitomycin  
o To investigate the effect of combined gemcitabine or mitomycin C therapy with 
hyperthermia treatment on cytotoxicity 
AIM 2: INVESTIGATION OF THE MECHANISMS OF GEMCITABINE TOXICITY 
o To determine if reactive oxygen species production is altered in non-malignant vs  
malignant urothelial cells after gemcitabine treatment 
o To assess the contribution of the human equilabrative nucleoside transporter 1 
(hENT1) in gemcitabine toxicity 
AIM 3: INVESTIGATION OF THE MECHANISMS OF ADVERSE EFFECTS AFTER IN VITRO 
GEMCITABINE TREATMENT 
o To examine the ability of UROtsa cells to release the urothelial mediators ATP, 
acetylcholine and prostaglandin E2 under basal and stretched conditions 
o To assess the immediate and late effects of gemcitabine treatment alone and in 
combination with hyperthermia on the release of the aforementioned mediators  
o To determine the effects of gemcitabine treatment alone and in combin ation with 
hyperthermia on inflammatory cytokine release 
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3.3 MATERIALS AND METHODS 
CELL CULTURE 
Three cell lines were used within this study. The bladder cancer cell lines RT4 and T24 were 
obtained from the European Collection of Cell Cultures, while the non-malignant human 
urothelial cell line UROtsa was received as a gift from Professor Scott Garrett (University of 
North Dakota). All cells were stored in freeze medium containing DMSO (10%) in liquid nit rogen 
until required. 
 
RT4 CELLS 
RT4 cells are derived from a recurring transitional cell papilloma tumour of the human urinary 
bladder and are widely used as a model of superficial bladder cancer.  Culturing of these cells 
produces consistent morphology and chromosome patterns, and xenografts of RT4 cells into 
both mouse and hamster specimens have been shown to produce tumours of similar 
morphology to those of original biopsies (Masters et al., 1986, Rigby and Franks, 1970).  
RT4 cells were cultured in McCoys 5A culture medium (Invitrogen, Victoria, Australia) containing 
L-glutamine and phenol red, supplemented with 10% foetal bovine serum (FBS), and 500 U/mL 
penicillin-streptomycin (Invitrogen, Victoria, Australia), as described previously (McDermott et al., 
2012). Cells were maintained at 37
o
C in a 5% CO2 incubator, passaged when 80-90% confluent, 
with a doubling time of approximately 35 hours (Dubeau and Jones, 1987). The subculture 
method is described later in this section.  
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T24 CELLS 
T24 cells are a derivative of a human urinary bladder transitional cell carcinoma as shown in 
Figure 3.1 and exhibit characteristics of high grade, invasive tumours, including spreading and 
separating during cell motility (Kabaso et al., 2011). T24 cell growth in tissue culture has been 
characterised by a multi -layered, mixed epithelial to fibroblastoid morphology, and the presence 
of tumour specific antigens (TSA) (Bubenik et al., 1973). This cell line was grown in the same 
culture medium used for RT4 cells, described previously.  
 
 
  
A B 
Figure 3.1: T24 cells at A) approximate 50% confluence and B) approximate 90% confluence. Pictures from the 
American Type Culture Collection database. 
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UROTSA CELLS 
The UROtsa cell line is an immortalized cell line from cultures of the normal human urothelium 
from the proximal ureter using the SV40 T-antigen (Petzoldt et al., 1995). These cells are 
considered non-tumorigenic due to their inability to form colonies in soft agar and nude mice,  
growing as a contact-inhibited monolayer in an undifferentiated form consistent with the basal 
cells of the human urothelium, as seen in Figure 3.2 (Somji et al., 2008, Petzoldt et al., 1995). 
UROtsa cells were grown in low-glucose Dulbecco’s modified Eagle’s medium (DMEM - Sigma-
Aldrich, NSW, Australia) supplemented with 5% FBS, 1% glucose and 1% penicillin-
streptomycin (Invit rogen, Victoria, Australia). For experiments, UROtsa cells were used and 
grown in serum-supplemented and serum-free media, for models of proli ferative and non-
proli ferative urothelial cells respectively. Incubation of UROtsa cells in serum-free media leave 
the cells in a non-proli ferative state while UROtsas grown in serum -supplemented media are 
used as a model of undifferentiated, proli ferative urothelial cells that grow as a single cell 
monolayer (Rossi et al., 2001). In the human bladder, the normal urothelium is mitotically 
quiescent with a slow rate of cell turnover and a low proportion of cells in the cell cycle 
(Marceau, 1990). Therefore, to best mimic this condition, consequent experiments examining 
urothelial functioning used UROtsas in the non-proliferative state. 
However, in response to tissue damage, the urothelium has a high capacity for proliferation 
(Limas, 1993). It has been shown that growth of UROtsa cells in serum-free medium consisting 
of a mixture of DMEM and Ham’s F12, supplemented with selenium, insulin, transferrin, 
hydrocortisone, triiodothyronine and epidermal growth factor results in the differentiation of 
these cells to form a multilayered, stratified cell cultures. These cells display characteristics 
found in differentiated intermediate urothelial cells, including desmosomes and gap junctions 
(Rossi et al., 2001, Lewis, 2000, Jost et al., 1989). Therefore, UROtsa cells are an excellent 
model of the human urothelial cells, as they are non-proli ferative in unsupplemented media, but 
have the capacity to rapidly differentiate. 
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Figure 3.2: UROtsa cell culture at stages of confluency (10X magnification). A) UROts as at approximately 50% 
confluency 1 day after subculture, B) confluent UROtsa cells maintained in serum-containing media 7-days 
after subculture, C) UROtsa cells 14-days after subculture remaining as a monolayer (Rossi et al., 2001) 
 
CELL SUBCULTURE  
The subculture procedure was standard across all cell lines, with the exception of culture media 
used. When cells were 80-90% confluent, media was removed and cells were washed with 
approximately 6mL of 1X phosphate buffered solution (PBS, Life -Technologies, Victoria, 
Australia). Two mL of trypsin-EDTA (Life-Technologies, Victoria, Australia) was added to the 
cells and cultures incubated at 37
o
C in a 5% CO2 incubator until the cells detached. Six mL of 
the respective culture media for the cell line undergoing passage was added and the resulting 
cell suspension was transferred to a 15mL centrifuge tube and cells were spun in a centrifuge at 
800rpm for 3 minutes. The supernatant solution was discarded and cells were resuspended in 
6mL of fresh culture media for passaging. Typical cell splits were 1:3 for UROtsa and RT4 cells, 
and 1:4 for T24 cells. Cell viability was assessed by trypan blue exclusion using Countess  
Automated Cell Counter (C10227 Invitrogen, Victoria, Australia) and only cultures with 
viability >95% were used for experiments. A final volume of 20mL was added to the T75 flasks 
after passage.  
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AIM 1: INVESTIGATION OF CYTOTOXICITY OF GEMCITABINE 
CELL SEEDING DENSITIES 
Cells were seeded in 24 or 96-well microtiter plates at a density determined during initial 
optimisation experiments. Table 3.1 describes the cell densities plated for the various 
experiments. Cells were left to attach for 24 hours in their respective media before treatment 
with gemcitabine or mitomycin C and consequent experiments.  
Table 3.1: Typical seeding densities used for experiments for each cell line, NA – not applicable 
Cell Line Seeding Density in 
96 well plates 
Seeding density in 
24 well plates 
Seeding Density in 
T25 flasks 
Non-Proliferative 
UROtsa 
2.5 x 10
4
  per well 1.5 x 10
5
 per well 2 x 10
6
 per flask 
Proliferative UROtsa 1.0 x 10
4
  per well NA NA 
RT4 1.0 x 10
4
  per well NA NA 
T24 0.5 x 10
4
  per well NA NA 
 
GEMCITABINE TREATMENT 
Cells were treated with increasing concentrations of gemcitabine from 4ng/mL (15nM) up to the 
maximum clinical dose of 40mg/mL (150mM). After incubation at 37
o
C or 42
o
C for 60 minutes 
(clinical duration of treatment), cells were rinsed twice with sterile PBS before aspiration and 
measurement of viability using a resazurin reduction assay. 
 
MITOMYCIN C  TREATMENT 
Cells were treated with increasing concentrations of mitomycin C from 20ng/mL (60nM) up to 
the maximum clinical dose of 2mg/mL (6mM). After incubation at 37
o
C or 42
o
C for 120 minutes 
(clinical duration of treatment), cells were rinsed twice with sterile PBS before aspiration and 
measurement of viability using a resazurin reduction assay. 
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RESAZURIN VIABILITY ASSAY 
The effects of the treatments were measured using the resazurin reduction assay, a commonly 
used assay for cell proli feration, viability and cytotoxicity without causing damage to the cells 
(O'Brien et al., 2000). Blue resazurin is reduced intracelluarly by viable, metabolically active 
cells to resorufin and dihydroresorufin. Resorufin is pink and highly fluorescent, with 
fluorescence increasing proportionally to the number of cells present. A significant positive 
correlation between live cell number and resorufin fluorescence was determined, as shown in 
Figure 3.3 (p<0.01).  
After treatment and washing, 100µL of 44uM resazurin solution made up in the respective 
culture media was incubated at 37°C for approximately 2 hours or until control wells had 
developed in colour. This process was repeated 24, 48 and 72 hours after treatment, replacing 
the removed resofurin product with 200µL of the respective culture media. Fluorescence of the 
reduced resofurin product was then measured using a Modulus Microplate reader (Ex. 530/ Em. 
590nm). All experiments were performed in triplicate and repeated at least six times.  
 
Figure 3.3: Resazurin in a 96 well plate. (A) Cell number increasing from left to right, colour indicative of 
resorufin from reduced resazurin and (B) Pearson correlation analysis of the relationship between live cell 
number and corresponding resorufin   
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AIM 2: MECHANISM OF GEMCITABINE TOXICITY 
 
GEMCITABINE AND NBMPR  TREATMENT 
Cell viability was also assessed after treatment of urothelial cells with gemcitabine in the 
presence of 1µM NBMPR (Tocris, NSW, Australia), an inhibitor of the hENT1 equilibrative 
nucleoside transporters. Cells were seeded in 96-well plates and left to attach for 24 hours as 
previously described. Cells were incubated with gemcitabine and 1µM NBMPR at 37
o
C for 60 
minutes, rinsed twice with sterile PBS before aspiration and replacement with culture medium 
and incubated for up to 72 hours. Measurement of viability used a resazurin reduction assay as 
described previously. 
 
REACTIVE OXYGEN SPECIES PRODUCTION 
The production of reactive oxygen species (ROS) was measured using the 2’, 7’ -
dichlorofluorescin diacetate assay (DCFH-DA) (Sigma-Aldrich, Australia). This assay is based 
on the intracellular oxidation and consequent de-esterification of the non-fluorescent DCFH-DA 
to the highly fluorescent 2’, 7’-dichlorofluorescein (DCF). The cell lines were seeded in 96-well 
microtiter plates as previously described. Cells were treated with increasing concentrations of 
gemcitabine at 37
o
C for 1 hour, before being washed with PBS and incubated for a further 24, 
48 or 72 hours in their respective culture media. Cells were incubated with 10µM DCFH-DA 
solution, protected from light for 40 minutes. The production of ROS was quantified using a 
Modulus Microplate reader (Ex. 530/ Em. 590nm). DCF fluorescence was normalized to controls 
using corresponding resazurin reduction data.  
 
  
83 
 
AIM 3: MECHANISMS OF ADVERSE EFFECTS AFTER INTRAVESICAL GEMCITABINE 
TREATMENT 
TIME COURSE MEDIATOR RELEASE: OPTIMISATION EXPERIMENTS 
UROtsa cells cultured in serum-free media were used for all urothelial mediator release studies. 
Twenty-four well plates were seeded at a density of 1.2 x 10
5
 cells per well and incubated in 
serum-free media overnight. To determine the optimal incubation time of mediator release from 
UROtsa cells with isotonic and hypotonic solutions, three time points (5, 10 and 15 minutes) 
were tested and samples analysed.  
Cells were washed twice with PBS and replaced with 200µL isotonic solution (Table 3.2) for 15 
minutes. This solution was replaced with 150µL isotonic solution and incubated for 5, 10 or 15 
minutes at 37
o
C, before collection for basal mediator release. For stretch release of urothelial 
cell mediators, 150µL hypotonic solution (Table 3.2) was added to the wells and incubated for 5,  
10 or 15 minutes before being collected analysis.  
Table 3.2: Ingredients used for isotonic and hypotonic solutions. All chemicals obtained from Sigma Australia 
Isotonic Solution Hypotonic Solution 
NaCl 130mM KCl 5mM 
KCl 5mM CaCl2 1.5mM 
CaCl2 1.5mM MgCl2 1mM 
MgCl2 1mM NaHEPES 25mM 
NaHEPES 25mM BSA (0.1%) 1mg/mL 
BSA (0.1%) 1mg/mL Glucose 5mM 
Glucose 5mM  
. 
Mediators were measured using commercially available ATP, acetylcholine and prostaglandin 
E2 kits as described in Section 2.0. 
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UROtsa cells were found to release ATP, acetylcholine and prostaglandin E2 both under basal 
and hypotonic-stimulated conditions (Figure 3.4). Stimulated release of ATP was significantly 
higher (p<0.001) than basal release at all time-points tested, decreasing in a time dependent 
manner (Figure 3.4A). Urothelial cells released acetylcholine at both basal and stimul ated 
conditions (Figure 3.4B); however there was a significant increase with stretch only in the 10 
(p<0.01) and 15 minute (p<0.05) incubation groups. Prostaglandin E 2 was released from 
UROtsa cells basally and with stretch, significantly after incubation in hypotonic solution for 5, 
10 (p<0.001) and 15 minutes (p<0.01). The optimum time for release was determined to be 
after a 10 minute incubation period, which yielded significant increased stimulated release from 
basal of the urothelial mediators ATP, acetylcholine and prostaglandin E2. 
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Figure 3.4: Basal and hypo-osmotically stimulated ATP (A), acetylcholine (B) and prostaglandin E2 (C) mediator 
release from UROtsa cells after 5, 10 and 15 incubation period. Data shown as the mean ± SEM (n≥3), analysed 
by a paired two-tailed t-test (*p>0.05, **p>0.01, ***p>0.001 vs basal release). 
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UROTHELIAL MEDIATOR R ELEASE: IMMEDIATE EFFECT OF GEMCITABIN E ALONE AND 
IN COMBINATION WITH HYPERTHERMIA 
UROtsa cells were plated as previously described and incubated in unsupplemented media 
overnight. Cells were treated with gemcitabine diluted in serum-free media (0 – 4mg/mL) and 
incubated at 37
o
C or 42
o
C for 1 hour. Incubation media was aspirated and cells were washed 
twice with sterile PBS prior to the addition of 200µL isotonic solution, before removal and 
replacement with 150µL of fresh isotonic solution, incubated for a 10 minute period. Samples of 
urothelial mediator release were obtained as described above, stored frozen at -30
o
C before 
measurement using commercially available ATP, acetylcholine and prostaglandin E2 kits as 
described in Section 2.0. 
 
UROTHELIAL MEDIATOR R ELEASE: LATE (24H)  EFFECT OF GEMCITABIN E ALONE AND 
IN COMBINATION WITH HYPERTHERMIA 
UROtsa cells were plated as previously described and incubated in unsupplemented media 
overnight. Cells were treated with gemcitabine diluted in serum-free media (0 – 4mg/mL) and 
incubated at 37
o
C or 42
o
C for 1 hour. Incubation media was aspirated and cells were washed 
twice with sterile PBS before the addition of serum-free culture media. Cells were incubated for 
a further 24 hours. Prior to the addition of 200µL isotonic solution, cells were rinsed twice with 
sterile PBS solution. Samples of urothelial mediator release were obtained as described above,  
stored frozen at -30
o
C before measurement using commercially available ATP, acetylcholine 
and prostaglandin E2 kits as described in Section 2.0. 
 
INFLAMMATORY CYTOKINE ANALYSIS  
UROtsa cells were seeded into T25 flasks at densities according to Table 1, grown to 
confluence, and subsequently incubated in serum-free culture media for a further 24 hours, 
before treatment with 4mg/mL gemcitabine incubated at 37
o
C or 42
o
C for 1 hour. Cells were 
washed twice with sterile PBS and incubated for a further 24 hours in serum-free media. This 
cell free media was collected and the presence of inflammatory cytokines (Interleukin-1β, -6, -8, 
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-10, 12p70 and tumour necrosis factor) was analysed using a BD Cytometric Bead Array 
Human Inflammatory Cytokines Kit according to the manufacturer’s protocol. This kit uses 
beads conjugated with a specific antibody to each of the cytokines tested. A detection agent 
comprised of a mixture of phycoerythrin-conjugated antibodies provides a fluorescent signal in 
proportion to the amount of bound analyte. When the capture beads and detector reagent are 
incubated with an unknown sample containing recognized analytes, a sandwich complex is 
formed (capture bead + analyte + detection reagent). These complexes can be measured using 
flow cytometry to identify particles with fluorescence characteristics of both the bead and the 
detector.  
Standard and sample fluorescence were analysed on a BD FACS Calibur flow cytometer. The 
concentration of inflammatory cytokines measured were normalised to c ontrols using 
corresponding resazurin reduction data.  
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3.4 RESULTS 
PART A – CYTOTOXICITY OF GEMCITABINE  
CYTOTOXICITY OF GEMCITABINE WITH COMPARISON TO MITOMYCIN C 
The cytotoxicity of gemcitabine with comparison to mitomycin C was assessed in malignant and 
non-malignant urothelial cells, measured in terms of changes in cell viability immediately, 24, 48 
and 72 hours post treatment. Both gemcitabine and mitomycin C reduced viability of all cell lines 
in a time and concentration dependent manner (Figure 3.5 & 3.6). The clinical concentrations of 
40mg/mL gemcitabine and 2mg/mL mitomycin C were initially tested on all cells lines. Cell 
viability was reduced to <1% across all cell lines for both drugs (data not shown), and these 
concentrations were consequently not tested for subsequent experiments. 
The concentration of gemcitabine or mitomycin C which resulted in a 50% reduction in cell 
viability (LC50) was used to determine the relative potency of these drugs in each of the cell 
lines.  A significant time dependent decrease (p<0.001) in the LC50 was observed across all cell  
lines treated with gemcitabine or mitomycin C, with the exception of the non-proliferative 
UROtsa cells (p=0.09, Figure 3.5A, Table 3.3 & 3.4).  
The effects of gemcitabine on cell viability were significantly different between the cell lines 
measured 72 hours post treatment (p>0.001) (Figure 3.7A, Table 3.5). Cytotoxicity of 
gemcitabine was greatest in the urothelial cancer cell lines RT4 and T24, with an approximate 
11,000 and 25,000-fold greater potency respectively with comparison to the non-malignant 
UROtsa cell line in its non-proliferative state (Table 3.5).   
Mitomycin C was 10-fold more potent on the UROtsa cell lines (in both non-proliferative and 
proli ferative states) with comparison to the malignant bladder cell lines RT4 and T24 (Figure 
3.7B, Table 3.5).  In the non-malignant UROtsa cells, mitomycin C was significantly more 
cytotoxic than gemcitabine. The LC50 values for mitomycin C were significantly (p<0.001) lower 
with comparison to those for gemcitabine in both the non-proliferative [0.5(0.4-0.5)µM vs 
11.5(4.5-28.9)mM for gemcitabine] and proli ferative [0.9(0.6-1.2)µM vs 2.3(1.2-4.4)mM for 
gemcitaine] forms of UROtsa measured 72 hours post treatment (Table 3.5).  
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In comparison, gemcitabine was significantly more toxic than mitomycin C in the urothelial 
cancer cell lines RT4 and T24. The mean LC50 values in these cell lines were significantly lower 
for gemcitabine compared to mitomycin C, 1.0(0.5-2.0) µM compared to 18.2(11.2-29.6) µM 
(p<0.001) in RT4 cells and 0.4(0.3-0.6) µM compared to 5.1(3.6-7.3) µM (p<0.001) in T24 cells 
(Table 5). 
 
 
Figure 3.5: Effect of 1 hour gemcitabine treatment (A & B) or 2 hour mitomycin C treatment incubated at 37oC 
on UROtsa cell viability in their non-proliferative and proliferative states, assessed immediately, 24, 48 and 72 
hours post treatment. Data are shown as a percentage of control (mean ± SEM, n≥6), with the 72hr group 
analysed by a one-way ANOVA with Dunnett post-test (* p>0.05, ** p>0.01 vs gemcitabine control, ^^ p>0.01 vs 
mitomycin C control). 
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Figure 3.6: Effect of 1 hour gemcitabine treatment (A & B) or 2 hour mitomycin C treatment incubated at 37oC 
on RT4 and T24 cell viability assessed immediately, 24, 48 and 72 hours post treatment. Data are shown as a 
percentage of control (mean ± SEM, n≥6), with the 72hr group analysed by a one -way ANOVA with Dunnett 
post-test (** p>0.01 vs gemcitabine control, ^ ^ p>0.01 vs mitomycin C control). 
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Table 3.3: Cytotoxic effect of gemcitabine and mitomycin C on UROtsa cells in their non-proliferative and proliferative states, measured immediately, 24, 48 and 72 hours after 
treatment at 37oC using resazurin reduction assay. Data is reported as pLC50 and standard error (n=6), analysed with an F-test (multiple comparison of the non-linear curve fits). 
37
o
C Incubation 
 Non-Proliferative UROtsa Cells Proliferative UROtsa Cells 
 Gemcitabine Treatment Mitomycin C Treatment Gemcitabine Treatment Mitomycin C Treatment 
 pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  
24hrs -1.2 0.9  
p=0.09 
 
-2.7 0.03  
p<0.001 
-0.2 1.0  
p<0.001 
 
-3.2 0.1  
p<0.001 
 
48hrs -1.3 0.5 -3.4 0.02 -2.1 0.2 -3.5 0.1 
72hrs -2.0 0.2 -3.8 0.03 -2.6 0.1 -3.5 0.1 
 
Table 3.4: Cytotoxic effect of gemcitabine and mitomycin C on RT4 and T24 cells, measured immediately, 24, 48 and 72 hours after tre atment at 37oC using resazurin reduction 
assay. Data is reported as pLC50 and standard error (n=6), time dependent cell death analysed with an F-test (multiple comparison of the non-linear curve fits). Ambiguous 
regression data was excluded from analysis. 
37
o
C Incubation 
 RT4 Cells T24 Cells 
 Gemcitabine Treatment Mitomycin C Treatment Gemcitabine Treatment Mitomycin C Treatment 
 pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  
24hrs Excluded   
p<0.001 
 
-1.7 0.2  
p<0.001 
-2.9 0.4  
p<0.001 
 
-1.3 0.2  
p<0.001 
 
48hrs -4.4 0.3 -1.8 0.1 -5.3 0.2 -2.4 0.1 
72hrs -6.0 0.1 -2.2 0.1 -6.4 0.1 -2.8 0.1 
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Figure 3.7: Effect of gemcitabine (A) and mitomycin C (B) on urothelial cell viability was measured 72hours after 
pre-treatment. Data are shown as a percentage of control (mean ± SEM, n≥6), analysed with an F-test (multiple 
comparison of the non-linear curve fits). 
  
93 
 
 
Table 3.5: LC50 of urothelial cell lines 72 hours post gemcitabine and mitomycin C treatment. LC50s were 
calculated as mean values of n≥6, analysed with an F-test (multiple comparison of the non-linear curve fits). 
LC50 at 
72hours post 
treatment 
Non-
Proliferative 
UROtsa  
Proliferative 
UROtsa 
RT4 T24 Comparison 
of drug 
cytotoxicity  
between cell 
lines 
Gemcitabine 
37
o
C 
(95% CI) 
11.5 (4.5-
28.9) mM 
2.3 (1.2-4.4) 
mM 
1.0 (0.5-2.0) 
µM 
0.4 (0.3-0.6) 
µM 
P<0.001 
Mitomycin C 
37
o
C 
 (95% CI) 
0.5 (0.4-0.5) 
µM 
0.9 (0.6-1.2) 
µM 
18.2 (11.2-
29.6) µM 
5.1 (3.6-7.3) 
µM 
P<0.001 
Comparison 
of cytotoxicity 
of 
gemcitabine 
to mitomycin 
C on cell lines 
P<0.001 P<0.001 P<0.001 P<0.001  
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CYTOTOXICITY OF GEMCITABINE WITH COMPARISON TO MITOMYCIN C: EFFECTS OF 
TEMPERATURE 
The effect of increased temperature in conjunction with gemcitabine or mitomycin C treatment 
was assessed in malignant and non-malignant urothelial cells, measured immediately, 24, 48 
and 72 hours after pre-treatment at 42
o
C. Similar to treatment at 37
o
C, both gemcitabine and 
mitomycin C treatment at 42
o
C reduced viability of all cell lines in a time and concentration 
dependent manner (Figure 3.8 & 3.9).  
A significant time dependent decrease (p≤0.001) in the LC50 was observed across all cell lines 
treated with gemcitabine or mitomycin C at 42
o
C (Table 3.6 & 3.7).  
Combined hyperthermia and gemcitabine treatment had a significantly greater cytotoxic effect 
on UROtsa cells in the non-proli ferative state with comparison to gemcitabine treatment alone, 
with a significant decrease in LC50 [1.2(0.3-4.9)mM to 11.5(4.5-28.9)mM respectively, p=0.01, 
Table 3.5 & 3.8]. This effect was not observed in the other cell lines tested. The cytotoxicity of 
gemcitabine combined with hyperthermia had similar selectivity for malignant urothelial cells as 
when measured at 37
o
C by a factor greater than 1,000 to the malignant RT4 and T24 cells with 
comparison to the non-malignant UROtsa cells (p<0.001, Table 3.8, Figure 3.10A). 
Similarly, comparison of LC50 values indicated that combined hyperthermia and mitomycin C 
had a significant increased cytotoxic effect on UROtsa cells in the non -proliferative state 
[0.1(0.1-0.1) µM to 0.5(0.4-0.5)µM, p<0.001] and malignant RT4 cells with comparison to 
mitomycin C treatment alone [0.8(0.6-1.0) µM to 18.2(11.2-29.6) µM, p<0.001]. The cytotoxicity 
in T24 cells was not significantly affects (p>0.05) by this combined regime.  
The cytotoxicity of mitomycin C in combination with hyperthermia was again significantly 
different (p>0.001) between the urothelial cell lines tested, with UROtsa cells more susceptible 
to the cytotoxicity of treatment than the malignant cell lines (Table 3.8, Figure 3.10B).  
Despite the additive cell killing effect of gemcitabine in combination with hyperthermia on 
UROtsa cells, mitomycin c was significantly more toxic than gemcitabine on both the non-
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proliferative (p<0.001) and proli ferative (p<0.001) UROtsa cells when pre-incubated at 42
o
C 
(Table 3.8).  
In comparison, there was no difference between the cytotoxicity of gemcitabine or mitomycin C 
on RT4 and T24 cells when pre-incubated at 42
o
C (Table 8). 
 
 
Figure 3.8: Effect of 1 hour gemcitabine treatment (A & B) or 2 hour mitomycin C treatment incubated at 42oC 
on UROtsa cell viability in their non-proliferative and proliferative states, assessed immediately, 24, 48 and 72 
hours post treatment. Data are shown as a percentage of control (mean ± SEM, n≥6), with the 72hr group 
analysed by a one-way ANOVA with Dunnett post-test (* p>0.05, ** p>0.01 vs gemcitabine control, ^^ p>0.01 vs 
mitomycin C control).
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Figure 3.9: Effect of 1 hour gemcitabine treatment (A & B) or 2 hour mitomycin C treatment incubated at 37oC 
on RT4 and T24 cell viability assessed immediately, 24, 48 and 72 hours post treatment. Data are shown as a 
percentage of control (mean ± SEM, n≥6), with the 72hr group analysed by a one -way ANOVA with Dunnett 
post-test (* p>0.05, ** p>0.01 vs gemcitabine control, ^ ^ p>0.01 vs mitomycin C control). 
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Table 3.6: Cytotoxic effect of gemcitabine and mitomycin C on UROtsa cells in their non-proliferative and proliferative states, measured immediately, 24, 48 and 72 hours after 
treatment at 42oC. Data is reported as pLC50 and standard error (n=6), analysed with a comparison of the non-linear curve fits. 
42
o
C Incubation 
 Non-Proliferative UROtsa Cells Proliferative UROtsa Cells 
 Gemcitabine Treatment Mitomycin C Treatment Gemcitabine Treatment Mitomycin C Treatment 
 pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  
24hrs 1.1 2.1  
p<0.001 
-3.6 0.1  
p<0.001 
-1.0 0.6  
p=0.001 
 
-3.2 0.1  
p=0.001 
 
48hrs -3.1 0.4 -4.2 0.1 -2.2 0.3 -3.4 0.1 
72hrs -2.4 0.4 -4.5 0.03 -2.3 0.1 -3.5 0.1 
 
Table 3.7: Cytotoxic effect of gemcitabine and mitomycin C on RT4 and T24 cells, measured immediately, 24, 48 and 72 hours after treatment at 42oC. Data is reported as pLC50 
and standard error (n=6), analysed with a comparison of the non-linear curve fits. Ambiguous regression data was excluded from analysis. 
42
o
C Incubation 
 RT4 Cells T24 Cells 
 Gemcitabine Treatment Mitomycin C Treatment Gemcitabine Treatment Mitomycin C Treatment 
 pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  pLC50 Std. 
Error 
p value  
24hrs Excluded   
p<0.001 
-1.6 0.2  
p<0.001 
-2.9 0.5  
p<0.001 
-2.0 0.3  
p<0.001 48hrs -3.5 0.6 -3.0 0.2 -5.2 0.2 -2.6 0.2 
72hrs -6.1 0.1 -3.6 0.1 -6.2 0.1 -3.0 0.1 
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Figure 3.10: Effect of gemcitabine (A) and mitomycin C (B) on urothelial cell viability was measured 72hours 
after pre-treatment at 42oC. Data are shown as a percentage of control (mean ± SEM, n≥6), analysed with a 
multiple comparisons F-test (p<0.0001) 
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Table 3.8: LC50 of urothelial cell lines 72 hours post gemcitabine and mitomycin C treatment, incubated at 42oC. 
LC50s were calculated as mean values of n≥6, compared using an F-test. 
 
  
LC50 at 72hours 
post treatment 
Non-
Proliferativ
e UROtsa  
Proliferativ
e UROtsa 
RT4 T24 Comparison 
of drug 
cytotoxicity  
between cell 
lines 
Gemcitabine 42
o
C 
 (95% CI) 
1.2 (0.3-
4.9) mM 
4.6 (2.5-
8.5) mM 
0.7 (0.5-
1.1) µM 
0.6 (0.4-
0.9) µM 
p<0.0001 
Comparison of  
combined 
gemcitabine/hypert
hermia to 
gemcitabine alone 
P=0.0119 P=0.1239 0.3992 0.1544  
Mitomycin C 42
o
C 
 (95% CI) 
0.1 (0.1-
0.1) µM 
0.9 (0.6-
1.3) µM 
0.8 (0.6-
1.0) µM 
3.0 (1.9-
4.8) µM 
p<0.0001 
Comparison of  
combined 
mitomycin 
C/hyperthermia to 
mitomycin C alone 
p<0.001 p=0.9717 p<0.0001 p=0.0738  
Comparison of  
cytotoxicity of  
gemcitabine to 
mitomycin C on cell 
lines treated at  
42
o
C 
p<0.001 p<0.001 p=0.94 p=0.44  
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PART B – MECHANISMS OF GEMCITABINE TOXICITY 
REACTIVE OXYGEN SPECIES PRODUCTION 
The basal levels of reactive oxygen species was measured in the urothelial cell lines 12 hours -
post seeding (Figure 3.11). ROS levels in the malignant urothelial cell lines RT4 and T24 was 
1.7- and 2.4-fold greater than the UROtsa cell line in its proliferative state (p>0.05 and p>0.0001 
respectively). UROtsa cells in the non-proli ferative form produced significantly less ROS under 
basal conditions than the T24 cells (p<0.05), but had significantly greater basal ROS production 
with comparison to UROtsa cells in the proliferative state (p<0.05).  
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Figure 3.11: Basal reactive oxygen species (ROS) production measured 12 hours post seeding in non-
malignant and malignant urothelial cells. Data is shown as DCF fluorescence normalised by cell number (mean 
± SEM, n=6) and analysed using a one-way ANOVA with Tukey-Kramer multiple comparisons test (*p<0.05, 
***p<0.001 vs T24 cells, ^ p<0.05 vs RT4 cells, #p<0.05 vs non-proliferative UROtsa cells). 
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One of the antiproli ferative mechanisms of gemcitabine is through the induction of oxidative 
stress in tumours. ROS formation was also measured after treatment with gemcitabine, 24, 48 
and 72 hours post-treatment in all urothelial cell lines. ROS production after gemcitabine 
treatment tended to increase as cell viability decreased, similarly in a time-dependent manner.  
Gemcitabine had no effect on ROS production in non-proliferative UROtsa cells measured 24 
and 48hrs post-treatment (Figure 3.12A&B). However, treatment (0.04-4mg/mL) caused a 17-
54% increase in ROS production in non-proliferative UROtsa cells 72 hours after treatment 
(Figure 3.12C).  
Similarly, gemcitabine did not increase ROS production in proli ferative UROtsa cells measured 
24 hours post treatment (Figure 3.12D). ROS production was significantly enhanced in the 
proli ferative UROtsa cells by 42% and 118% 48 hours after treatment with 0.4 and 4mg/mL 
(Figure 3.12E), and 30%, 45% and 335% 72hrs post treatment with 0.04-4mg/mL (Figure 
3.12F). 
Increased ROS production was noted in RT4 and T24 cells compared to UROtsa cells. ROS 
production increased in RT4 and T24 cells in a time and concentration dependent manner 
following gemcitabine treatment. In RT4 cells, ROS production was significantly enhanced by 2-
3.5 fold and 3.7-12.3 fold measured 48- and 72hrs respectively after gemcitabine treatment 
≥0.0004mg/mL (Figure 3.13 B&C). 
In T24 cells, gemcitabine (≥0.0004mg/mL) induced significantly increased DCF fluorescence 
(p<0.01) at all time points tested, with an increase up to 9.5-fold at 72hrs post treatment (Figure 
3.13D-F).  
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Figure 3.12: Reactive oxygen species production in UROtsa cells in their non-proliferative (A-C) and 
proliferative (D-F) states 24 (A&D), 48 (B&E) and 72 (C&F) hours post 1 hour gemcitabine treatment at 37oC. 
Data is shown as a percentage of control (mean ± SEM, n≥6) and analysed using a one -way ANOVA with 
Dunnett post-test (*p>0.05, **p>0.01 vs gemcitabine control). 
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Figure 3.13: Reactive oxygen species production in RT4 (A-C) and T24 (D-F) cells 24 (A&D), 48 (B&E) and 72 
(C&F) hours post 1 hour gemcitabine treatment at 37oC. Data is shown as a percentage of control (mean ± SEM, 
n≥6) and analysed using a one -way ANOVA with Dunnett post-test (*p>0.05, **p>0.01 vs gemcitabine control). 
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CELL VIABILITY IN THE PRESENCE OF NBMPR 
The effect of blocking the human equilibrative nucleoside transporter (NBMPR (1µM)) on 
gemcitabine (0.0004mg/mL) induced changes in cell viability was assessed in each of the 
urothelial cell lines.  
The viability of UROtsa cells in their non-proli ferative states were unchanged by concurrent 
gemcitabine (0.0004mg/mL) and NBMPR (1µM) treatment at all time points tested ( Figure 
3.14A). The cell viability of the proli ferative UROtsa cells treated with 0.0004mg/mL gemcitabine 
were significantly (p<0.05) increased in the presence of NMBPR assessed 48hrs, however this 
was not observed after 72hrs (Figure 3.14B).  
In comparison, the viability of the cancer cell lines RT4 and T24 treated with 0.0004mg/mL 
gemcitabine were significantly (p<0.05) increased in the presence of NMBPR assessed 48 and 
72 hours after treatment (Figure 3.14 C&D). The T24 cell line was also protected from the 
cytotoxicity of gemcitabine at 24 hours.  Blocking the human equilibrative nucleoside transpo rter 
using NBMPR offered greater protection in T24 cells than in RT4, with cell viability close to 
control levels in gemcitabine-NBMPR co-treated T24 cells (Figure 3.14D). 
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Figure 3.14: Effect of 1 hour 0.0004mg/mL gemcitabine treatment w ith and without the presence of the hENT1-
blocker NBMPR on UROtsa cells in their non-proliferative (A) and proliferative (B) states, RT4 (C) and T24 (D) 
cells, assessed 24, 48 and 72 hours post treatment. Data is shown as a percentage of untreated control (mean ± 
SEM, n≥5) and analysed using an unpaired students t-test (*p>0.05, **p>0.01, ***p>0.001 vs gemcitabine treated 
cells w ithout the presence of NBMPR). 
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PART C – MECHANISMS OF ADVERSE EFFECTS OF GEMCITABINE TREATMENT 
IMMEDIATE EFFECT OF GEMCITABINE ALONE AND IN COMBINATION WITH 
HYPERTHERMIA ON UROTHELIAL MEDIATOR RELEASE 
Release of mediators from the urothelium of the bladder has been found to play a significant 
role in coordinating responses of the micturition reflex. Given this role in bladder function, the 
effect of gemcitabine alone and in combination with hyperthermia immediately post treatment on 
the basal and stimulated release of mediators from UROtsa cells was investigated.  
UROtsa cells release ATP under basal conditions, with a significant increase in release when 
stretched. Basal release of ATP increased in a concentration dependent manner in gemcitabine 
treated cells (Figure 3.15A), with a significant increase in cells treated with 4mg/mL (p<0.01). 
The increased ATP release with stretch was abolished in UROtsa cells treated with gemcitabine 
at concentrations ≥0.4mg/mL. Pre -incubation of UROtsa cells at 42
o
C did not change the basal 
or stretch release of ATP (Figure 3.15B), however gemcitabine in combination increased 
temperature abolished the stretch response of ATP at concentrations ≥0.04mg/mL.  
Stretch induced release of acetylcholine from control incubated UROtsas was enhanced 2.5 fold 
from basal release (p<0.01). Incubation with gemcitabine had no effect on basal or stimulated 
release of acetylcholine at 37
o
C (Figure 3.15C). Pre-incubation of UROtsa cells at 42
o
C had no 
effect on acetylcholine release, nor did gemcitabine treatment at the increased temperature 
(Figure 3.15D). 
Hypotonic stimulation caused a 5-fold increase from basal in prostaglandin E2 (Figure 3.15E). 
While incubation with gemcitabine did not change the stretch release of prostaglandin E2, basal 
release was decreased to levels below the limits of detection in most of the gemcitabine 
treatment groups.  Therefore, it was not possible to statistically analyse the stretch response in 
comparison to basal in the gemcitabine groups due to the low basal sample number within the 
measureable range.  Unlike incubation at 37
o
C, gemcitabine treated UROtsa cells did release 
prostaglandin E2 under basal conditions (Figure 3.15F), and while an increase in prostaglandin 
E2 release in response to stretch was evident, this was not significant at this temperature.  
Prostaglandin E2 release was not significantly affected by gemcitabine treatment at 42
 o
C. 
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Figure 3.15: Effect of 1-hour pre-incubation of UROtsa cells w ith gemcitabine at 37oC (A, C & E) or 42oC (B, D & 
F) on basal and hypo-osmotically stimulated ATP (A & B), acetylcholine (C & D) and prostaglandin E2 (E & F) 
mediator release from UROtsa cells immediately post-treatment. Data shown as the mean ± SEM (n≥4), 
analysed by a paired two-tailed t-test (*p>0.05, **p>0.01 vs basal release, ) and a one -way ANOVA with 
Dunnett’s post-test (^^p > 0.01 vs control).  
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EFFECT OF GEMCITABINE ALONE AND IN COMBINATION WITH HYPERTHERMIA ON 
UROTHELIAL MEDIATOR RELEASE 24-HOURS POST TREATMENT 
Basal release of ATP from UROtsa cells returned to control levels 24 hours after 37
o
C 
gemcitabine treatment (Figure 3.16A). The stretch response however remained abolished in 
cells treated ≥0.04mg/mL. In contrast, the stretch response was maintained in UROtsa cells 
treated with gemcitabine at 42
o
C (Figure 3.16B). Stimulated release of ATP decreased in a 
concentration-dependent manner, with a significant (p<0.05) decrease in cells treated with 
0.4mg/mL gemcitabine.  
There was no significant difference between the basal and stretch release of acetylcholine from 
UROtsa cells 24 hours after gemcitabine treatment at either 37
o
C or 42
o
C (Figure 3.16 C&D). A 
concentration dependent increase in basal acetylcholine release was observed in UROtsa cells 
treated at 42
o
C, significantly (p<0.05) at 4mg/mL gemcitabine (Figure 3.16D). 
Hypotonic stimulation significantly enhanced (p<0.05) the release of prostaglandin E2 in control 
UROtsa cells 24 hours after incubation at 37
o
C and 42
o
C (Figure 3.16 E&F ). Basal 
prostaglandin E2 release was measureable in gemcitabine treated samples at 24 hours, unlike 
those analysed immediately after treatment. The significant stretch response seen immediately 
after incubation with gemcitabine was abolished after 24 hours at 37
O
C, but still present in 
samples from 42
o
C gemcitabine pre-incubation (Figure 3.16 E&F). 
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Figure 3.16: Effect of 1-hour pre-incubation of UROtsa cells w ith gemcitabine at 37oC (A, C & E) or 42oC (B, D & 
F) on basal and hypo-osmotically stimulated ATP (A & B), acetylcholine (C & D) and prostaglandin E2 (E & F) 
mediator release from UROtsa cells 24-hours post-treatment. Data shown as the mean ± SEM (n≥4), analysed by 
a paired two-tailed t-test (*p>0.05, **p>0.01 vs basal release) or a one-way ANOVA with Dunnett’s post-test (^p > 
0.05 vs control). 
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EFFECT OF GEMCITABINE PRE-TREATNENT ON INFLAMMATORY CYTOKINE RELEASE 
The release of inflammatory cytokines (Interleukin -1β, -6, -8, -10, 12p70 and tumour necrosis 
factor) from urothelial UROtsa cells was measured in cell free media 24hrs after 1hr 
gemcitabine treatment at 37
o
C or 42
o
C. Interleukin-6 and interleukin-8 were secreted by control 
urothelial cells (Figure 3.17 A&B), and this was not significantly affected by increased 
temperature.  
Secretion of IL-6 by UROtsa cells was significantly enhanced by 4mg/mL gemcitabine treatment, 
with an 11- and 10- fold increase from the 37
o
C and 42
o
C control incubations to 1816 ± 108 
pg/mL and 2628 ± 334 pg/mL respectively (Figure 3.17A). The effect of increased temperature 
(42
o
C) in combination with gemcitabine treatment significantly enhanced (p<0.05) IL-6 release 
with comparison to gemcitabine treatment at 37
o
C. 
A significant increase in IL-8 release was also observed after 4mg/mL gemcitabine treatment at 
37
o
C (5.6 fold increase) and 42
o
C (6 fold) (Figure 3.17B).  
Interleukin-1β release was not detected in samples from control UROtsa cells, however it was 
detected in gemcitabine treated samples following incubation at 37
o
C or 42
o
C (Figure 3.17C). 
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Figure 3.17: Effect of 1-hour gemcitabine incubation at 37oC or 42oC on cytokine release from UROtsa cells 24 
hours post-treatment. Data shown as the mean ± SEM (n≥3), analysed by a one-way ANOVA with Bonferroni 
post-test (** p<0.01, *** p<0.001 comparing gemcitabine treated to 37oC control release and # p<0.05 comparing 
37oC and 42oC gemcitabine treated cells). 
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3.5 DISCUSSION 
While gemcitabine has only recently been used in the treatment of bladder cancer, its efficacy 
and toxicity profile has been shown to be favourable with comparison to other commonly used 
treatments, including mitomycin C and bacillus Calmette-Guerin therapy (Shelley et al., 2012). 
To the best of my knowledge, this study is the first to report the selectivity of gemcitabine for 
cancer vs non-cancer urothelial cell lines, which may explain in part the reported superior 
toxicity profile. 
 
CYTOTOXICITY OF GEMCITABINE 
The results of this study demonstrated that the cell survival of malignant and non-malignant 
urothelial cells was reduced by gemcitabine and mitomycin C in a time and conc entration 
dependent manner. Mitomycin C is the most frequently used chemotherapy for non-muscle 
invasive bladder cancer (NMIBC) (Hendricksen and Witjes, 2007). Numerous studies have 
investigated the potency of both mitomycin C and gemcitabine on cancer cel ls, but to the best of 
my knowledge, this study is the first to report the cell killing effect of these chemotherapeutics 
on normal urothelial cells.  
The cytotoxic actions of both drugs were significantly different between the malignant and non-
malignant urothelial cell lines. Gemcitabine was found to be selectively cytotoxic (>10,000 fold) 
to the cancer cell lines RT4 and T24 with comparison to the UROtsa urothelial cell line. In direct 
comparison, the cytotoxic actions of mitomycin C were approximately 10-fold more potent on 
normal urothelial cells compared to bladder cancer cells.  
The concentration of mitomycin C is reduced 35-fold across the urothelium (Wientjes et al., 
1993). As the clinical dosage for this drug is 2mg/mL, the results of this study indicate that the 
concentration of mitomycin C penetrating the urothelium of patients would be almost completely 
cytotoxic to the normal urothelial cells in the bladder (<10% cell viability of non -proli ferative and 
proli ferative UROtsa cells). While the penetration ability of gemcitabine across the urothelium is 
unknown, a concentration similarly reduced 35-fold from the 40mg/mL clinical dose would result 
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in a reduction in urothelial cell viability by approximately 35 -55% (based on interpolation from 
UROtsa cell viability in Figure 3.7). As the primary role of the urothelium is to form a protective 
barrier for the underlying bladder nerves and muscle from the contents of urine, it could be 
assumed that this function may be impaired after int ravesical treatment  with cytotoxic drugs. It 
has been shown that urothelial damage to the apical umbrella cells and GAG layer induced by 
intravesical protamine sulphate in rat bladders results in bladder hyperactivity and increased 
pain sensitivity to noxious stimuli, although the mechanisms behind these changes are still 
unclear (Okada et al., 2014). These symptoms are similar to those reported by patients 
undergoing intravesical chemotherapy for NMIBC, and it could suggested that urothelial 
damage by cytotoxic drugs and consequent increased permeability of the urothelium is in part 
responsible for these side effects. Furthermore, as the incidence of reported side effects 
including dysuria and bladder pain is significantly greater in patients treated with mitomycin C 
compared to gemcitabine (72% to 39%) (Addeo et al., 2010), the results of the present study 
may explain this effect.  
Previous studies have investigated the cytotoxicity of gemcitabine between both human and rat 
bladder cancer cell lines and fibroblasts cultured alone or with a TCC as a spheroid co-culture 
(Kilani et al., 2002). The human bladder tumour cell lines MGH-U3 and RT-112 (derived from 
human non-invasive TCC bladder tumour and epithelial bladder carcinoma respectively) and rat 
TCC line AY-27 were selectively killed by gemcitabine t reatment with relative sparing of the 
fibroblast cells studied in in vitro spheroid models (Lin et al., 1985, Kilani et al., 2002). This 
correlates with the results of the present study, where gemcitabine was selectively cytotoxic to 
malignant bladder cancer cell lines RT4 and T24 with comparison to normal urothelial cells.  
The cytotoxic actions of gemcitabine are dependent on several mechanisms. It is considered a 
prodrug, requiring transport into the cell primarily through nucleoside transporters before being 
converted to its active forms through the enzymes deoxycytidine kinase (dCK) and thymidylate 
kinase 2 (TK2). These phosphorylated forms of gemcitabine act by being incorporated into DNA 
strands, causing masked chain termination and inhibiting ribonucleotide reductase (RNR), 
dCMP deaminase and DNA polymerase (Gandhi et al., 1996, Candelaria et al., 2010, Cerqueira 
et al., 2007, Gandhi and Plunkett, 1990).  Gemcitabine moves into cells through nucleoside 
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transporters, acting as a substrate for five of the human equilibrative and concentrative 
nucleoside transporters, with hENT1 having the greatest affinity for gemcitabine (Mabel W. L. 
Ritzel, 2001).   
The functional effect of concurrent incubation of the nucleoside transporter inhibitor S-(4-
nitrobenzyl)-6-thioinosine (NBMPR) with gemcitabine on changes in urothelial cell viability  was 
tested in this study. Concurrent gemcitabine and 1µM NBMPR treatment significantly improved 
cell survival in the urothelial cancer cell lines, RT4 and T24. Previous work has shown that RT4 
cells have a higher number of total NBMPR binding sites, the fastest initial uptake of [
3
H] 
gemcitabine and largest intracellular accumulation of gemcitabine after 2 hour exposures with 
comparison to T24 cells (Damaraju et al., 2010). The results presented here confirm the 
findings of the previous study which concluded that there is no link between basal levels of cell 
surface NMBPR-sensitive nucleoside t ransporters and gemcitabine sensitivity, as it found in the 
present study that  T24 cells are more sensitive to gemcitabine than RT4 cells (LC50 0.4[0.3-
0.6]µM and 1.0[0.5-2.0]µM respectively) (Rauchwerger et al., 2000).  In addition, co-incubation 
with NBMPR offered greater protection from gemcitabine induced cytotoxicity in T24 cells 
compared to RT4 cells. 
However, there was no protective effect of NMBPR observed in the UROtsa cells measured 72 
hours post treatment. Although there is no correlation between basal levels of hENT 
transporters and gemcitabine sensitivity, further studies have reported that the presence of 
these transporters is required for gemcitabine toxicity (Mackey et al., 1998). These results 
suggest that the expression pattern of hENT1s may be significantly reduced in normal urothelial  
cells with comparison to bladder cancer cell lines RT4 and T24 and therefore play a role in the 
observed selectivity.  
Gemcitabine cytotoxicity is also reliant on the intracellular conversion by dCK and TK2 to its 
monophosphate form. This is considered to be the rate limiting step to the accumulation of the 
active forms of gemcitabine di- and tri-phosphate (Plunkett et al., 1995). Quantification of dCK 
activity found that T24 cells had a greater than twofold higher dCK activity with comparison to 
RT4 cells (Damaraju et al., 2010). While RT4 cells display a fourfold increase in the number of 
total hENT1 binding sites, it appears that T24 cells possess a more efficient phosphorylation of 
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cytidine analogues, which may account for the enhanced cytotoxicity of gemcitabine on these 
cells seen within this study.  TK2 is a mitochondrial enzyme that phosphorylates pyrimidine 
deoxynucleosides and their analogues to the monophosphate form. However, the substrate 
specificity of gemcitabine for TK2 is only 5-10% of that of dCK, suggesting gemcitabine toxicity 
is predominantly reliant of the dCK phosphorylation of gemcitabine (Wang et al., 1999). The 
dCK/TK2 activity of UROtsa or normal urothelial tissue has not been confirmed within the 
literature, and may be a further mechanism for the resistance to gemcitabine observed in 
UROtsa cells in this study.  
 
CYTOTOXICITY OF GEMCITABINE AND HYPERTHERMIA 
Hyperthermia (42
o
C) did not enhance the cell killing effect of gemcitabine in RT4, T24 or 
proli ferative UROtsa, however, a significant increase in the cytotoxicity was observed in the 
non-proli ferative UROtsa cells  with comparison to incubation at 37
o
C (LC50 1.2[0.3-4.9]mM to 
11.5[4.5-28.9]mM respectively). This result is in contrast to previously reported gemcitabine and 
hyperthermia synergism on T24 and RT4 cells, however cell death was measured in that study 
only 24 hours after 1 hour gemcitabine treatment at hyperthermic conditions, which may 
account for the variance in this result (van der Heijden et al., 2005). As the effects of 
hyperthermia in vivo are multifactorial, including injury to tumour vasculature and increased 
immune response, combined hyperthermia and gemcitabine t reatment may have therapeutic 
benefits in patients that cannot be observed in a simple urothelial cell culture model  
(Rampersaud et al., 2010).  
This study found that hyperthermia enhanced the cytotoxicity of mitomycin C on non-
proli ferative UROtsas and the cancer cells RT4 and T24. This result correlates with previous 
studies finding enhanced cytotoxicity of mitomycin C and hyperthermia on cancer cells (van der 
Heijden et al., 2005).  
UROtsa cells grown in serum supplemented media have been found to express the basal 
patterns of metallothionein and heat shock proteins 27, 60 and 70, in agreement with that 
known to occur in in situ urothelium (Somji et al., 2001, Lebret et al., 2003, Rossi et al., 2001). 
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Rossi and colleagues (2001) found that UROtsa cells grown in serum -free media expressed 
significantly reduced levels of Hsp 70 with comparison to UROtsa cells grown in serum-
supplemented media.  Hsp70 has been reported to block apoptosis, and its down -regulation, 
inhibition or under-expression can facilitate the induction of apoptosis (Nylandsted et al., 2000, 
Burkart et al., 2000). Exposure of cells to temperatures of 42
o
C activates Hsp70 and its 
apoptotic-protective effect (Abravaya et al., 1992). This may explain enhanced cell death in non-
proli ferative UROtsa cells (grown in serum-free media) with increased temperature and 
gemcitabine/mitomycin C, while no change was observed in the proli ferative UROtsa cells 
(grown in serum-supplemented media) treated at the same conditions.  
 
GEMCITABINE AND THE INDUCTION OF REACTIVE OXYGEN SPECIES 
With comparison to normal cells, cancer cells experience greater oxidative stress associated 
with oncogenic stimulation, altered metabolic activity and increased reactive oxygen species 
(Pelicano et al., 2004). In line with this observation, this study found that the cancer cell lines 
T24 and RT4 have a significantly greater basal ROS production with comparison to non-cancer 
UROtsas cells.  
However, cancer cells that are exposed to persistent intrinsic ROS stress adapt to these 
mechanisms by activating transcription factors including nuclear fac tor kappa-light-chain-
enhancer of activated B cells and hypoxia-inducible factor-1α (Pervaiz and Clement, 2004, 
Sullivan and Graham, 2008, Tiligada, 2006). This in turn leads to enhanced activation of the 
antioxidant defence system including superoxide dismutase and promotes expression of cell  
survival proteins, a mechanism that has been observed in bladder cancer cell lines (Gupta et al., 
2012, Hour et al., 2004).  
ROS production induced by gemcitabine has been associated with its cytotoxicity, through 
increasing mitochondrial membrane permeability and promoting apoptosis  (Donadelli et al., 
2007). The inherent basal production of reactive oxygen species of pancreatic adenocarcinoma 
cells and sensitivity to gemcitabine has been compared, implicating cell lines with a lower basal 
level of ROS to be more resistant to gemcitabine (Donadelli et al., 2007). However, it has 
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recently been reported that pancreatic cancer cell lines resistant to gemcitabine also have 
enhanced antioxidant mechanisms, including glutathi one (GSH) production (Ju et al., 2015). 
However, Ju et al. (2015) found that reducing GSH production by the addition of β -phenylethyl 
isothiocyanate inhibited the ROS antioxidant mechanism. This may provide a future treatment 
avenue for bladder cancer cells resistant to gemcitabine induced ROS-mediated cell death. 
The bladder cancer cell lines RT4 and T24 treated with gemcitabine displayed greater than 10-
fold increase in ROS production from controls, with comparison to a less than 3-fold ROS 
production in the normal bladder epithelial UROtsa cells after treatment with g emcitabine. The 
resistance of the normal urothelial cells to the cytotoxic effect of gemcitabine may in part be 
explained by the lower basal levels of ROS , or an antioxidant mechanism capable of mitigating 
the ROS-induced effects in comparison to the cancer cell lines.  
 
MECHANISMS OF ADVERSE EFFECTS AFTER GEMCITABINE TREATMENT 
While intravesical therapy for bladder cancer limits systemic absorption of chemotherapies, the 
urothelium lies in direct contact with cytotoxic drugs. Insult to the urothelium from these 
therapies may explain the commonly reported urological side effects, including dysuria, 
increased frequency and urgency of urination, suprapubic pain and cystitis (Thrasher and 
Crawford, 1992, Bolenz et al., 2006). Gemcitabine treatment for bladder cancer has reported to 
have a better toxicity profile and fewer reported side effects with comparison to other 
chemotherapies, including mitomycin C, epirubicin and doxorubicin (Shelley et al., 2012). A 
randomized Phase III trial reported the incidence of adverse effects in only 39% of the patient 
cohort treated with gemcitabine in comparison to 72% of patients treated with mitomycin C 
(Addeo et al., 2010). 
As the urothelium is in direct contact with cytotoxic drugs during intravesical therapy, it is likely 
that the commonly reported side effects of dysuria, increased frequency and urgency of 
urination and in some cases subpubic pain are in part due to the changes in release of 
urothelial mediators. Doxorubicin, a commonly used chemotherapeutic for bladder c ancer, has 
been reported to enhance stretch induced release of prostaglandin E2 and inflammatory 
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cytokines interleukin-8 and -1β from urothelial cells, which may explain the symptoms of bladder 
dysfunction experienced in patients (Kang et al., 2013a). It has also recently been shown that 
mitomycin C induces inflammatory cytokine and nitric oxide release from urothelial cells which 
persist after recovery periods (Kang et al., 2015). 
This study found that UROtsa cells release ATP under basal conditions, and release was 
significantly enhanced with stretch, in line with previous studies investigating mediator release 
from UROtsa cells (Ochodnický et al., 2013, Mansfield and Hughes, 2014b). UROtsa cells 
treated with gemcitabine at 37
o
C had significant increase in basal ATP release immediately 
after treatment.  Urothelial ATP acts on the purinergic receptors in the Aδ sensory nerve fibres 
to initiate the micturition reflex and on high threshold C fibres to induce perception of pain 
(Burnstock, 2009). Commonly reported side effects after intravesical gemcitabine treatment 
include subpubic pain and dysuria (Addeo et al., 2010), which may be a result of the increased 
ATP release from the urothelium. However, this enhanced basal ATP release was transient and 
was not observed 24 hours post treatment, indicating recovery of urothelial ATP  release 
mechanisms. Similarly, Kang et al. (2015, 2013a) found that mediator release recovered over 
time in doxorubicin and mitomycin treated urothelial cells.  
Similarly, UROtsas incubated at 42
o
C released significantly enhanced ATP levels with hypotonic 
stimulation. However, after twenty-four hours of recovery from treatment, combined gemcitabine 
and hyperthermia treated cells released significantly less ATP with hypotonic stimulation. This 
may suggest the pain reported by patients may be due to sensitization of bla dder C afferent 
nerves rather than enhanced ATP release, which has been observed painful bladder syndrome 
and other bladder disorders (Kumar et al., 2005). However, in the intact bladder, urothelial cells 
are not the only source of ATP, as myofibroblasts found in the sub-urothelial layer have been 
shown to release ATP (Cheng et al., 2011). The close contact of myofibroblasts to nerves within 
the bladder may implicate their role in mechanosensation of the bladder (Wiseman et al., 2003), 
and it is unknown as to the effect that gemcitabine has on these cells. 
UROtsa cells have the components necessary for the synthesis of acetylcholine and express 
muscarinic receptors (Arrighi et al., 2011). It was found in this study that UROtsa cells release 
acetylcholine under basal conditions, and this release was enhanced with stretch. The role of 
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urothelial derived acetylcholine is uncertain but it may influence sensory nerve activity or 
stimulate the underlying detrusor muscle, acting in an autocrine and paracrine manner on the 
urothelium itself (Daly et al., 2010, Hanna-Mitchell et al., 2007). A study by Kanai et al. (2007) 
reported that muscarinic receptor stimulation on strips of rat bladder released intracellular Ca
2+
 
and induced membrane-potential transients which originate at the urothelial -suburothelial 
interface, spreading to the detrusor muscle. Furthermore, they found that enhanced 
spontaneous activity was inhibited with atropine, thus suggesting that acetylcholine released 
from the urothelium plays a role in spontaneous, non-voiding contractions of the bladder (Kanai 
et al., 2007). 
From the present study, it appears that gemcitabine, increased temperature or combined 
gemcitabine and hyperthermia therapy has no effect on the cholinergic mecha nisms of the 
bladder urothelium measured immediately after treatment. There was no significant difference 
between acetylcholine released under basal and stretched conditions 24 hours after 
gemcitabine, although this may be due to changes in cellular components due to serum 
starvation.  Interestingly, basal acetylcholine release increased in a concentration dependent 
manner 24 hours after incubation of UROtsa cells treated with gemcitabine at 42
o
C, significantly 
at 4mg/mL. Similarly, mitomycin C enhanced basal release of acetylcholine from urothelial cells 
after a twenty-four hour period of recovery (Kang et al., 2015). Hence, increased release of 
basal acetylcholine from urothelial cells may influence the underlying detrusor muscle tone and 
enhance spontaneous contractions of the bladder mediated by the muscarinic receptors, a trait 
of unstable bladders from both humans and animals (Steers, 2002). This may explain in part the 
symptoms of bladder overactivity reported by patients undergoing intravesical therapy with 
these agents. 
Prostaglandin E2 is released by the urothelium with mechanical stretch and is believed to 
stimulate release of ATP from urothelial cells, and modulate afferent nerve activity and efferent 
neurotransmission, potentiated by obstructive and overactive bladder disorders (Pinna et al., 
2000, Anderson, 1993, Tanaka et al., 2011). Prostaglandin E2 release from control UROtsa cells 
were measured basally and after hypotonic stimulation, both immediately and twenty-four hours 
after vehicle t reatment. While basal release of prostaglandin immediately after incubation was 
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below detectable levels in gemcitabine treated (37
o
C) samples, there was measureable release 
from UROtsa cells with hypotonic stretch, which was not significantly different from control cells . 
The decrease in basal prostaglandin E2 release may be a compensatory mechanism to 
desensitize afferent nerves in order to reduce the impact increased basal ATP might have on 
sensory activity.  Twenty-four hours after treatment, UROtsa cells treated with gemcitabine 
released prostaglandin E2 basally, with no significant stretch response in 37
o
C incubated cells. 
An enhanced-stretch response was measured from cells treated at 42
o
C, comparably to 
controls. This result is in contrast to the effect of doxorubicin on urothelial cells, which enhanced 
stretch release of prostaglandin E2 from urothelial cultures 24 hours post-treatment, and could 
explain reduced incidence of patient bladder toxicity with intravesical gemcitabine compared to 
doxorubicin given the role of prostaglandin E2 in sensitizing bladder afferents (Kang et al., 
2013a). 
Elevated levels of inflammatory cytokines have been found in the urine of patients with cystitis 
and overactive bladder syndrome (Tyagi et al., 2010). Altered visceral sensations from the 
bladder in these conditions have been suggested to be in part due to increased cytokine 
expression (Gonzalez et al., 2014). Pro-inflammatory cytokines have been implicated in the 
sensitization of bladder afferents by altering voltage-gated K
+
 channel expression, possibly 
contributing to increased bladder afferent neuron excitability and leading to enhanced 
sensations of pain (Cheng and Ji, 2008, Hayashi et al., 2009). Furthermore, Heinrich et al. 
(2011) found that enhanced cytokines modified cell -cell-communication mediated by gap 
junctions in human bladder smooth muscle cells and suburothelial myofibroblasts, indicating a 
possible role in the etiology of the overactive bladder.  
Specifically, elevated levels of interleukin-6 have been suggested to indicate the severity of 
inflammation and correlate with the degree of pain in patients with overactive bladder (Lotz et al., 
1994, Erickson et al., 2002). While interleukin-8 was originally implicated as a mediator of the 
inflammatory process, it also plays a role as a growth and essential survival factor for normal 
human urothelial cells, mediated through the protein kinase B (Akt) pathway (Dobreva et al., 
2006, Tseng-Rogenski and Liebert, 2009). The interleukin-1 cytokine family is associated with 
acute and chronic inflammation, interleukin-1β in particular being associated with a pro-
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inflammatory response and implicated in the pathogenesis of haemorrhagic cystitis (Dinarello, 
2011, Macedo et al., 2012, Ribeiro et al., 2002).  The 10-fold increase in interleukin-6 and -8 
and presence of interleukin-1β from urothelial cells treated with gemcitabine may account for 
the reported side effects of overactive and painful bladder associated with intravesical 
gemcitabine treatment for bladder cancer. Furthermore, as the present study has shown that 
gemcitabine is cytotoxic to urothelial cells, it is likely that the enhanced IL -8 release plays a role 
in urothelial proli feration to restore the intact barrier. Urothelial cells treated with the 
chemotherapeutic agent doxorubicin similarly released enhanced cytokines IL-8 and IL-1β, 
implicating a common role of the inflammatory response in the reported bladder dysfunction by 
patients undergoing intravesical chemotherapy (Kang et al., 2013a). Mitomycin C also induced 
IL-8 release from urothelial cells, at a substantially greater fold-change compared to doxorubicin 
or gemcitabine (Kang et al., 2015). Furthermore, Kang et al. (2015) found that the enhanced IL-
8 release persisted after two weeks of recovery, which may account for the inc reased severity of 
side effects reported with intravesical treatment using this agent in comparison to gemcitabine 
(Addeo et al., 2010) 
 
  
122 
 
CONCLUSION 
While the side effects from intravesical gemcitabine treatment include dysuria, subpubic pain 
and overactive bladder, the frequency of these symptoms reported in patients are significantly 
less than other commonly used cytotoxic agents, including mitomycin C (Addeo et al., 2010). 
This is the first investigation that shows selectivity of gemcitabine for malignant cancer cells with 
comparison to non-malignant urothelial cells, with no synergism observed in combined 
gemcitabine and hyperthermia therapy except on non-proli ferative UROtsa cells. This selective 
cytotoxicity may be in part explained by the decreased p resence of hENT1 receptors in normal 
urothelial cells, and the lower levels of reactive oxygen species production in non-malignant 
urothelial cells post gemcitabine treatment. In addition, the minor changes and consequent 
recovery and inhibition of ATP, acetylcholine and prostaglandin E2 release from urothelial cells 
after gemcitabine t reatment at both 37
o
C and 42
o
C may account for the less frequent adverse 
effects with comparison to other commonly used chemotherapeutics such as mitomycin C and 
doxorubicin. The most likely explanation for the bladder dysfunction and associated pain after 
intravesical gemcitabine in bladder cancer patients would be from the induction of inflammatory 
cytokines interleukin-6, -8 and -1β and the consequent sensitization of bladder nerves. 
The results of the present study also form a solid compilation of basic evidence supporting the 
use of gemcitabine in patients in preference to the current first -line chemotherapy, mitomycin C. 
Comparatively, gemcitabine is significantly less and more cytotoxic than mitomycin C to normal 
and malignant urothelial cells respectively.  In addition, gemcitabine induces recoverable 
changes to urothelial mediator release and stimulates a smaller fold-change in cytokine 
production in comparison to those reported for MMC by Kang et al (2015).  
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CHAPTER 4: 
EFFECTS OF GEMCITABINE ON THE FUNCTION OF 
ISOLATED PORCINE BLADDER 
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4.1 INTRODUCTION 
The previous chapter investigated the effect of gemcitabine and hyperthermia treatment at a 
cellular level. While cell culture is a useful model to examine the mechanisms of gemcitabine 
cytotoxicity on urothelial cells, the bladder is a multi-layered organ made up of urothelium, 
lamina propria and detrusor muscle. Normal functioning of the bladder requires  complex 
communication and interaction between the various cell types, and coordination of these layers. 
This chapter investigates the effect of luminal gemcitabine and/or hyperthermia on the normal 
functioning of intact bladder tissue and the isolated urothelium/lamina propria and detrusor 
layers.   
 
PORCINE BLADDER AS A MODEL OF HUMAN TISSUE 
Porcine bladder is frequently used as a model of the human urinary bladder. Multiple studies 
have reported the resemblance of the anatomy and physiology of the porcin e bladder to human, 
including similarities in neural control, urodynamic and structural characteristics (Crowe and 
Burnstock, 1989, Sibley, 1984, Parsons et al., 2012). 
As described in Chapter 1, the urothelium of human bladders is protected by a 
glycosaminoglycan layer. Immunofluorescence studies in porcine urothelium have confirmed 
the presence of a GAG-layer of similar expression and distribution to human (Janssen et al., 
2013). The family of uroplakins (including UIa, UIb, UII and UIII) present in the human 
asymmetrical unit membrane (AUM) similarly form the majority of the protein component in the 
urothelial plaques in porcine urothelium (Wu et al., 1994). Furthermore, cytokeratin 20, a protein 
expressed by umbrella and differentiated intermediate cells  in the human urothelium, and 
cytokeratin 7, expressed by all cells of the urothelium, are similarly present in both human and 
porcine species (Southgate et al., 1999, Turner et al., 2008). 
Rhythmic spontaneous activity from bladder strips originating in the trigone and dome sections 
of porcine tissues has been found to be comparable in both frequency and amplitude to that in 
humans (Sibley, 1984). Spontaneous activity of the bladder is influenced by the presence of the 
urothelium, and has been confirmed to be myogenic in origin, dependent on calcium entry 
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through voltage-dependent Ca
2+
 channels and release from the sarcoplasmic reticulum through 
ryanodine receptors (Buckner et al., 2002, Brading, 1997, Akino et al., 2008). The role of this 
activity has been suggested to allow individual muscle bundles to adjust their length in response 
to filling (Brading, 2006). However, isolated porcine urothelium/lamina propria also displays 
spontaneous contractile activity, regulated by acetylcholine and M3 muscarinic receptors (Moro 
et al., 2011). 
Activation of the detrusor smooth muscle in the micturition reflex is primarily mediated by the 
release of acetylcholine from parasympathetic nerves acting upon muscarinic receptors. While 
the expression of muscarinic subtypes is species specific, the density of muscarinic receptors in 
human detrusor was found to be similar to porcine detrusor (Chess-Williams, 2002). M2 and M3 
receptors are present in a 3:1 ratio in both human and porcine bladder, with the M3 receptor 
primarily responsible for mediating tissue contractility, stimulating release of intracellular Ca
2+
 
(Fetscher et al., 2002, Yamanishi et al., 2000, Chess-Williams, 2002). Furthermore, the 
inhibitory effect of the urothelium on the detrusor muscle through the release of UDIF has been 
shown in both human and porcine tissue in response to both endogenous muscarinic 
stimulation and efferent nerve mediated responses (Chaiyaprasithi et al., 2003, Hawthorn et al., 
2000). 
As discussed in Chapter 1, ATP is released from both the human and animal bladder in 
response to stretch and other stimuli (Ferguson et al., 1997). Recently, ATP has been found to 
be released spontaneously and this is enhanced with hypotonic stretch by urothelial, 
myofibroblast cells and detrusor muscle cells isolated from porcine tissues (Cheng et al., 2011). 
ATP has been implicated as a mediator for the non -adrenergic, non-cholinergic (NANC) 
contractions of the bladder, where it is released from nerves and acts upon G-protein-coupled 
P2Y and ionotropic P2X receptors, inducing contraction by opening nonselective cation 
channels causing depolarisation and Ca
2+
 entry through L-type Ca
2+
 channels and subsequent 
intracellular release (Burnstock, 2007). Furthermore, it is well established that the 
characteristics of ATP release from porcine and human bladders are similar (Kumar et al., 2004).  
Noradrenaline is released by the sympathetic nerves of the bladder and binds to the α- and β-
adrenoceptors found in the bladder base and detrusor muscle respectively. Activation of the α - 
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adrenoreceptors cause contraction of the bladder base/trigone, preventing urine leakage, and 
stimulation of the β-adrenoceptors induce relaxation of the detrusor muscle to accommodate 
bladder filling. Similar to human, the β3-subtype is the most populous of the adrenoceptors 
found in the porcine bladder (Yamanishi et al., 2002b, Nomiya and Yamaguchi, 2003). 
Relaxation to the adrenergic agonist isoprenaline is similarly mediated via the β3-AR in both 
human and pig species (Igawa et al., 1999, Igawa et al., 1998, Takeda et al., 1999, Yamanishi 
et al., 2002b, Yamanishi et al., 2002a). 
Electrical field stimulation of bladder nerves induces contraction of the detrusor mediated 
through the post-ganglionic release of acetylcholine and ATP. Investigation of the electrical 
properties of the detrusor smooth muscle from pig and human bladder found similarities in the 
contractile responses, which make them a suitable model to investigate human bladder function 
(Hashitani and Brading, 2003). These included similarities between species in the fast after-
hyperpolarization of action potentials and a dependence on Ca
2+
-activated K
+
 and voltage-
dependent K
+
 channels on the regulation of electrical activity of the detrusor smooth muscle.  
 
INTRAVESICAL GEMCITABINE: EFFECT ON STRUCTURE AND FUNCTION OF THE 
BLADDER 
Numerous studies have investigated the pharmacokinetics and tolerability of intravesical 
gemcitabine for bladder cancer. Common urological side effects of treatments in humans of 
doses between 500-2000mg/50mL include increased urinary frequency and urgency of urination,  
haematuria, dysuria and in  some cases, interstitial cystitis and subpubic pain (Dalbagni et al., 
2002, Laufer et al., 2003, Witjes et al., 2004, De Berardinis et al., 2004).  
A study of repeated  instillations (once per week for 6 weeks) of 175 and 350mg (in 50mL 0.9% 
saline) gemcitabine in pigs reported no systemic absorption, bladder toxicity or s ystemic toxicity 
(Witjes et al., 2003). Thickening of the urothelial layer was observed after 6 instillations of 
350mg gemcitabine in the porcine bladder. A preclinical study in beagle dogs of three 
instillations per week for 4 weeks of 1g gemcitabine (in 50mL saline) similarly observed 
urothelial thickening due to haemorrhage and cystitis in histological sectioning of the treated 
130 
 
bladders (Cozzi et al., 1999). While various dose regimes and concentrations have been 
investigated within animal studies, intravesical gemcitabine at 40mg/mL has been reported as a 
tolerable and effective dose in human patients with bladder cancer and is hence used within this 
study (Addeo et al., 2010, Mattioli et al., 2005). 
To the best of my knowledge, no studies have investigated the effect of gemcitabine on the 
normal function of the bladder, and the aetiology of the reported side effects after intravesical 
gemcitabine. The previous chapter found urothelial cells treated with gemcitabine t ransiently 
released enhanced levels of basal ATP with comparison to control cells, with little change in 
release of acetylcholine and prostaglandin E2. However, the urothelium/lamina propria in the 
bladder form a complex network comprised of urothelial cells in various states of differentiation 
and myofibroblasts, the latter of which have also been found to release ATP spontaneously and 
in response to stretch (Cheng et al., 2011). Changes in mediator release from the 
urothelium/lamina propria have been implicated in many pathological conditions  of the bladder, 
as discussed in Chapter 3. Additionally, the effect of gemcitabine on detrusor muscle function 
will be examined within this study. 
 
EFFECT OF HYPERTHERMIA ON THE BLADDER 
Hyperthermia treatment has been extensively investigated as an adjunc t treatment with 
chemotherapy for cancer. A review of treatment with mitomycin C and localised hyperthermia 
treatment in bladder cancer patients has reported significant benefits in recurrence of NMIBC 
(Lammers et al., 2011).  While there is a significant place for hyperthermia in cancer treatment, 
little investigation has been performed on the thermal pathology of this treatment (Fajardo, 
1984). Combined mitomycin C and hyperthermia is associated with increased adverse effects in 
patients manifesting as urological symptoms (including urgency, haematuria and pain) 
compared to treatment with mitomycin C alone, however this has not been reported as 
statistically significant (Lammers et al., 2011, Colombo et al., 1996). Endoscopic and histologic 
features of combined mitomycin C and hyperthermia have shown selective damage to the 
neoplastic area with minimal changes in the normal urothelium (Rigatti et al., 1991).   
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The effect of hyperthermia on the bladder wall was investigated in dogs, and no gross or 
microscopic alterations with irrigation of water at temperatures between 35 -44.5
o
C were found 
(Netto et al., 1973). Similarly, a study of 1-hour intravesical treatment with water at temperatures 
between 41-43
o
C in rats found no reduction in bladder capacity (Haveman et al., 2003). 
Incubation temperatures of 44
o
C induced increased blood urea nitrogen and transient 
decreases in bladder volume, while 1 hour bladder hyperthermia at 45
o
C resulted in the death in 
4 (out of 7) rats within a week of treatment. No functional studies using porcine tissue have 
investigated the effect of hyperthermia on the bladder, or a combination with the 
chemotherapeutic gemcitabine.   
Thus, this study examined the effect of luminal gemcitabine and/or hyperthermia treatment on 
the structure and function of the porcine bladder. To simulate intravesical treatment, a technique 
recently described by Smith et al. (2014) was employed. This involves mounting full thickness 
bladder sections in a bath, exposing the adventitial side in Krebs -bicarbonate solution and 
applying gemcitabine (40mg/mL) to the urothelial side. This technique allows the selective 
treatment of urothelium of the bladder, mimicking intravesical treatment in human bladder 
cancer patients. Consequent dissection of the intact porcine tissue into isolated detrusor and 
urothelium/lamina propria strips was used as a model to study the effect of gemcitabine  on 
bladder function (Moro et al., 2011, Yamanishi et al., 2000, Yamanishi et al., 2002b).  
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4.2 AIMS 
The aim of the present study was to investigate the effect of gemcitabine and hyperthermia 
treatment on the structure and function of the porcine bladder. Specific aims were:  
1. To examine the effect of gemcitabine and/or hyperthermia on the urothelium/lamina 
propria structure 
2. To determine the effect of gemcitabine and/or hyperthermia on urothelial mediator 
release 
3. To investigate whether gemcitabine and/or hyperthermia effect changes in the 
contractility and relaxation of the urothelium and detrusor muscle 
4. To determine the effect of gemcitabine and/or hyperthermia on the efferent nerve 
mediated responses on the detrusor muscle 
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4.3 MATERIALS AND METHODS 
ANIMALS 
Bladders from mature female pig (sow, >1 year old) were obtained from a local abattoir 
(Highchester Meats, Beaudesert Queensland) and immediately placed in Krebs-bicarbonate 
solution (composition in mmol/L: NaCl 118.4, NaHCO3 24.9, KCl 4.7, CaCl2 1.9, MgSO4 1.15, 
KHPO4 1.15, glucose 11.7) at 4
o
C until use. 
 
TISSUE DISSECTION AND EXPERIMENTAL SETUP 
The excess adventitial tissue, urethra and ureters were dissected from the bladder. The bladder 
was opened from the urethra to the dome, and circular sections of intact tissue were cut from 
the dome of the bladder and mounted in modified Ussing chambers (as described by Smith et al. 
(2014)) containing Krebs-bicarbonate solution, gassed with 5% CO2 in oxygen (Figure 4.1). The 
temperature of the Krebs was either 37
o
C or 42
o
C, and 0.9% saline or 40mg/mL gemcitabine 
(dissolved in 0.9% saline) was applied to the luminal side (urothelial surface) o f the bladder for 1 
hour. Aluminium foil was placed over the entire unit to regulate temperature.  
 
Figure 4.1: Schematic figure of the modified Ussing chamber w ith a section of intact bladder tissue secured 
within the apparatus. The tissue was incubated in Krebs-bicarbonate solution on the adventitial side at 37oC or 
42oC for 1 hour, w ith 0.9% saline or 40mg/mL gemcitabine (dissolved in 0.9% saline) applied to the luminal side. 
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After treatment, the tissues were washed with warm (37
o
C) Krebs solution and the treated 
bladder portions were sectioned into strips of intact, denuded detrusor and urothelium/lamina 
propria tissue, approximately 10mm x 5mm in dimensions. Strips from the respective control 
and treated tissues were anchored in individual organ baths in Krebs-bicarbonate solution, 
gassed with 5% CO2 in oxygen at 37
o
C (Figure 4.2). Tissues were equilibrated for 1 hour under 
a resting tension of 150mN during which time they were washed with fresh, warmed Krebs -
bicarbonate solution every 15 minutes. Tension was measured by as isometric force transducer 
(ADInstruments, Ltd Australia), recorded by a Powerlab 8/30 recording system (ADInstruments 
Ltd.) via an Octal Bridge Amp (ADInstruments Ltd.) and analysed using LabChart (version 7.0.3) 
software (ADInstruments Ltd.). 
 
Figure 4.2: Individual organ bath containing a strip of isolated intact, denuded detrusor or urothelium/lamina 
propria. Tissues were anchored to the bath and connected to an isometric force transducer to record tension 
developed. The side view is a schematic illustration of the tissue setup, with electrodes placed either side of 
the tissue.  
 
SPONTANEOUS ACTIVITY 
After equilibration of the tissues, the spontaneous activity of the denuded detrusor and isolated 
urothelial tissue was investigated. The frequency of phasic contractions was measured after the 
135 
 
equilibration period, recorded as contractions per minute and amplitude measured from the 
peak to trough of the contraction. 
 
FUNCTIONAL STUDIES: PHARMACOLOGICAL AGENTS 
The strips of bladder tissue were contracted to 60mM potassium chloride (KCl), 1mM ATP and a 
cumulative-concentration curve to carbachol (5.5nM - 165µM). Tissues were washed twice with 
fresh Krebs-bicarbonate solution and left for at least 15 minutes between agonist additions.  
A dose of 16.5µM carbachol (submaximal contraction) was applied to the tissue and 
contractions allowed to plateau. A cumulative-concentration curve to isoprenaline (48pM - 48µM) 
was recorded. Responses of each tissue were taken by measuring the change in tension of 
agonist from baseline (tension prior to addition of agonist). The effect of gemcitabine on the 
contractility/relaxation response of the detrusor and urothelium/lamina propria was compared to 
strips of tissue from matched bladders. A comparison of responses of intact bladder tissue with 
urothelium-denuded tissue was used to examine the inhibitory effect of the urothelium on the 
detrusor muscle.  
 
UROTHELIAL MEDIATOR TRANSMITTER RELEASE 
For mediator release, three strips of isolated urothelium/lamina propria from either control or 
treated bladders were tied together and anchored to organ baths as described above. Following 
the equilibration period, 3mL of fresh Krebs solution was added to the bath and left for a period 
of two minutes. Samples of the Krebs solution were taken immediately after the two-minute 
period (0min) and 1, 5, 10 and 15 minutes after, with fresh Krebs replacing the volume of 
collected sample. The Krebs was immediately refreshed and the urothelial strips stretched over 
a two minute period, evoking approximately 100mN tension. Samples of stimulated (stretched) 
mediator release were collected immediately, 1, 5, 10 and 15 minutes after the two minute 
stretch period, with fresh Krebs replacing the volume of collected sample. Samples were st ored 
frozen at -30
o
C until the levels of ATP, acetylcholine and prostaglandin E2 from each sample 
were measured using the respective assay kits, as described in Chapter 2.  
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ELECTRICAL FIELD STIMULATION 
Strips of denuded detrusor from control and gemcitabine treated porcine bladders were 
dissected and anchored in individual organ baths as described above. The tissue strips were 
electrically stimulated (20V, 1ms pulse-width, 5s train delivered every 100s) at frequencies of 1, 
5, 10 and 20Hz until consistent contractions were obtained (approximately 5-6 
contractions/frequency). These stimulations were repeated in the presence of 1µM atropine 
(competitive muscarinic antagonist) and 10µM α,β-mATP (P2X purinoceptor agonist) to 
investigate the contributions of acetylcholine and ATP in nerve-mediated contractions.  
The addition of 1µM tet rodoxin (TTX) to the strips of denuded detrusor during preliminary 
experiments confirmed the neural selectivity of contraction of the tissue by abolishing the 
evoked responses of EFS.  
 
HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
After luminal treatment of gemcitabine or saline at 37
o
C or 42
o
C, tissues were dissected into 
thin (~1-2mm wide) strips of intact bladder and placed in neutral buffered formalin (10%) at 4
o
C 
for 24 hours. Preparation into wax blocks, processing and staining with haematoxylin and eosin 
as per the protocol in Chapter 2 was performed to visualise possible urothelial damage.  
Sections of tissues were prepared into wax blocks as per the protocol in Chapter 2, and given to 
Professor Gordon Wright, who kindly performed immunohistochemical staining using 
commercially available human cytokeratin-7 and -20 antibodies at the Pathology Department of 
the Gold Coast University Hospital.  
 
STATISTICAL ANALYSIS 
Results were expressed as mean ± standard error of the mean (SEM). Data were analysed 
using an ANOVA with Dunnett or Bonferroni post-test using Graphpad Instat (version 3.06, San 
Diego, CA), and whole curve analyses were performed with a multiple comparisons F-test using 
GraphPad Prism (version 5.0). Significance levels were defined as *p<0.05, **p<0.01 and 
***p<0.001.  
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4.4 RESULTS 
Luminal treatment of the bladder involves direct contact between the urothelium and cytotoxic 
drugs. The damaging effect of gemcitabine alone and in combination with hyperthermia on the 
urothelium was investigated with H&E staining of intact sections of porcine bladders treated with 
gemcitabine (40mg/mL) at 37
o
C and 42
o
C, and compared to matched controls treated with 
saline (0.9%) (Figure 4.4). Typical histological features of a porcine bladder including an intact, 
folded urothelium and lamina propria layer sitting atop a smooth muscle layer were apparent in 
the control tissues incubated at both temperatures (Figure 4.4 A&B, E&F). The urothelium of 
the gemcitabine t reated tissues appeared to have a less folded appearance, minor damage and 
thinning in some sections with comparison to the control tissues (Figure 4.4C&D, G&H). 
However, while the thickness of the urothelium in gemcitabine and/or hyperthermia pre-treated 
tissues was less than control; this difference was not significant (Figure 4.3).   
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Figure 4.3: Urothelial thickness (µM) in control and gemcitabine treated tissues at 37oC and 42oC. Data 
represented as mean ± SEM (taken from the average of >10 measurements from n=3 bladders) 
 
  
138 
 
Pre-Treatment 
 
Figure 2: Histological sections (H&E stain) of bladder wall from bladders pre-incubated with saline (A&B) or gemcitabine (C&D) at 37oC or pre-incubated at 42oC with saline (E&F) 
or gemcitabine (G&H). Red arrows indicate the width of the urothelium. 
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The typical features of porcine bladders were similarly apparent in the cytokeratin 7 
immunohistochemically stained sections (Figure 4.5). Cytokeratin 7 is a protein expressed by 
all cells of the urothelium – basal, intermediate and umbrella cells. The luminal side of the 
urothelium in control treated tissues (Figure 4.5 A&B, E&F ) is smooth and folded, while there is 
evident damage of the urothelial barri er and a less folded appearance in gemcitabine pre-
treated tissues (Figure 4.5 C&D, G&H). As previously described, cytokeratin 20 is expressed in 
the urothelium, usually restricted to the umbrella and occasionally intermediate cell layers as it 
is associated with differentiation (Romih et al., 1998, Romih et al., 2005, Moll et al., 1992, Moll, 
1991). The expression of this protein was in abundance (indicated by red arrows) in the control 
tissues incubated at 37
o
C (Figure 4.6 A&B). In the gemcitabine treated tissues at 37
o
C (Figure 
4.6 C&D), staining for cytokeratin 20 was sporadic, while both the control (Figure 4.6 E&F) and 
gemcitabine pre-t reated tissues incubated at 42
o
C (Figure 4.6 G&H) had very few stained cells. 
This is indicative of sloughing of the luminal layers of the urothelium by gemcitabine and 
hyperthermia treatment. 
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Pre-Treatment 
 
Figure 4.5: Cytokeratin 7 stained sections of bladder wall from bladders pre-incubated with saline (A&B) or gemcitabine (C&D) at 37oC or pre-incubated at 42oC with saline (E&F) 
or gemcitabine (G&H). Red arrows indicate the width of the urothelium. 
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Pre-Treatment 
 
Figure 4.6: Cytokeratin 20 stained sections of bladder wall from bladders pre-incubated with saline (A&B) or gemcitabine (C&D) at 37oC or pre-incubated at 42oC with saline (E&F) 
or gemcitabine (G&H). The cells stained for cytokeratin 20 (maroon in colour) are indicated by red arrows. 
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UROTHELIAL MEDIATOR RELEASE: INCUBATION AT 37OC 
The effect of luminal gemcitabine on basal and stretched urothelial mediator release was 
measured from strips of isolated urothelium/lamina propria. In control pre-incubated tissues, no 
difference was observed between release of mediators ATP, acetylcholine or prostaglandin E 2 
between basal or stretched states. However, luminal gemcitabine pre-treatment decreased ATP 
release both basally and with stretch, significantly reduced by approximately 80% after 1 and 15 
minutes, and reduced to approximately 10% of control response after 1, 5 and 10 minutes after 
stretch (Figure 4.7 A&B). 
The bath concentration of acetylcholine increased in a time dependent manner under basal 
conditions in tissues from control and gemcitabine pre -treated bladders (Figure 4.7C). Stretch 
did not enhance acetylcholine release and luminal gemcitabine pre -treatment also had no effect 
on release (Figure 4.7 C&D). 
Prostaglandin E2 release similarly increased in a time-dependent manner (Figure 4.7 E&F ). 
This was also seen in gemcitabine pre-t reated tissues. Luminal pre-treatment with gemcitabine 
significantly enhanced subsequent prostaglandin release compared to matched control tissues, 
by a factor of 3 in both the basal and stretched conditions at each time point measured.  
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Figure 4.7: Basal and stretch induced ATP (A&B), acetylcholine (C&D) and prostaglandin E2 (E&F) from isolated 
strips of urothelium/lamina propria from porcine bladders pre-treated with luminal saline (0.9%) or gemcitabine 
(40mg/mL) at 37oC for 1 hour. Data is represented as mean ± SEM (n≥4), analysed by an one -way ANOVA with 
Bonferroni post-test (*p<0.05, **p<0.01 and ***p<0.001 vs control) 
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UROTHELIAL MEDIATOR RELEASE: INCUBATION AT 42OC 
The effect of incubation of tissues at 42
o
C and in combination luminal gemcitabine treatment 
was examined. With comparison to control tissues incubated at 37
o
C, the release of ATP both 
basally and with stretch from control tissues incubated at 42
o
C was reduced by >80% across all 
time points after 1 minute (Figure 4.7 A&B, 4.8 A&B). With hyperthermia pre-treatment, there 
was no difference between basal and stretch-induced release of ATP, nor did gemcitabine alter 
the release of ATP with comparison to the matched controls.  
As observed following pre-incubation at 37
o
C, release of acetylcholine at basal conditions 
increased in a time dependent manner in both control and gemcitabine pre-treated tissues at 
42
o
C (Figure 4.8 C&D). No change was observed in the release of acetylcholine from tissues 
pre-incubated at 42
o
C with comparison to the 37
o
C, nor did luminal gemcitabine pre-treatment 
have any effect on acetylcholine release with comparison to control tissues pre-incubated at 
42
o
C. 
Pre-incubation at 42
o
C enhanced basal release of prostaglandin E2 from control tissues with 
comparison to the 37
o
C incubation (Figure 4.8 E&F ). Luminal gemcitabine pre-t reatment at 
42
o
C enhanced release of prostaglandin E2 from control tissues, however this was not 
significant as some samples were below the level of detection of the assay.  
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Figure 4.8: Basal and stretch induced ATP (A&B), acetylcholine (C&D) and prostaglandin E2 (E&F) from isolated 
strips of urothelium/lamina propria from porcine bladders, pre -treated with luminal saline (0.9%) or gemcitabine 
(40mg/mL) at 42oC for 1 hour. Data is represented as mean ± SEM (n≥4), analysed by an one -way ANOVA with 
Bonferroni post-test (*p<0.05, **p<0.01 and ***p<0.001 vs control) 
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SPONTANEOUS ACTIVITY OF THE BLADDER 
Spontaneous contractions of denuded detrusor strips and urothelium/lamina propria tissue 
strips after one hour equilibration were examined. The urothelium/lamina propria contracted 
spontaneously, as seen in Figure 4.9. Isolated strips of denuded detrusor also displayed 
spontaneous contraction, although in tissues treated at 42
o
C, these contractions we only 
discernible in 3 (out of 8) tissues. Both amplitude and frequency of contractions evoked by 
denuded detrusor strips were significantly depressed with comparison to the matched isolated 
urothelial strips (Figure 4.10 A&B). Treatment with gemcitabine or increased pre-incubation 
temperature did not change the spontaneous contraction of either denuded detrusor or 
urothelium/lamina propria 
 
 
Figure 4.9: Representative trace of spontaneous activity from strips of isolate d porcine urothelium/lamina 
propria 
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Figure 4.10: Frequency (A) and amplitude (B) of spontaneous contractions from isolated strips of porcine 
urothelial and denuded detrusor tissue from bladders pre -treated with luminal saline (0.9%) or gemcitabine 
(40mg/mL) for 1 hour, incubated at 37oC or 42oC. Data represented as mean ± SEM (n≥3), contraction 
normalised by tissue weight, analysed with an unpaired two-tailed t-test (*p<0.05, **p<0.01 vs matched 
urothelial strips)  
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CONTRACTILITY OF TISSUE STRIPS 
The effect of pre-incubation gemcitabine and increased temperature on tissue contractility was 
examined in urothelium/lamina propria, denuded detrusor and intact bladder strips. Contraction 
to KCl (60mM) and ATP (1mM) was investigated first. 
In urothelial and intact bladder strips, neither gemcitabine nor hyperthermia pre -treatment had 
any effect on either responses to KCl (Figure 4.11 A&C) or ATP (Figure 4.12 A&C). For the 
denuded detrusor strips, combined gemcitabine and hyperthermia pre-treatment reduced 
contraction to KCl by 80% (Figure 4.11B), while contraction to ATP was reduced by 
approximately 75% and 90% respectively by hyperthermia pre-treatment alone and in 
combination with gemcitabine (Figure 4.12B). 
Also, the inhibitory effect of the urothelium on the detrusor muscle was observed in the control 
intact tissues; inhibiting contraction to KCl by 65% and 62% at pre-incubation temperatures 
37
o
C and 42
o
C respectively, while this effect was abolished with gemcitabine pre -treatment 
(Figure 4.11C). This inhibitory effect of the urothelium on intact tissues was observed in 
contraction to ATP of control tissues, reducing by 60%. This was effect was not observed in 
gemcitabine pre-treated tissues, nor the 42
o
C pre-incubated control (Figure 4.12C).  
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Figure 4.11: Effect of 1hr luminal pre-treatment w ith saline (0.9% - control) or gemcitabine (40mg/mL) at either 
37oC or 42oC on the contractility of isolated urothelial (A), denuded detrusor (B) and intact (C) porcine tissue to 
60mM KCl. Data represented as mean ± SEM (n≥7), contraction normalised by tissue weight, analysed by a one-
way ANOVA with Dunnett post-test (** p<0.01 vs 37oC control). 
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Figure 4.12: Effect of 1hr luminal pre-treatment w ith saline (0.9% - control) or gemcitabine (40mg/mL) at either 
37oC or 42oC on the contractility of isolated urothelial (A), denuded detrusor (B) and intact (C) porcine tissue to 
1mM ATP. Data represented as mean ± SEM (n≥7), contraction normalised by tissue weight, analysed by a one-
way ANOVA with Dunnett post-test (* p<0.05, ** p<0.01 vs 37oC control). 
  
151 
 
RESPONSE TO PHARMACOLOGICAL AGENTS 
Next, the effect of pre-treatment with gemcitabine and/or increased temperature on response of 
strips of porcine tissue to the muscarinic agonist carbachol and β-adrenergic agonist 
isoprenaline was investigated.  
CONTRACTION RESPONSE TO CARBACHOL  
Figure 4.13 depicts representative contractions of a denuded detrusor muscle strip to 
cumulative concentrations of carbachol. In all tissues, contractions to cumulative additions of 
carbachol were depressed across the curve by gemcitabine and/or hyperthermia pre -treatment 
(Figure 4.14 A-C). However, when presented as % contraction to the maximum, the potency of 
carbachol was similar in all tissue groups (Figure 4.14 D-F).  
The maximal contractions to carbachol in the isolated urothelium were depressed in the 
gemcitabine pre-treated tissues, being reduced by 42% and 48% in the 37
o
C and 42
o
C 
incubation groups respectively (Figure 4.14A, Table 4.1).  
Similarly, with comparison to the 37
o
C control response of the denuded detrusor, the maximal 
contraction to carbachol was reduced 42% and 80% by gemcitabine pre-treatment at 37
o
C and 
42
o
C respectively (Figure 4.14B, Table 4.1). 
Finally, contraction to carbachol was measured in strips of intact bladder tissue. The inhibitory 
effect of the urothelium on detrusor maximal contraction to carbachol was observed in control 
tissues pre-incubated at both 37
o
C (449±106mN/g denuded detrusor, 224±53mN/g intact, 
p=0.04) and 42
o
C (308±103mN/g denuded detrusor, 64±14mN/g intact, p=0.03), while this 
inhibitory effect was abolished in gemcitabine pre -treated tissues. The maximal contraction of 
the intact tissue to carbachol was significantly reduced from control tissues in the hyperthermia 
pre-treated group, by 75% (control 42
o
C) and 71% (gemcitabine 42
o
C) respectively (Figure 
4.14C, Table 4.1). 
Although pre-incubation with gemcitabine, increased temperature, or combined gemcitabine 
and hyperthermia reduced the maximal contractions to carbachol; there was no change in the 
pEC50 values of carbachol in each tissue type between treatment groups (Table 4.1). 
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Figure 4.13: Representative trace of denuded porcine detrusor response to cumulative concentrations of 
carbachol.  
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Figure 4.14: Effect of 1hr luminal pre-treatment with saline (0.9% control) or gemcitabine (40mg/mL) at 37oC or 
42oC on the contraction of isolated urothelium (A&D), denuded detrusor (B&E) and intact (C&F) porcine tissue 
to cumulative carbachol concentrations (A-C) and contraction represented as a % of the maximum of the 
respective control/treatment groups (D-F). Data represented as mean ± SEM (n≥7), contraction normalised by 
tissue weight.  
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Table 4.1: Effect of 1hr luminal pre-treatment w ith saline (0.9% - control) or gemcitabine (40mg/mL) incubation 
at 37oC or 42oC on the pEC50 (SEM) and EC50 (95% CI) values for carbachol in isolated porcine urothelial, 
denuded detrusor and intact tissue strips. Data analysed with a multiple comparison F test (n≥7) and one-way 
ANOVA using Dunnett post-test (*p<0.05 w ith comparison to 37oC Control) 
 
 
 
 
 
  
 37
o
C Control 37
o
C 
Gemcitabine 
42
o
C  Control 42
o
C 
Gemcitabine 
Isolated Urothelial/Lamina Propria Tissue 
pEC50 (± SEM)  6.0 ± 0.2 5.5 ± 0.2 5.8 ± 0.2 5.4 ± 0.2 
EC50 (95% CI) 1.1 (0.5–2.9) µM 3.0 (1.2–7.8) µM 1.6 (0.7–3.7) µM 3.9 (1.4–10.9) 
µM 
Maximum 
Response 
(mN/g) 
641.6 ± 111.6 371.2 ± 64.4* 456.8 ± 66.8  335 ± 66 
Denuded Detrusor Tissue 
pEC50 (± SEM)  5.9 ± 0.3 5.7 ± 0.2 5.9 ± 0.3 5.9 ± 0.2 
EC50 (95% CI) 1.2 (0.4–4) µM 2.0 (0.9–4.4) µM 1.4 (0.3–5.5) µM 1.3 (0.4–3.7) µM 
Maximum 
Response 
(mN/g) 
449 ± 105.8 260.7 ± 34.8 307.6 ± 102.9 82.8 ± 19.3** 
Intact Tissue 
pEC50 (± SEM)  5.4 ± 0.2 5.6 ± 0.2 5.7 ± 0.2 5.7 ± 0.1 
EC50 (95% CI) 3.6 (1.2–10.6) 
µM 
2.8 (0.9–8.6) µM 2.0 (0.8–4.8) µM 1.9 (1.1–3.3) µM 
Maximum 
Response 
(mN/g) 
224.5 ± 52.8 180.9 ± 30.5 64.4 ±14.4* 68.2 ± 9* 
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RELAXATION RESPONSE TO ISOPRENALINE 
After pre-contraction of the tissues with carbachol, the addition of isoprenaline caused a 
concentration-dependent relaxation. In strips of urothelium/lamina propria, denuded detrusor 
and intact tissue, relaxation to cumulative additions of isoprenaline were depressed by 
gemcitabine and/or hyperthermia pre-treatment (Figure 4.15 A-C). However, when presented 
as % contraction to the maximum, there was no change between treatment groups in each of 
the tissue types (Figure 4.15 D-F). 
The maximal relaxation to isoprenaline in the isolated urothelium was depressed by over 50% in 
all pre-t reatment groups (Figure 4.15A). However, this was only significant in the 37
o
C 
gemcitabine pre-treated group (Table 4.2). 
In the denuded detrusor tissue, only the gemcitabine and combined hyperthermia pre -treatment 
group significantly reduced the maximal response to isoprenaline by >80% (Figure 4.15B, 
Table 4.2). 
While the maximal response to isoprenaline was reduced from control in strips of intact bladder 
tissue pre-treated with gemcitabine and/or hyperthermia, this effect was not significant (Figure 
4.15C, Table 4.2). The presence of the urothelium did not affect relaxation to isoprenaline.   
Although pre-incubation with gemcitabine and/or hyperthermia reduced the maximal relaxation 
response to isoprenaline; there was no difference in the potency of this response as evidenced 
by the unchanged pEC50 values of isoprenaline in each tissue type between treatment groups 
(Table 4.2).  
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Figure 4.15: Effect of 1hr luminal pre -treatment w ith saline (0.9% - control) or gemcitabine (40mg/mL) 
incubation at 37oC or 42oC on the relaxation response of isolated urothelial (A&D), denuded detrusor (B&E) and 
intact (C&F) porcine tissue to cumulative isoprenaline concentrations (A-C) and relaxation represented as a % 
of the maximum of the respective control/treatment groups (D-F). Data represented as mean ± SEM (n≥6), 
relaxation normalised by tissue weight. 
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Table 4.2: Effect of 1hr luminal pre-treatment with saline (0.9% - control) or gemcitabine (40mg/mL) at 37oC or 
42oC on the pEC50 (SEM) and EC50 (95% CI) values for isoprenaline in isolated porcine urothelial/lamina 
propria, denuded detrusor and intact tissue strips. Data analysed with a multiple comparison F test (n≥6) and 
one-way ANOVA using Dunnett post-test (*p<0.05 with comparison to 37oC Control) 
 
 
  
 37
o
C Control 37
o
C 
Gemcitabine 
42
o
C  Control 42
o
C 
Gemcitabine 
Isolated Urothelial/Lamina Propria Tissue 
pEC50 (± SEM)  6.3 ± 0.4 6.1 ± 0.3 6.6 ± 0.4 6.1 ± 0.4 
EC50 (95% CI) 0.5 (0.1–4.0) µM 0.9 (0.3–3.0) µM 0.3 (0.1–1.3) µM 0.7 (0.1–4.3) µM 
Maximum 
Response 
(mN/g) 
279.9 ± 66.8 136.7 ± 23.3* 137.3 ± 19.5 133.8 ± 33.1 
Denuded Detrusor Tissue 
pEC50 (± SEM)  6.7 ± 0.4 6.7 ± 0.2 7.2 ± 0.2 7.1 ± 0.4 
EC50 (95% CI) 0.2(0.03–1.2) 
µM 
0.2 (0.1–0.5) µM 0.03 (0.02–0.5) 
µM 
0.08 (0.01–0.6) 
µM 
Maximum 
Response 
(mN/g) 
83.2 ± 32.1 39.9 ± 6.3 28.1 ± 3.9 14.1 ± 2.4* 
Intact Tissue 
pEC50 (± SEM)  6.7 ± 0.3 6.7 ± 0.3 7.1 ± 0.2 7.3 ± 0.8 
EC50 (95% CI) 0.2 (0.05–0.9) 
µM 
0.2 (0.05–0.8) 
µM 
0.07 (0.03–0.2) 
µM 
0.06 (0.001–1.6) 
µM 
Maximum 
Response 
(mN/g) 
41.3 ± 12 37.5 ± 9 21.4 ± 3.2 18.6 ± 3.2 
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CONTRACTION TO ELECTRICAL FIELD STIMULATION 
Electrical field stimulation was used to investigate the effect of pre-treatment with gemcitabine 
and hyperthermia on the efferent nerve mediated contraction in porcine bla dders. Figure 4.16A 
depicts a trace of control (37
o
C pre-treatment) denuded detrusor contraction to EFS. The 
contractile response increased with increasing frequency of stimulation, and was knocked down 
with the addition of atropine (1µM) and α,β-mATP (10µM). 
The addition of the muscarinic antagonist atropine significantly reduce d contraction of the 
denuded detrusor at high frequencies by 74% (10Hz) and 85% (20Hz) respectively (Figure 
4.16B, Table 4.3). Desensitization of the P2X purinergic receptors with α,β-mATP reduced 
contraction by 90-84% from initial values at low stimulation frequencies (1 & 5Hz) as shown in 
Table 4.3, although there was no significant further reduction of contractions from atropine at 
higher frequencies (10 & 20Hz, Table 4.3).  
 
Table 4.3: Nerve-mediated contractile responses of control (37oC pre-treatment) porcine denuded detrusor 
muscle to electrical field stimulation, Data represented as mean ± SEM (n≥10), analysed by a one -way ANOVA 
with Tukey post-test(*p<0.05, **p<0.01 vs Initial response) 
Mean ± SEM 1Hz 5Hz 10Hz 20Hz 
Initial (mN/g) 28.6 ± 9.0 78.3 ± 20.2 140.9 ± 34.0 228.0 ± 72.0 
+ Atropine (1µM)  
(mN/g) 
18.4 ± 6.7 31.3 ± 11.4 37.4 ± 12** 33.5 ± 10.6** 
+ Atropine (1µM) 
+ α,β-mATP 
(10µM) (mN/g) 
3.1 ± 1.6* 12.6 ± 4.8** 15.6 ± 5.7** 17.6 ± 6** 
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Figure 4.16: A – Representative trace of contractile responses of a porcine denuded detrusor strip to electrical 
field stimulation (20V, 1ms pulse-width, 5s train). B – Contraction to EFS in the presence of atropine and α,β-
mATP. Data is represented as mean ± SEM (n≥10), normalised  by tissue weight. 
 
 
  
A 
160 
 
At 37
o
C luminal pre-treatment with gemcitabine (40mg/mL) reduced the contractile response to 
EFS at all frequencies by 37-45%. Similarly, control porcine tissues pre-incubated at 42
o
C also 
displayed reduced nerve-mediated contractions, and synergic effects of gemcitabine and 
hyperthermia were observed resulting in significantly reduced contractions to EFS across all 
frequencies with comparison to the control 37
o
C responses (Figure 4.17A). 
The addition of atropine (1µM) reduced the EFS contraction by 85% of the inital response at the 
20Hz frequency in all tissues, showing acetylcholine having the largest contribution to the EFS 
mediated contraction in all groups. The effect of combined gemcitabine and hyperthermia pre-
treatment significantly reduced the contraction to EFS from control responses at frequencies 10 
and 20Hz with atropine (Figure 4.17B). 
There was no difference between EFS responses with the addition of α,β -mATP between 
control and tissues pre-treated with gemcitabine and/or hyperthermia (Figure 4.17C).  
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Figure 4.17: Effect of luminal control (0.9% saline) and gemcitabine (40mg/mL) pre-treatment at 37oC and 42oC 
on contraction of porcine denuded detrusor strips to electrical field stimulation (20V, 1ms pulse -width, 5s train). 
Data is represented as mean ± SEM (n≥7), analysed by a two-way ANOVA with Bonferroni post-test (#p<0.05 
Gemcitabine 37oC vs Control 37oC, ^p<0.05 Control 42oC vs Control 37oC, *p<0.05, ***p<0.001 Gemcitabine 42oC 
vs Control 37oC). 
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4.5 DISCUSSION 
This study aimed to investigate the effect of pre-incubation with luminal gemcitabine, increased 
temperature and the combination on the porcine bladder. Intravesical chemotherapy for bladder 
cancer involves instillation of cytotoxic drugs to lie in direct contact with the urothelium. To 
mimic this treatment, a modified Ussing’s chamber was used to ensure gemcitabine was applied 
only on the luminal side of the bladder, while the adventitial side was bathed in Krebs -
bicarbonate solution. Thus, our model simulated the clinical setting, where tissues are exposed 
to luminal gemcitabine at a concentration of 40mg/mL and incubated for 60 minutes at either 
body temperature (37
o
C) or under hyperthermic conditions (42
o
C).  
 
UROTHELIAL EFFECTS OF LUMINAL GEMCITABINE AND/OR HYPERTHERMIA 
As the urothelium lies in direct contact with gemcitabine during intravesical treatment, it is likely 
that damage to the urothelium may in part be responsible for the urological side effects  reported 
by patients. This study examined histological specimens of porcine bladder stained with 
haematoxylin and eosin after 1hr treatment of gemcitabine incubated at 37
o
C or 42
o
C. A 
decrease in urothelial thickness was observed in porcine tissue treated with gemcitabine, further 
enhanced by combined hyperthermia and gemcitabine. The distinct crypt -like folded 
appearance of the urothelium in the control tissues was similar in appearance to that reported in 
other mammalian urothelium (Desantis et al., 2013). Furthermore, as observed in normal human 
bladder specimens, a clearly defined basal lamina separates the urothelium from the lamina 
propria, characterised by smooth contours (Jost et al., 1989). Loss of the tightly folded structure 
of the urothelium was noted in bladder portions treated with gemcitabine, however the basal 
lamina remained intact and appeared undamaged by luminal gemcitabine treatment or 
incubation at either temperature. 
Staining with cytokeratin 7, a protein expressed by simple epithelial cells including the 
urothelium (Moll et al., 1982), showed disruption of the apical membrane in samples of porcine 
tissue treated with gemcitabine, which was amplified in tissues treated with gemcitabine at 42
o
C. 
As previously discussed in Chapter 1, the apical membrane is made up of an arrangement of 
uroplakin proteins (UP Ia, UP Ib, UP II and UPIII) with intervening plaques (Lee, 2011, Apodaca, 
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2004). Additionally, the presence of a glycosaminoglycan layer (GAG) layer on the apical side of 
the urothelium is the principle defence barrier against bacteria, proteins and molecules typically 
present in urine. The GAG layer is made up of chains of disaccharides which attract water 
molecules and form a gel-like barrier to the urothelium. Recent studies have found that the 
disaccharide chondroitin sulphate present in the GAG layer plays an important role in the 
urothelial barrier function (Janssen et al., 2013, Hauser et al., 2009). Furthermore, the 
combination of chondroitin sulphate and gemcitabine has a synergistic cytotoxic effect on the 
bladder cell line HT-1376, inducing apoptosis through the activation of capsase 3 and 9 (Ferro 
et al., 2012). Damage to the GAG layer, in particular the chondroitin sulphate disaccharide, has 
been linked to the development of interstitial cystitis (characterised by urinary frequency, 
bladder pain and urgency) and urinary tract infections (Iavazzo et al., 2007, Morales et al., 1996,  
Hurst et al., 1987, Theoharides et al., 2001, Parsons, 1986). Histological staining of rat 
urothelium following cyclophosphamide-induced cystitis produced similar disruption to the apical 
surface of the urothelium, comparable to that observed within this study (Birder and Andersson, 
2013). It may be inferred from the results of this study that gemcitabine damages the protective 
barrier of the urothelium, by inducing apotosis by chondroitin sulphate expressing cells.  
The presence of cytokeratin 20 was also examined on specimens of isolated porcine tissue 
treated with gemcitabine and the vehicle control. The expression of cytokeratin 20 is restricted 
to superficial umbrella cells and highly differentiated intermediate cells of the urothelium in 
normal human bladders (Harnden et al., 1996). It is thought to facilitate membrane transport 
during bladder filling and contraction (through fusing/internalisation of vesicles to the cytoplasm),  
and is used as a marker for urothelial dysplasia (Veranic and Jezernik, 2002, Mallofre et al., 
2003). The control tissues incubated at 37
o
C in this study similarly displayed cytokeratin 20 
staining restricted to the apical cells of the urothelium. In tissues treated with gemcitabine, there 
was a distinct decrease in number of cells stained for cytokeratin 20, further exacerbated by 
combined gemcitabine and hyperthermia pre-incubation. This effect was similarly observed in 
control tissues incubated at 42
o
C, indicative of urothelial sloughing by hyperthermia.  
While this study provides conclusive evidence of erosion by gemcitabine and hyperthermia pre-
treatment of the apical layer of umbrella cells, there was no significant change in urothelial width 
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measured with histological staining. Witjes et al (2003) noted mild signs of the inflammatory 
response, and epithelial cellular and nuclear enlargement in pig bladders after repeated 
intravesical gemcitabine. Additionally, a study investigating the effect of intravesical saline 
irrigated through the bladder at a temperature of 45
o
C (temperature of the saline within the 
bladder was unclear due to crude methodology) noted the cystoscopic appearance of the 
urothelium as oedematous compared to pre-treatment (Hall et al., 1974). This finding may 
explain why urothelial sloughing observed after gemcitabine and hyperthermia pre-treatment 
was not associated with change in the width of the urothelium. 
Some conditions of the bladder, including painful bladder syndrome/interstitial cystitis, 
senescence and spinal cord injury are also associated with changes in the urothelial barrier 
function (Apodaca et al., 2003, Lavelle et al., 2000, Parsons et al., 1991). Studies profiling 
urothelial keratin composition in human patients with painful bladder syndrome/interstitial cystitis 
have found altered cytokeratin 20 expression, with 17% of patients exhibiting an entirely 
negative stain (Laguna et al., 2006). This study conclusively shows damage to the urothelium  
by gemcitabine treatment, in particular, sloughing of the apical umbrella cells. As in other 
pathological bladder conditions, the pain and increased frequency/urgency of urination reported 
by patients treated with intravesical gemcitabine may be in part due to the compromised barrier 
function of the urothelium, and the exposure of the underlying bladder nerves and detrusor 
muscle to irritants and mediators released by the urothelium.  
 
UROTHELIAL MEDIATOR RELEASE AFTER GEMCITABINE AND/OR HYPERTHERMIA 
PRE-TREATMENT 
Next, the effect of luminal gemcitabine and pre-incubation of porcine tissue at 37
o
C and 42
o
C on 
the function of the urothelium/lamina propria was investigated by measuring the basal and 
stretch –induced release of the mediators ATP, acetylcholine and prostaglandin E 2. Release of 
mediators within this study was measured over a time period of 15 minutes.  
 In control tissues, there was no change between the basal and stretch -induced release of 
mediators ATP, acetylcholine or prostaglandin E2. Previous studies found that stretch 
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significantly enhanced the release of ATP from strips of porcine urothelium/lamina propria 
(Sadananda et al., 2012, Smith et al., 2014, Kang et al., 2013b), but there have been no reports 
of change in release of acetylcholine and prostanglandin E2 between basal and stretched states. 
While this study saw modest increases in ATP release with stretch across all time points 
measured, this change was not statistically significant. This may be due to slight differences in 
protocol, namely the size of urothelial tissue tested, the magnitude of stretch stimulus and the 
time points over which samples were collected. 
Pre-treatment with luminal gemcitabine significantly decreased both basal and stretch-induced 
release of ATP. This is in direct contrast to a previous study by Kang et al (2013b) investigating 
the effect of the chemotherapeutic doxorubicin on urothelial mediator release. ATP release was 
significantly enhanced after luminal doxorubicin treatment. While the present study found that 
gemcitabine sloughed the apical umbrella cells from the urothelium, there was no his tologically 
measured change in urothelial thickness of porcine bladders treated with doxorubicin (Kang et 
al., 2013b). Doxorubicin has a molecular weight of 589D and it has been estimated that only 3% 
of the intravesically administered doxorubicin penetrat e the GAG-layer. Gemcitabine has a 
much smaller molecular weight of 299D, which may enable it to penetrate the apical membrane 
of the bladder urothelium. In addition, the urothelial erosion and hence fewer urothelial cells, 
observed after gemcitabine treatment may account for the depressed ATP release with 
comparison to control.  
Ferguson and colleagues (1997) first reported the release of ATP from the serosal, but not 
mucosal surface of the bladder. Further investigation has since examined the relative 
contribution of this release from isolated urothelium from the mucosal (umbrella cell) and 
serosal (basal cell) surfaces using Ussing’s chambers (Wang et al., 2005). ATP release with 
hydrostatic pressure was enhanced with stretch from both sides of the urothelium, the amount 
released into the apical hemichamber was approximately 50 -fold greater than that released into 
the serosal hemichamber. The gemcitabine-induced stripping of the umbrella cells of the 
urothelium may be responsible for the depressed release of ATP seen in the present study. As 
damage to the umbrella cell layer induces functional and structural changes to the underlying 
cells to restore the barrier properties of the urothelium (Kreft et al., 2009a, Kreft et al., 2009b, 
166 
 
Lavelle et al., 2002), it would be interesting to investigate the release of ATP from gemcitabine-
treated urothelium/lamina propria after cellular recovery.   
Interestingly, control porcine tissues pre-incubated at 42
o
C released less ATP measured basally 
and during stretch. Histology and staining for cytokeratin 7 and 20 of this tissue also displayed 
sloughing of the apical layer of umbrella cells, which may account for the depressed release of 
ATP measured in this study. 
As previously described, there was no enhanced release of acetylcholine from the 
urothelium/lamina propria with stretch. This concurs with the results of previous studies 
quantifying urothelial mediator release (Kang et al., 2013b, Smith et al., 2014). Both basal and 
stretched release of acetylcholine accumulated in a time dependent manner in control cells 
incubated at both 37
o
C and 42
o
C. Pre-t reatment with gemcitabine at incubation temperature of 
37
o
C did not change the manner of release, increasing significantly from initial basal release 
after 15 minutes. However, there was no difference between acetylcholine release of control 
and gemcitabine treated tissues, nor did hyperthermia pre-treatment have any effect.  
Finally, prostaglandin E2 release was measured from strips of isolated urothelium/lamina propria.  
While no difference of prostaglandin E2 release was observed between basal or stretched 
conditions in control tissues, a time-dependent accumulation was evident. Gemcitabine pre-
treatment significantly enhanced release of prostaglandin E2, although it was similarly 
accumulated in a time-dependent manner.  
Prostaglandins are formed from arachidonate by the action of cyclooxygenase (COX) enzymes, 
and prostaglandin E2 in particular has been found to be released from both the detrusor and 
urothelium, contributing to the basal tone of the detrusor muscle and activating afferent nerves. 
It is well documented that enhanced release of prostaglandins play a role in mediating the 
inflammatory response within tissues (Ricciotti and FitzGerald, 2011). Patients with overactive 
bladder symptoms have significantly increased urinary levels of prostaglandin E 2 (Kim et al., 
2005, Kim et al., 2006). Using a rat model of acute (4 hours) and chronic (10 days) 
cyclophosphamide-induced cystitis, Hu et al. (2003b) found that COX-2 mRNA was increased 
12- and 9-fold respectively in acute and chronically inflamed bladders. COX-2 protein 
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expression paralleled the mRNA profile, and prostaglandin E2 release was also significantly 
increased from the rat bladder. Interstitial cystitis is characterised by increased frequency and 
painful urination, similar to the symptoms reported by patients undergoing intravesical 
gemcitabine treatment.  
 A further investigation of the role of prostaglandins on sensory nerve activity found that the 
addition of loxoprofen (a cyclooxygenase inhibitor) and ONO-8711 (prostaglandin E2 receptor 1 
antagonist) inhibited the enhanced neuronal activity in inflamed rat bladders (Ikeda et al., 2006). 
As prostaglandin E2 was enhanced with gemcitabine pre-treatment in porcine tissues, the above 
evidence supports its role in inducing an inflammatory response within human patients 
undergoing intravesical therapy with gemcitabine. This may explain the symptoms of 
overactivity and painful urination in this treatment.  
Basal release of prostaglandin E2 from control tissues pre-incubated at hyperthermic conditions 
(42
o
C) was enhanced from the 37
o
C tissue response. Pyrexia induced prostaglandin E2 is 
dependent on COX-2 enzyme activity in both mice and humans (Schwartz et al., 1999, Li et al., 
1999). This indicates that the increased formation of prostaglandin E2 in hyperthermic conditions 
may result from increased COX-2 activity.  Due to this enhanced release in hyperthermic control 
tissues, the enhanced release of prostaglandin E2 with gemcitabine and hyperthermia pre-
treatment was not observed. 
There was no change in stretched conditions in control tissues between the 37
o
C and 42
o
C 
incubation temperatures. However, release of prostaglandin E2 from gemcitabine pre-treated 
tissues at 42
o
C was enhanced from the 37
o
C gemcitabine group, possibly a synergistic effect 
from both heat and gemcitabine inducing enhanced release of prostaglandin E2.  
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EFFECT OF GEMCITABINE AND/OR HYPERTHERMIA ON CONTRACTILE AND 
RELAXANT RESPONSES OF THE BLADDER 
This study shows conclusive evidence that luminally applied gemcitabine and the effect of 
increased temperature causes damage to the urothelium, and alters the release of urothelial 
mediators ATP and prostaglandin E2. However, the micturition cycle of bladder filling and 
emptying is dependent upon the contraction and relaxation of the detrusor muscle. Furthermore, 
bladder specimens from patients with painful bladder syndrome and idiopathic detrusor 
overactivity are correlated with overexpression of M2 and M3 muscarinic receptors and a 
phenotype of increased frequency and urgency respectively (Mukerji et al., 2006).  Anti-
muscarinics are considered the first-line treatment for patients with overactive bladder, inhibiting 
muscarinic receptor-induced contractions of the bladder, and recently suggested to block 
bladder afferent nerve activity (Abrams et al., 2006, Yamaguchi, 2010). A further treatment for 
overactive bladder is β-adrenoceptor agonists, which act to improve the storage capacity of the 
bladder by inducing relaxation of the detrusor muscle, suppress involuntary detrusor contraction 
and improve symptoms of increased frequency (Yamaguchi and Chapple, 2007). Furthermore, 
it has recently been demonstrated that β-AR activation by isoprenaline in rat urothelial cells can 
trigger production and release of nitric oxide due to increased Ca
2+
 following stimulation of the 
adenylyl cyclase pathway in urothelial cells (Birder et al., 2002). This NO release is suggested 
to further relax the detrusor muscle and alter the perceptions of bladder sensation by acting on 
the bladder afferent nerves (Pandita et al., 2000). 
The following sections will elucidate the effects of luminal pre-treatment with gemcitabine and/or 
hyperthermia on the contractile and relaxant responses of the denuded detrusor, intact tissue 
and isolated urothelium. 
 
DETRUSOR MUSCLE 
During voiding, contraction of the detrusor muscle is initiated by the efferent nerves of the 
bladder. As previously discussed, parasympathetic postganglionic fibres release acetylcholine, 
acting upon the M3 muscarinic receptors in the detrusor muscle to cause contraction. In addition,  
parasympathetic stimulation causes the release of non-adrenergic, non-cholinergic (NANC) 
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transmitters which similarly induce contraction of the bladder smooth muscle. ATP was first 
implicated as a NANC transmitter through early experiments of the gut and later con firmed 
within the bladder (Burnstock et al., 1970, Kasakov and Burnstock, 1982).  
This study investigated the contribution of muscarinic and purinergic receptors to nerve 
mediated contractions induced by EFS. In the presence of the neurotoxin TTX, no contraction of 
the bladder tissue was recorded during preliminary experiments, confirming responses to these 
EFS parameters were nerve induced. The addition of atropine (a muscarinic antagonist) 
significantly depressed contraction to EFS at frequencies above 10Hz, reducing contraction at 
20Hz by 85%. This was similarly found in the porcine bladder by Sibley (1984), who reported 
atropine was least effective at blocking nerve-mediated contraction at low frequencies, while 
only 17% of contraction persisted at high frequency stimulation. Contraction of the healthy 
human detrusor muscle is considered to be almost purely cholinergic, however atropine-
resistance in nerve mediated contractions from human detrusor have been reported in patients 
with interstitial cystitis, unstable and obstructed bladders (Palea et al., 1993, Sibley, 1984, 
Bayliss et al., 1999). Contraction of these tissues is abolished in the presence of α,β-mATP, 
indicative of a role of enhanced neurally released ATP in contraction of the pathological bladder 
(Bayliss et al., 1999).   
ATP is co-released with acetylcholine from the bladder nerves, acting upon the P2X (ion 
channel family) and P2Y (G-protein coupled receptor family) purinoceptors present in the 
detrusor muscle. The purinergic agonist α,β-mATP acts to stimulate and then desensitize the 
P2X-purinoceptors. The addition of this agonist with atropine to the strips of denuded detrusor 
almost abolished the contraction to EFS at low frequencies, but had only a small further 
inhibitory effect on high frequency-induced contractions.  
This indicates that there may be a role of α,β-mATP resistant purinergic receptors within the 
porcine detrusor muscle that mediate contraction to neural stimulation. The presence of P2Y 
receptors within the porcine bladder detrusor have recently been confirmed, and it has been 
demonstrated that direct stimulation of these receptors in mouse bladder induced increases in 
bladder smooth muscle tone (Bahadory et al., 2013, Yu et al., 2013). Therefore, the atropine, 
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α,β-mATP-resistant contractions of the porcine bladder measured within this study may be 
mediated by ATP acting upon P2Y purinergic receptors. 
Pre-treatment with gemcitabine and/or hyperthermia depressed contraction to EFS at all 
frequencies tested. A significant reduction in contraction amplitude was measured in the 
combined gemcitabine and hyperthermia pre-treated group above 5Hz. This result is suggestive 
of the role of gemcitabine in reducing the nerve-induced contractions of the bladder; however 
the contraction of the detrusor muscle to endogenous agonists was also reduced, as discussed 
below. 
The contraction of the denuded detrusor muscle to KCl was reduced with gemcitabine pre-
treatment. This was significant in the combined gemcitabine and hyperthermia group, where  
contraction was reduced by approximately 80%. Contraction to cumulative additions of 
carbachol and ATP were similarly reduced by gemcitabine and/or hyperthermia pre -treatment in 
the denuded detrusor tissue. Furthermore, the maximal response to isoprenaline was reduced 
by 50-85% with gemcitabine and/or hyperthermia pre-treatment. However, there were no 
differences in the potency of responses of both carbachol and isoprenaline of the denuded 
detrusor. This is indicative of the loss of contractile and relaxat ion capacity of the detrusor 
muscle with gemcitabine and/or hyperthermia treatment.  Similarly, the cholinergic and P2X-
mediated components of contraction stimulated by EFS were unchanged by gemcitabine and/or 
hyperthermia treatment. Therefore, it seems that gemcitabine reduces the contractile activity of 
the detrusor muscle, rather than altering the activity of efferent bladder nerves. However, 
whether this is a transient or prolonged effect was not measurable in the present study, as 
tissue viability was compromised after ~16 hours.  
The extent to which gemcitabine can penetrate the urothelium and reach the underlying lamina 
propria and detrusor muscle is currently unknown. Luminal pre -treatment with the 
chemotherapeutic doxorubicin enhances efferent nerve activity, without directly affecting the 
detrusor muscle which is in contrast to findings of the present study (Kang et al., 2013b). 
However, only ~3% of intravesically administered doxorubicin permeates through the urothelium  
(Wientjes et al., 1996), while the penetrative effect of gemcitabine through the bladder wall is 
unknown. One of the mechanisms of increased cytotoxicity associated with combined 
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hyperthermia and intravesical chemotherapy for bladder cancer is increased cellular membrane 
permeability (Lammers et al., 2011), and this study has shown that gemcitabine strips the apical 
layer of umbrella cells. Gemcitabine may directly induce cellular damage on the detrusor muscle,  
or allow the permeation of noxious substances from the urine through the urothelium, thus 
resulting in underactive or impaired contractile function.  
INTACT TISSUE 
The presence of an intact urothelium/lamina propria on isolated porcine bladder strips has been 
found to inhibit contractions induced by the muscarinic agonist carbachol and KCl (Hawthorn et 
al., 2000, Wuest et al., 2005). In human bladder tissue, both KCl and carbachol -induced and 
nerve-mediated contractions are significantly inhibited by the presence of the urothelium, but 
not neurokinin A (part of the tachykinin family of neurotransmitters) (Chaiyaprasithi et al., 2003, 
Propping et al., 2013).  
In the present study, the contractile response of the intact control tissue (37
o
C) to KCl and ATP 
were significantly lower than the denuded detrusor contractile magnitude. As discussed in 
Chapter 1, the urothelium of intact porcine bladder tissue strips releases a diffusible inhibitory 
factor (UDIF) in response to muscarinic stimulation and the addition of KCl, which inhibits the 
contraction of the underlying detrusor (Hawthorn et al., 2000, Wuest et al., 2005). Similarly, 
removal of the urothelium from rat isolated bladder rings increased the contractile response to 
ATP (Khattab and Al-Hrasen, 2006). In the present study, the presence of the urothelium/lamina 
propria reduced the responses of the detrusor by 50-65% in control tissues (37
o
C) to carbachol, 
KCl and ATP, correlating with the inhibitory effect of the urothelium reported within these studies.  
Furthermore, Masungaga et al (2010) investigated whether the presence of the urothelium had 
any effect on relaxation responses to β-adrenoceptor agonists of the detrusor muscle, finding no 
differences between maximal responses of intact and denuded detrusor, similar to the results of 
the present study. However, it was found by Murakami et al (2007) that isoprenaline was more 
potent at inhibiting porcine detrusor contractions induced by carbachol in the presence of the 
urothelium. From this observation, it was suggested that the urothelium releases UDIF in 
response to isoprenaline stimulation, as it was confirmed not to be mediated by nit ric oxide 
(Murakami et al., 2007). The mechanism of action of UDIF has not yet been identified, however 
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its effects are not prevented with inhibition of nitric oxide synthase, cyclo-oxygenase production, 
catecholamines, adenosine, GABA, purinergic receptors, potassium channels or endothelium-
derived hyperpolarizing factor are inhibited (Chaiyaprasithi et al., 2003, Hawthorn et al., 2000, 
Masunaga et al., 2010). In the present study, the inhibitory effect of the urothelium to cholinergic 
contraction of the detrusor was observed, although similar to previously reported studies, there 
was no enhanced relaxing effect. This supports the involvement of UDIF, which inhibits 
contraction but does not change relaxation of the detrusor muscle. 
Interestingly, the inhibitory effect of the urothelium with contraction to KCl, ATP and carbachol 
was not observed in gemcitabine pre-treated tissues at either temperature. Additionally, in 
comparison to controls, gemcitabine and/or hyperthermia pre-treatment generally attenuated 
intact tissue responses to KCl, ATP, carbachol and isoprenaline However this effect was only 
significant in the maximal contraction to carbachol, although there was no change in the 
potency of this response. 
Taken together, it would appear that luminal gemcitabine has a significant effect on the release 
of the urothelial-derived inhibitory factor. This may be a result of altered urothelial function due 
to physical damage to the urothelium of porcine bladders that was shown in the present study 
with luminal gemcitabine. A previous study by Smith et al (2014) observed that the inhibitory 
effect of the urothelium on porcine detrusor contraction was significantly reduced following 
luminal DMSO. Furthermore, reduction in inhibitory mechanisms of the urothelium on 
contraction of the detrusor muscle have similarly been observed in the human neurogenic 
overactive bladder (Chess-Williams et al., 2009). Consequently, the observed reduction in 
urothelial inhibition of the detrusor after gemcitabine pre-treatment as seen in the present study 
may contribute to the symptoms of overactive bladder as reported by patients undergoing 
intravesical therapy with this agent.  
 
ISOLATED UROTHELIUM/LAMINA PROPRIA 
This study shows conclusive evidence that luminally applied gemcitabine and the effect of 
increased temperature causes damage to the urothelium, and alters the release of urothelial 
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mediators ATP and prostaglandin E2. The urothelium and underlying lamina propria have been 
confirmed in recent years to play a significant role in normal bladder functioning, releasing 
factors that modulate detrusor contraction and sensory nerve activity (Hawthorn et al., 2000, 
Birder, 2011). It has previously been shown that the urothelium has contractile properties 
distinct from the detrusor muscle, suggested to be mediated by the suburothelial myofibroblasts 
(Sadananda et al. 2008). However, it has also been suggested by Heppner et al. (2011) that 
contraction of the urothelium/suburothelium may be generated by a component of muscularis 
mucosae in the suburothelium that is distinct from the detrusor.  
Furthermore, the urothelium/lamina propria has been found to exhibit spontaneous phasic 
activity and contracts to carbachol, mediated by the M3  muscarinic receptor (Moro et al., 2011). 
There is some evidence that indicates that this spontaneous activity of the urothelium may drive 
detrusor muscle activity. In the rat bladder, calcium and membrane potential t ransients 
produced by carbachol begin at the urothelial interface before spreading to the detrusor 
(Zygmunt et al., 1993). This effect is enhanced in overactive bladders from cats with feline 
cystitis, also associated with super sensitivity to muscarinic stimulation in the urothelium/lamina 
propria (Ikeda et al., 2009) 
As the urothelium is damaged by gemcitabine and the effect of hyperthermia, it is logical to 
assume that the contractile component of the urothelium will also be altered. The spontaneous 
phasic contractions were examined in isolated urothelium/lamina propria and denuded detrusor 
after pre-treatment with gemcitabine and/or hyperthermia. Both the amplitude and frequency of 
contractions were significantly less in the denuded detrusor strips compared to the isolated 
urothelium/lamina propria across all tissue groups. Moro et al. (2011) first reported a 
significantly lower rate of spontaneous contractions in the detrusor muscle compared to the 
urothelium/lamina propria, similar to the findings of the present study. Gemcitabine pre-
treatment had no effect on the spontaneous contraction of the tissues, nor did pre-incubation 
with saline at 42
o
C, although a trend of increasing frequency on contractions was observed with 
gemcitabine treatment. In spinal cord transected mice with bladder overactivity, Ikeda and Kanai 
(2008) found bladders exhibited significantly enhanced amplitude and frequency of 
spontaneous contractions, suggested to be associated with the over-expression of muscarinic 
174 
 
receptors in the urothelium/lamina propria. This effect was measured two weeks after spinal 
cord transection, while in the present study, spontaneous activity was measured immediately 
after gemcitabine pre-treatment. The development of enhanced spontaneous contraction of the 
urothelium after intravesical gemcitabine in patients over a prolonged period may contribute to 
the symptoms of increased frequency of urination. 
This study also investigated the contraction of the isolated urothelium/lamina propria to KCl, 
ATP and carbachol, and the relaxant response mediated by isoprenaline. While gemcitabine 
and/or hyperthermia pre-treatment did not change the response of the urothelium/lamina propria 
to KCl and ATP, contraction to carbachol and relaxation to isoprenaline were attenuated. This 
result was not unexpected, as the urothelial sloughing that was observed after luminal 
gemcitabine pre-treatment most likely altered the contractile and relaxation component of the 
urothelium as well.  
 
CONCLUSIONS 
A previous study by Kang et al. (2013b) investigated the effects of luminal doxorubicin on 
porcine bladder using similar protocols to the present study. Similar to treatment with 
gemcitabine, the side effects of intravesical doxorubicin for NMIBC reported by patients include 
symptoms of painful and overactive bladder (Koya et al., 2006). Interestingly, pre-treatment with 
doxorubicin on porcine tissue increased basal urothelial ATP release, enhanced the 
urothelium/lamina propria contraction to muscarinic stimulation and enhanced neurogenic 
responses of the detrusor muscle (Kang et al., 2013b). Taken together, these changes in 
bladder function induced by doxorubicin were suggested to lead to bladder overactivity through 
a combination of sensitization of afferent nerves, and the contractile component of the detrusor 
muscle through enhanced neurogenic responses.  
This is in contrast to the results of the present study, where pre -treatment of gemcitabine on 
porcine tissue generally depressed the neurogenic and myogenic responses, although 
enhanced urothelial prostaglandin E2 release and abolished the effect of UDIF. From this, it 
appears that the symptoms of bladder overactivity are similarly induced by sensitized afferent 
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nerves due to enhanced urothelial mediator release, and dysfunction of the inhibitory effect of 
the urothelium on the detrusor muscle, likely due to direct urothelial sloughing. The depressed 
contractile response of the detrusor muscle to endogenous muscarinic and purinergic 
stimulation seen in the present study mimic the actions of the current treatments for overact ive 
bladder. However, the reduced response to efferent nerve stimulation after gemcitabine 
treatment may also contribute to the symptoms of increased frequency and urgency, as this has 
similarly been observed in the overactive detrusor muscle from obstructed and idiopathic 
unstable bladders (Sibley, 1997, Steers, 2002).  
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CHAPTER 5: 
EFFECTS OF GEMCITABINE IN VIVO AND ON 
ISOLATED WHOLE BLADDER FUNCTION IN MICE 
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5.1 INTRODUCTION 
The previous chapter investigated the immediate effects of intraves ical gemcitabine on the 
porcine urothelium. However, chemotherapy for bladder cancer in human patients is given as a 
repeated schedule, with periods of recovery between treatments. This chapter investigates the 
effect of single and repeated doses of intravesical gemcitabine and subsequent recovery 
periods in mice.  
 
TREATMENT SCHEDULE 
As described previously, doses of 2000mg gemcitabine administered in 50mL of 0.9% saline 
(40mg/mL) has proven efficacy against superficial bladder cancer and is well tolerated in 
humans (Addeo et al., 2010, Mattioli et al., 2005). A study reported improved tumour response 
rates with intravesical gemcitabine given as repeated instillations, with complete remission rates 
reported in 44% of patients undergoing 6 weekly doses, compared to 40% with 3 bi-weekly 
doses and 10% undergoing a single post-operative transurethral resection dose (Gardmark et 
al., 2005). Furthermore, multiple Phase I, II and III studies have examined the tolerability of 
treatment schedules using intravesical gemcitabine in patients with non-muscle invasive bladder 
cancer (NMIBC) (Shelley et al., 2012). Table 5.1 highlights the incidence following urological 
side effects of intravesical gemcitabine at a dosage of 40mg/mL given once weekly for 6 weeks.  
As the weekly treatment schedule of 2000mg/50mL (40mg/mL) gemcitabine has been proven to 
be the most effective regime in human patients with NMIBC, the present study investigated the 
effect of intravesical treatments in mice. Ethical approval was obtained from the Griffith 
University Ethics Committee for single and repeated intravesical (2 instillations) treatments on a 
once-weekly schedule in mice.  
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Table 5.1: Local toxicity reports of patients undergoing treatment schedules with intravesical gemcitabine 
Study Participants Gemcitabine 
Schedule 
Toxicity & Side 
Effects  
Gontero et al. (2004) 
Phase II study 
39 patients with Ta or 
T1 (grade 1 & 2) 
NMIBC patients 
2000mg/50mL saline, 
once/week for 6 
weeks 
15% Hematuria 
38% Dysuria 
8% Frequency 
8% Urgency 
De Berardinis et al. 
(2004) 
Phase I study 
12 patients with Ta or 
T1 NMIBC patients 
500, 1000, 1500 or 
2000mg/50mL saline 
(3 patients/group), 
once/week for 6 
weeks 
1 (out of 3) patient  
treated with 2000mg 
reported frequency, 
urgency and dysuria  
Bartoletti et al. 
(2005) 
Phase II study 
116 patients with 
intermediate to high 
risk NMIBC 
2000mg/50mL saline, 
once/week for 6 
weeks 
22 patients (19%) 
reported frequency, 
urgency, dizziness 
and abdominal pain 
Addeo et al. (2010) 
Phase III study 
54 patients with Ta or 
T1 (grade 1-3) 
NMIBC 
2000mg/50mL saline, 
once/week for 6 
weeks 
38.8% patients  
reported side effects 
including dysuria,  
suprapubic pain,  
haematuria and 
cystitis 
 
COMPARISON OF HUMAN AND MOUSE BLADDER FUNCTION 
The structural anatomy of bladders in mice and humans are comparable. Similar to the human 
urinary system, the urothelium lines the luminal side of the bladder, sitting atop the 
suburothelium/lamina propria and detrusor muscle layers. Although the urothelium in murine 
bladders are only 2-3 cell layers thick (compared to 5-7 in humans), these layers are 
morphologically distinct and similarly play a role in sensory transmission (Treuting et al., 2012). 
Furthermore, the superficial layer of the urothelium expresses both uroplakins and 
glycosaminoglycans (GAG) in similar patterns to human tissue (Ramesh et al., 2004, 
Aboushwareb et al., 2009).  
There are similarities and differences in the physiological functioning of the mouse bladder with 
comparison to human tissue. As in human tissue, the detrusor of mouse bladders s imilarly 
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display spontaneous contractile activity, and the presence of the urothelium similarly attenuates 
the amplitude of detrusor contraction (Meng et al., 2008, Sibley, 1984).  
Contraction to muscarinic stimulation is also mediated via the M3 receptor in the mouse, 
confirmed through the lack of cholinergic contraction to carbachol in M2/M3 knock-out mice 
(Matsui et al., 2002). However, the contribution of Ca
2+
 influx in detrusor contraction differs 
between the human and mouse species (Choppin and Eglen, 2001, Wuest et al., 2007). The 
relaxation of the bladder during filling is mediated via the release of noradrenaline from 
sympathetic nerves acting on the β-adrenoceptors present in the detrusor muscle. In humans, 
the relaxation to the β-agonist isoprenaline is mediated via the β3 subtype, while in mice, 
antagonism of the β2-AR abolishes the response to isoprenaline, indicating that this receptor  
facilitates relaxation (Igawa et al., 2001, Igawa et al., 1998, Wuest et al., 2009).  
As discussed in previous chapters, nerve-mediated contraction in human and porcine bladders 
is almost completely mediated via the release of acetylcholine from the parasympathetic nerves 
(Sibley, 1984). In comparison, stimulation of the parasympathetic nerves in the mouse bladder 
causes the co-release of acetylcholine and ATP, inducing contraction through the muscarinic 
and purinergic receptors respectively, similar to the human bladder in pathological conditions. In 
vitro and in vivo studies on rodents have shown that contraction to EFS is mediated significantly 
by non-cholinergic, non-adrenergic stimulation (Igawa et al., 1993, Hegde et al., 1998). In mice, 
the purinergic component of contraction to electrical field stimulation has been reported to 
account for 55% of the nerve-mediated response (Lamarre et al., 2014). Furthermore, the P2X 
receptor-mediated component accounts for approximately 70% of the EFS response to short 
trains of stimuli (1s trains), as determined in P2X1 receptor deficient mice (Vial and Evans, 
2000). However, the purinergic component of human bladder contraction is enhanced in 
diseased states, and this response in mediated by ATP acting on the P2X1 receptors in both 
species (Elliott et al., 2013, Vial and Evans, 2000). 
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THE EFFECT OF INTRAVESICAL GEMCITABINE ON MOUSE BLADDER FUNCTION 
To the best of my knowledge, no studies have investigated the functional effect of intravesical 
gemcitabine on mouse bladders. A study involving treatment of the mouse bladder tumour 
(MBT-2) in female C3H/eb mice with 6-weekly instillations of gemcitabine (0.5, 2.5 and 10mg) 
reported no statistical differences in the histological changes of the bladder wall, including 
mucosal atypia, mucosal oedema, epithelial hyperplasia, mucosal erosion, sub-mucosal fibrosis 
and muscle thickness (Nativ et al., 2004).  
Bladder damage in mice after single and repeated intravesical instillations has been assessed 
using the chemotherapies mitomycin C and doxorubicin (Post et al., 1993). Bladder function 
was assessed as changes in urinary frequency, with both drugs inducing three-fold increases in 
the frequency of urination during weekly-treatments of 1mg/mL (mitomycin C) and 6mg/mL 
(doxorubicin). However, the above investigation into the effects of mitomycin C and doxorubicin 
did not report the mechanisms underlying the increased voiding frequency (Post et al., 1993). It 
has been shown that drugs specifically toxic (eg. cyclophosphamide) to the bladder induce rapid 
epithelial loss and an inflammatory response, causing functional bladder changes (Stewart, 
1986).  
A further study by Post et al. (1995b) noted acute functional damage in 80% of mice treated 
with intravesical mitomycin C, and that the mitotic activity of bladder epithelial cells was 
markedly increased 3 weeks after intravesical mitomycin C with comparison to control s, 
indicative of cell growth. This suggests damage to the epithelial lining of the bladder by 
intravesical instillation of cytotoxic drugs and the corresponding cell recovery mechanisms may 
account for the symptoms of increased voiding frequency in mice. F urther investigation of the 
mechanisms of the functional changes of the bladder after intravesical chemotherapy is 
required to elucidate appropriate treatment or preventative regimes.  
Cyclophosphamide (CPO) and ifosfamide (IFO) are chemotherapeutic drugs commonly used for 
the treatment of a variety of cancers, including breast, testicular, lung, cervical and lymphomas 
(Nichols, 1995, Buda et al., 2003, Gianni et al., 1990, Loehrer, 1990). It is well reported that 
systemic treatment with these drugs leads to bladder toxicity, bladder pain and dysfunction  
manifested as increased frequency and urgency of urination and dysuria (Korkmaz et al., 2007, 
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Fukuoka et al., 1991), not dissimilar to that reported by patients undergoing intravesical 
chemotherapy for bladder cancer. Rodents treated with CPO or IFO similarly demonstrate 
increased urinary frequency and decreased voiding pressure (Boudes et al., 2011, Macedo et 
al., 2011). Contraction of the bladder to muscarinic stimulation was depressed after systemic 
CPO/IFO treatment in rats (Macedo et al., 2011, Giglio et al., 2005), restored to control 
responses with the addition of the nitric oxide synthase inhibitor L-N
G
-Nitroarginine (L-NNA). 
Furthermore, animal models of bladder overactivity treated with CPO have also shown reduced 
detrusor contraction to P2X stimulation (Mok et al., 2000). These changes in bladder contractile 
responses have been suggested to play a role in the symptoms of bladder overactivity induced 
by CPO and IFO treatment. These parameters will be examined within this study to investigate 
the changes in bladders of mice induced by intravesical gemcitabine.  
 
EXPERIMENTAL PROTOCOLS 
Bladder cancer is often considered a disease of the elderly, with over 90% of Australian patients 
diagnosed over the age of 50 (Government, 2015). It is also well established that lower urinary 
tract symptoms increase in frequency with aging (Diokno et al., 1986, Diokno et al., 1992). In 
both men and women, post void residual volume increases, while bladder capacity and pe ak 
flow rate decrease with age (Madersbacher et al., 1998). It has been suggested that fibrosis of 
the bladder wall or alterations in nerve activity with aging are responsible for the changes in 
functional capacity, as the detrusor contraction strength in both men and women is preserved 
with age (Madersbacher et al., 1998, Malone-Lee and Wahedna, 1993). Symptoms of bladder 
overactivity, including increased voiding frequency, detrusor hyperexcitability and sensory 
stimulation have similarly been reported within aged mice (Triguero et al., 2014, Daly et al., 
2014). To account for these physiological changes in patients, an aged mouse model (female 
ex-breeders) was chosen, approximately 32-weeks in age.  
The human urinary system exhibits variations in urine output over a 24-hour period, coinciding 
with the day/night cycle. The circadian variations in urination patterns depend on daily urine 
production, the physical properties of the bladder and the neural control (Colwell, 2015). 
Rodents, including mice, are a nocturnal species. Mice demonstrate a circadian rhythm in 
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micturition frequency and volume, in part driven by the urine production by the kidney, which is 
linked to the circadian clock (Zuber et al., 2009, White et al., 2014). It has recently been 
reported that urinary bladder smooth muscle exhibit no diurnal differences in KCl or nerve-
evoked contractile properties (White et al., 2014). This is of significance as experiments in the 
present study were performed during the day.  
Voiding pattern analysis using filter paper has been confirmed in studies appearing in the 
literature as a valid method of analysis of voiding behaviours in rodents (Sugino et al., 2008). 
While the diurnal rhythm of bladder capacity and voiding frequency/volume is well documented, 
multiple studies have reported comparable micturition patterns during analysis in the day 
between mouse species and gender using the filter paper method (Sugino et al., 2008, Uvin et 
al., 2013, Daly et al., 2014).  
In humans, evaluation of bladder function is performed through cystometry, which records 
bladder filling/emptying and the consequent changes in int ravesical pressure. The previous 
chapter using porcine bladder tissue strips is an excellent model to determine the components 
of bladder contraction/relaxation; however a more physiologically relevant model is needed to 
assess the coordination between intact urothelium, underlying suburothelium containing bladder 
nerves and the detrusor muscle in its original form. Fabiyi and Brading (2006) validated the use 
of a whole-bladder model, which involved catheterisation of female mouse bladders through the 
urethra, measuring responses to various agonists and nerve stimulation as changes in 
intravesical pressure during an isovolumetric condition. Responses were found to be 
comparable to muscle strips, confirming the use of this model as an effective technique for 
assessing bladder functioning. Consequently, the isolated whole bladder experimental protocol 
was used within this study, similarly using female mice to investigate the effects of pre-treatment 
with intravesical gemcitabine. 
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5.2 AIMS 
The aims of the present study were to investigate the effects of in vivo single and repeated 
intravesical gemcitabine (40mg/mL) instillations on the mouse urinary bladder. Sp ecific aims 
were: 
1. To investigate the changes in voiding patterns with single and repeated intravesical 
gemcitabine instillations in mice 
2. To determine the effect of single and repeated intravesical gemcitabine instillations in 
mice bladders on the histological appearance of the urothelium  
3. To measure the release of ATP, acetylcholine and prostaglandin E2 from the urothelium 
and serosa of mouse bladders treated with single or repeated intravesical gemcitabine 
instillations 
4. To examine the effect of single and repeated intravesical gemcitabine instillations on 
spontaneous bladder contractions and responses to muscarinic, purinergic and 
adrenergic receptor stimulation 
5. To determine the effects of single and repeated intravesical gemcitabine instillations in 
mice bladders on the nerve-mediated contractions and assess the contributions of the 
nitric oxide, cholinergic and adrenergic components 
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5.3 MATERIALS AND METHODS 
ETHICAL APPROVAL 
Approval for this project was obtained from the Griffith University Animal Ethics Committee (GU 
Ref No: MSC/07/14/AEC) held by Dr Roselyn Rose’Meyer. Ethical considerations in keeping 
numbers of animals sacrificed to a minimum meant a control group (no intravesical treatment) 
was not approved and not investigated. 
 
ANIMALS 
Adult female C57BL/6JArc mice were obtained from the Animal Resource Centre (Canning Vale,  
WA, Australia) and housed in the Griffith University Animal House. Animal treatments and 
euthanasia were performed at the Griffith University Animal House and tissues were transported 
to Bond University for all experimental procedures (Bond University ethics RO1762).  
The female mice were ex-breeders, approximately 32-weeks in age. These mice were selected 
due to ease of intravesical treatment in females, and as a model of aged subjects. The 
C57BL/6JArc is a widely used inbred strain of mice. The animals were housed for one week 
prior to handling in a controlled environment with 12 hour light/dark cycles, temperature 23
o
C 
with free access to food and water. 
 
VOIDING PATTERN ANALYSIS 
The voiding pattern of the mice was examined before and after treatment using Whatman Filter 
paper #1 (Interpath Services, Victoria, Australia). Mice were housed singly in cages lined with 
15 x 21cm sheets of Whatman Filter paper #1 for 4 hours with free access to food and water. 
The filter paper was collected and urine spots detected using a Molecular Imager ChemiDoc 
XRS ult raviolet transilluminator (#720BR1293 BioRad, California USA). The papers were 
photographed, digitised, and analysed using Image J software. This protocol was based upon 
previously reported studies into the voiding patterns of aged and overactive bladder models in 
mice (Uvin et al., 2013, Daly et al., 2014, Boudes et al., 2011). Voiding analysis was performed 
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on the mice before intravesical treatment and was repeated 24hrs after treatment, before 
euthanasia. All voiding pattern analysis were performed in the morning, beginning at the 
change-over of the light/dark cycle (7.30am). Voided volume was determined by measuring the 
area of urine patches of known volume, shown by Figure 5.1.  
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Figure 5.1: Area (cm 2) of known volume of mouse urine used to determine voided volume from mice during VPA 
 
TREATMENTS AND SCHEDULES 
Bladder cancer chemotherapeutic drugs were instilled into the bladder by the intravesical route. 
Dr Glen Ulett provided technical assistance in intravesical treatments. Mice were anaesthetised 
with 1-3% isoflurane gas. Isoflurane is a potent anaesthetic that produces rapid induction and 
recovery, with easy control of the depth of anaesthesia. It is considered safe and effective for 
laboratory mice use (Szczesny et al., 2004). Isoflurane has also been shown to abolish the 
micturition reflex while being administered, which is an advantage during intr avesical treatments  
(Matsuura and Downie, 2000).  
Prior to bladder catheterisation, micturition was induced by mild abdominal massage to lubricate 
the urethra and to prevent dilution of solutions. Bladder catheterisation was performed with 
sterile intravenous 22x1 gauge catheters (Terumo, Japan) through the urethra. This technique 
was based on that reported by Reis et al. (2011). Briefly, under anaesthesia, mice were 
positioned in dorsal recumbence and the external urethral ostium was identified (Figure 5.2a). 
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The catheter was introduced to the external urethral ostium by approximately 3mm from a 
cranial to caudal direction, before a 180
o
 circular caudal movement was completed, with the 
proximal tip of the catheter remaining static (Figure 5.2b). The catheter was then inserted 
approximately 7mm further into the urinary bladder (Figure 5.2c).  
 
Figure 5.2: Urinary bladder catheterisation in mice. A – Catheter tip inserted 3mm in the external urethral 
ostium, inset picture: representative position of urinary bladder and female urethra after catheter insertion. B – 
Alignment of catheter with female urethra, inset picture: representative position of the catheter in urethra. C – 
Catheter introduction to the bladder, inset picture: representative position of the urinary bladder and female 
urethra after complete catheter insertion in the bladder. Arrows represent the movement of the catheter in the 
urethra and urinary bladder catheterization steps (Reis et al., 2011). 
Approximately 30µL of solution was instilled through the catheter, before removal. Mice were 
allowed to run freely in their cage with access to food, but not water, for 1 hour on Whatmann 
Filter Paper no. 1, ensuring they did not void during this treatment period. Micturition was 
induced 1 hour post-intravesical instillation to expel the drug or saline solution.  
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Animals were split into four treatment groups as per Table 5.2, treated with 30µL of gemcitabine 
(40mg/mL) dissolved in isotonic (0.9%) saline or isotonic saline alone, with voiding pattern 
analysis (VPA) performed directly prior to both intravesical treatment and euthanasia.  
Table 5.2: Voiding pattern analysis and treatment schedule for single and repeated saline and gemcitabine 
treated animal groups. 
 Single Saline 
Treatment 
Single 
Gemcitabine 
Treatment 
Repeated 
Saline 
Treatment 
Repeated 
Gemcitabine 
Treatment 
Day 0 VPA analysis 
1x intravesical 
injection of 
isotonic (0.9%) 
saline, duration 
1hr 
VPA analysis  
1x intravesical 
injection of 
40mg/mL 
gemcitabine, 
duration 1hr 
VPA analysis  
1x (first) 
intravesical 
injection of 0.9% 
saline, duration 
1hr 
VPA analysis  
1x (first) 
intravesical 
injection of 
40mg/mL 
gemcitabine, 
duration 1hr 
Day 1 
(+24hrs from  
Day 0) 
VPA analysis 
Animals 
euthanized for 
experiments 
VPA analysis 
Animals 
euthanized for 
experiments 
--- --- 
Day 7 --- --- 1x (second) 
intravesical 
injection of 0.9% 
saline, duration 
1hr 
1x (second) 
intravesical 
injection of 
40mg/mL 
gemcitabine, 
duration 1hr 
Day 8 
(+24hrs from  
Day 7) 
--- --- VPA analysis 
Animals 
euthanized for 
experiments 
VPA analysis 
Animals 
euthanized for 
experiments 
Number of 
Animals 
6 6 5 5 
 
Animals were returned to their original cages and monitored 12 hours post treatment for signs of 
distress or pain. Sacrifice of mice was humanely performed either 24hrs or 8 days post init ial 
treatment by cervical dislocation in accordance with ethical committee approval and the 
guidelines of the National Health and Medical Research Council of Australia. An incision was 
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made in the abdomen of the mouse, removing the skin and peritoneum of the abdomen. The 
gastrointestinal tract superior to the bladder was removed, revealing the kidneys. The vertebrae 
of the animals were severed above the kidneys at approximately the level of L2, and the tail and 
hind limbs removed. The remaining pelvic area was placed into ice-cold Krebs-bicarbonate 
solution for transport from the Griffith University animal facility to the research labs at Bond 
University.   
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ISOLATED BLADDER SET UP 
After transport to the Bond University laboratory, the pelvis area of the sacrificed mouse was 
secured in a 30mL bath, continually superfused with Krebs-bicarbonate solution (6mL/min) 
gassed with 95% O2 and 5% CO2, maintained at a constant temperature of 37
o
C. Using a 
dissection microscope (WPI, PZMIII), the ovaries, the superior po rtion of the uterus, fallopian 
tubes and surrounding connective tissue were dissected away from the bladder, exposing the 
pubic symphysis. The ureters were ligated with silk suture proximal to the bladder to prevent 
leakage of intraluminal fluid. The pubic symphysis was cut either side of the urethra and 
removed, along with the pelvic bone and remaining portions of the hind legs. The urethra was 
identified, and carefully dissected from the remaining uterus and vagina of the mouse. A three-
way catheter was inserted through the urethra into the bladder, and secured using silk sutures. 
The bladder was then dissected from the remaining pelvic area, with ureters cut above the level 
of the ligation. The isolated bladder was immediately placed in a 10mL organ bath containing 
8mL Krebs-bicarbonate solution at 37
o
C, gassed with 95% O2 and 5% CO2. 
The ends of the catheter inserted through the urethra to the bladder were attached respectively 
to an infusion pump to fill the bladder, another to a two-way outflow tap to allow emptying of the 
bladder and the third to a pressure transducer to measure intravesical pressure, shown by 
Figure 5.3.  
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Figure 5.3: A - Schematic of the isolated mouse bladder set up, depicting the bladder connected to the three-
way catheter. B – Photograph of a mouse bladder connected to a three-way catheter.  
 
The pressure transducer was attached to a Neurolog headstage (NL100, Digitmer Ltd, UK) 
connected to a pressure amplifier (NL 108, Digitmer Ltd, UK) which amplified the pressure 
signals before they were passed to a Micro1401 analogue to digital interface (Cambridge 
Electronic Design, UK) and then visualised on a computer using Spike2 software (version 7.1, 
Cambridge Electronic Design, UK).  
The bladder was distended by infusing isotonic saline (0.9%) solution at 30µL/min to a 
maximum pressure of 40mmHg to check the viability of the catheterisation (leakages). The 
infusion pump was stopped and the outflow tap opened to allow passive removal of the 
intraluminal contents of the bladder. Baseline pressure from the emptied bladder in the closed 
system was subtracted from the pressures during distensions and agonist/nerve-mediated 
responses to give the change in intraluminal pressure. The isolated bladder was washed with 
fresh Krebs bicarbonate solution, distended to 25mmHg and allowed to stabilize for ~1 hour.  
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BLADDER COMPLIANCE AND SPONTANEOUS PHASIC CONTRACTIONS 
The effect of intravesical gemcitabine pre-treatment on the compliance of the bladder was 
examined by plotting bladder volume vs pressure curves. Additionally, phasic intravesical 
pressure increases were observed during filling of the bladder. These spontaneous contractions 
were similarly observed during the accommodation period after distension of the bladder to 
25mmHg. The frequency and amplitude of spontaneous contractions during filling were 
measured over a 100s period directly following intraluminal pressure exceeding 20mmHg. 
During accommodation, the frequency and amplitude of spontaneous contractions was 
measured toward the end of the 1hr stabilization period.  
 
MEASUREMENT OF UROTHELIAL MEDIATORS 
After confirmation of the viability of the bladder system, samples of serosal and int raluminal 
contents were collected for analysis of urothelial mediator release. After bladder emptying, the 
outflow tap was closed and the bath was washed and replaced with 8mL of fresh Krebs -
bicarbonate solution. The infusion pump was turned on to fill the bladder with isotonic saline at a 
rate of 60µl/min, to a pressure of 25mmHg. Once the pressure reached 25mmHg, infusion was 
stopped and the outflow tap was opened. The luminal contents of the bladder were collected in 
a tube on ice and were stored at -20
o
C as soon as possible. A sample of the Krebs solution 
surrounding the bladder was taken for examination of release of mediators from the serosal 
tissue, also stored at -20
o
C for later analysis. This process was repeated after washing with 
fresh Krebs-bicarbonate solution. The luminal and serosal samples were later analysed for the 
release of ATP, acetylcholine and prostaglandin E2 using commercially available kits described 
in Chapter 2.  
 
RESPONSE TO PHARMACOLOGICAL AGENTS 
To investigate the effects of gemcitabine treatment on receptor-mediated muscle tension, the 
isolated bladder was filled to a set pressure o f 25mmHg and allowed to stabilise for 1 hour. 
Contraction of the detrusor was instigated with the addition of the muscarinic agonist carbachol 
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(10µM) to the bath. After emptying and washing with fresh Krebs-bicarbonate, the bladder was 
re-filled to 25mmHg pressure and allowed to re-stabilize. Contraction to carbachol was repeated 
in the presence of the competitive inhibitor of nitric oxide synthase (NOS) L-N
G
-Nitroarginine (L-
NNA, 10µM).  
To investigate the effect of gemcitabine on the β-adrenoceptor mediated relaxation of the 
bladder, the non-selective β-adrenoceptor agonist isoprenaline was used. After washing, filling 
to 25mmHg and stabilization, cumulative additions of isoprenaline were added to the bath 
(100ng - 100µg), and the effect of muscle tension recorded as change from baseline.  
 
ELECTRICAL FIELD STIMULATION 
As contraction of the bladder is mediated primarily via the efferent nerves, the effect of 
intravesical gemcitabine treatment in mice on bladder contractions induced via nerve stimulation 
was investigated. After washing, the bladder was filled to 25mmHg and allowed to stabilise. The 
effect of electrical field stimulation was induced by placing platinum electrodes either side of the 
bladder (Figure 5.4). The bladder was electrically stimulated (50V, 0.1ms delay, 0.2ms pulse 
duration), delivered as a 5-second train every 100 seconds, at frequencies 1, 5, 10 and 20Hz. 
The tissues were stimulated at each frequency until stable responses were obtained, generally 
4 spikes. Contraction strength was recorded as change in pressure from baseline.  
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Figure 5.4: Schematic diagram of the isolated mouse bladder and electrical field stimulation set up. The bladder 
was filled through the infusion pump, stimulated by the current passing through the positive and negative 
electrodes, recorded by the pressure transducer.   
 
The contribution of various receptors and mediators on the nerve -mediated contraction in 
gemcitabine pre-treated bladders was investigated. Electrical field stimulation was repeated in 
the presence (15 minute pre-incubation) of 10µM L-NNA (NOS inhibitor), 1µM atropine 
(muscarinic antagonist) and after desensitization of P2X receptors with 10µM α,β-mATP. 
Additionally, as α,β-mATP is a competitive agonist of the P2X purinoceptors, the tension 
developed through the addition of this drug was recorded. The nerve-mediated contraction of 
the bladder to EFS was confirmed during preliminary experiments through the addition of the 
neurotoxin tetrodotoxin (1µM), which abolished the contractile response to the EFS parameters 
used within this study.  
Finally, 60mM KCl was added to the system to measure the non-receptor mediated contractile 
response of the bladder tissue.  
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HISTOLOGY 
Whole isolated mouse bladders were fixed in 10% neutral buffered formalin for 24 hours at 4
o
C 
for histology. A catheter attached to a syringe containing formalin was inserted into the bladder 
through the urethra and secured using silk suture. The bladder was filled with formalin using the 
syringe and submerged in a beaker of formalin, fixing the tissue in a partially distended state. 
After 24 hours, the bladder was cut in two, before processing, sectioning and staining as 
described in Chapter 2.   
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5.4 RESULTS 
GENERAL EFFECTS OF TREATMENT ON ANIMALS 
Prior to intravesical treatment, there was no significant difference in body mass between 
animals allocated to each treatment group. On average, animals from all treatment groups 
experienced loss in body mass after intravesical injections; however there was no statistically 
significant difference between them (Table 5.3 & 5.4, Figure 5.5 B&E). Similarly, the weights of 
the isolated bladders were unchanged between intravesical treatment groups (Table 5.3 & 5.4, 
Figure 5.5 A&D). Water consumption during the 4-hour voiding pattern analysis was recorded, 
and while the mice from the single and repeated gemcitabine treatment groups on average 
consumed more water post-treatment (0.09mL and 0.13mL respectively), this was not 
significantly  different from the saline-treated animals (Figure 5.5 C&F). 
Table 5.3: Water consumption, body weight and bladder weight prior to and 24hrs after single intravesical 
treatment with saline or gemcitabine 
 Single Saline Treatment Single Gemcitabine Treatment 
 
 
Pre-Treatment Post-Treatment Pre-Treatment Post-Treatment 
Water 
Consumption 
(mL) 
0.57±0.2 0.53±0.07 0.53±0.03 0.62±0.06 
Body Weight 
(g) 
27.29±1.01 26.35±0.75 28.86±0.38 27.85±0.52 
Bladder Weight 
(g) 
 0.05±0.004  0.05±0.005 
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Table 5.4: Water consumption, body weight and bladder weight prior to and post repeated intravesical 
treatment with saline or gemcitabine 
 Repeated Saline Treatment Repeated Gemcitabine 
Treatment 
 
 
Pre-Treatment Post-Treatment Pre-Treatment Post-Treatment 
Water 
Consumption 
(mL) 
0.47±0.07 0.52±0.03 0.57±0.1 0.7±0.1 
Body Weight 
(g) 
27.08±0.73 26.35±0.46 28.55±0.86 27.94±1.29 
Bladder Weight 
(g) 
 0.05±0.003  0.04±0.002 
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Table 5.5: Effects of intravesical gemcitabine on bladder weight (A), body weight (B – measured as change from 
pre- to post-treatment) and water consumption during voiding pattern analysis. Data represented as mean ± 
SEM (n≥4). 
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VOIDING PATTERN ANALYSIS 
The voiding behaviour of mice treated intravesically was assessed by measuring and 
quantifying the urine output of freely moving mice during a four hour period. Voiding pattern 
analysis was performed before and after (24 hours) intravesical treatments. Figure 5.6A is a 
representative image of a photographed sheet of Whatmann Filter Paper 1 under UV light, with 
urine spots shown as fluorescent. Spots were defined as small if the area was measured to be 
less than 0.2cm
2
. 
 On average, mice urinated 5.7±0.7 times in a four hour period, with 1.7±0.4 of those spots on 
the filter paper being small (less than 0.2cm
2
), as shown in Figure 5.6B. The total volume of the 
voided area during the 4 hours period was on average 394.6±35.4µL. 
Representative images of the voiding patterns 24-hours post intravesical treatment with saline 
and gemcitabine are seen in Figure 5.7 A&B respectively. Single intravesical treatments 
increased the number of voided spots during the 4-hour voiding pattern analysis (Figure 5.7C). 
Intravesical treatment with saline increased the total voided spots by 1.4 fold, while intravesical 
gemcitabine (40mg/mL) significantly enhanced the number of voided urine spots in female mice 
by 3.3 fold. The increase in spot number was primarily due to an increase in small-voids (less 
than 0.2cm
2
). As seen in Figure 5.7D, intravesical saline and gemcitabine enhanced small urine 
spot production 24 hours after treatment, by 3.4 and 8.8 fold respectively. This change was 
significant in the intravesical gemcitabine group (p<0.001). Although the number of voids 
increased after intravesical treatments, the total area of voided spots was unchanged from pre- 
to post-intravesical treatments with both agents (Figure 5.7E).  
Voiding pattern analysis was also performed on mice undergoing repeated intravesical 
treatments with saline and gemcitabine (40mg/mL). Representative images of voided urine 
spots from animals 24 hours post repeated (two) treatments of saline and gemcitabine are 
shown in Figure 5.8 A&B. There was no change in the total number of voided spots pre- and 
post-intravesical treatments with saline, while repeated gemcitabine instillations significantly 
enhanced the number of voided spots, by 1.9 fold (Figure 5.8C). This increase in spot number 
was due to a 2.4-fold increase in small-voids (less than 0.2cm
2
) after repeated treatments with 
gemcitabine (Figure 5.8D), similar to the results seen within the single intravesical gemcitabine 
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instillation mouse group. However, there was no change in the total voided area pre- and post-
repeated intravesical treatments in either the gemcitabine or the saline groups (Figure 5.8E).  
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Figure 5.6: Representative images of voiding pattern analysis. Photographed sheet of Whatmann Filter Paper 1 
showing urine spot patterns obtained from a mouse prior to intravesical treatment (A) over a 4-hour period. 
Urine spot patterns in mice prior to intravesical treatment (B). Data represented as mean ± SEM (n=23).  
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Figure 5.7: Representative images of voiding pattern analysis. Photographed sheets of Whatmann Filter Paper showing urine spots obtained from mice 24hours after a single 
dose of (A) intravesical isotonic saline and (B) intravesical gemcitabine (40mg/mL). The total number of voiding events (C), number of small spots (D) and total voided area (E) 
were measured pre- and post- intravesical treatment with gemcitabine or isotonic saline solution. Data is represented as mean ± SEM (n=6), analysed using a one-way ANOVA 
with Bonferroni multiple comparisons post-hoc test (**p<0.01, ***p<0.001 vs. pre-treatment) 
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Figure 5.8: Representative images of voiding pattern analysis. Photographed sheets of Whatmann Filter Paper showing urine spots obtained from mice after repeated doses of 
(A) intravesical isotonic saline and (B) intravesical gemcitabine (40mg/mL). The total number of voiding events (C), number of small spots (D) and total voide d area (E) were 
measured pre- and post- intravesical treatment with gemcitabine or isotonic saline solution. Data is represented as mean ± SEM (n=5), analysed using a one-way ANOVA with  
Bonferroni multiple comparisons post-hoc test (*p<0.05 vs. pre-treatment)
A 
B A 
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HISTOLOGY 
The effects of single and repeated intravesical instillations of gemcitabine (40mg/mL) and saline 
(0.9%) on the urothelium was observed through histological sections of the murine bladder. The 
width of the urothelium was unchanged between the single and repe ated instillations of saline, 
however thickening of the urothelium was observed in the single and repeated gemcitabine-
treated mice bladders (Figure 5.9).  
Typical histological features of murine bladders, including an intact urothelium sitting atop the 
lamina propria/suburothelial and detrusor muscle layers, were observed in the saline treated 
mice (Figure 5.10 A&B, E&F). Slight oedema within the lamina propria/suburothelial layer 
resulting in detachment of urothelial cells from the detrusor muscle can be seen within the 
histological sections from mouse bladders treated with single and repeated intravesical 
instillations of gemcitabine (Figure 5.10 C&D, G&H respectively). Additionally, macroscopic 
signs of urinary bladder inflammation including redness and increased visible vasculature were 
observed in 3 and 4 (out of 6) bladders from single and repeated gemcitabine treated mice 
respectively. 
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Figure 5.9: Urothelial thickness as determined by analysis with Image J is representative of n=2 results. 
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Figure 5.10: Histological sections of isolated mouse bladders stained with haematoxylin and eosin from single treatments w ith  saline (A&B) or gemcitabine (C&D), and repeated 
treatments with saline (E&F) or gemcitabine (G&H) at 4X and 40X respectively. Arrows indicate the width of the urothelium.
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MEDIATOR RELEASE 
Samples of intraluminal and serosal fluid were collected from bladders distended to 25mmHg 
and analysed for release of mediators ATP, acetylcholine and prostaglandin E 2. Two 
distensions were performed consecutively with approximately 10 minutes recovery between, to 
measure the repeatability of mediator release in response to stretch. There was no change in 
the release of ATP, acetylcholine or prostaglandin E2 between distensions from either the 
luminal or serosal sides (Figure 5.11 A-C). 
As the volumes of fluid in the lumen and surrounding serosa were different (<0.5mL and 8mL 
respectively), the mediator concentrations were normalised to volume to measure total amount 
released by the respective sides of the bladder tissue. The serosal fluid contained more than 
30-fold the amount of ATP (pmoles) than the luminal fluid (p<0.001) (Figure 5.11A).  Similarly, 
the release of acetylcholine and prostaglandin E2 was significantly greater from the serosal 
samples compared to the luminal release, by approximately 34- and 28- fold respectively 
(p<0.001, p<0.05) (Figure 5.11 B&C) 
The effect of single and repeated intravesical treatments with saline and gemcitabine on 
mediator release from mouse bladders was investigated. The release of ATP into the lumen of 
the bladder was enhanced 2.8-fold following repeated instillations of intravesical gemcitabine 
compared to controls (Figure 5.12A). Furthermore, repeated gemcitabine treatments increased 
luminal ATP release by 370% (p<0.001) compared to a single gemcitabine treatment (Figure 
5.12A). No change was observed in ATP release from the serosal side between treatment 
groups (Figure 5.12D). Similarly, the release of acetylcholine from the bladder into the luminal 
and serosal fluid was unchanged with single or repeated intravesical instillations of gemcitabine 
(40mg/mL) (Figure 5.12 B&E). 
Repeated intravesical treatments with gemcitabine significantly enhanced release of 
prostaglandin E2 (p<0.05) compared to controls by 4.6- and 3.6-fold into the luminal and serosal 
fluid respectively (Figure 5.12 C&F). Furthermore, repeated instillations of gemcitabine 
enhanced prostaglandin E2 release by 3.2- and 2.2-fold compared to a single instillation of 
gemcitabine into the luminal and serosal fluid respectively (Figure 5.12 C&F). 
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Figure 5.11: Repeatability of total ATP (A), acetylcholine (B) and prostaglandin E2 (C) from consecutive luminal 
and serosal samples from stretched mouse bladders. Data represented as mean ± SEM (n=6), analysed using a 
one-way ANOVA with Dunnetts multiple comparisons post-hoc test (*p<0.05, ***p<0.001 vs luminal sample) 
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Figure 5.12: Effect of single and repeated intravesical gemcitabine treatments on the release of ATP (A&D), 
acetylcholine (B&E) and prostaglandin E2 (C&F) from the luminal (A-C) and serosal (D-F) surfaces of the bladder. 
Data is represented as mean ± SEM (n≥5), normalised to volume, analysed using a one-way ANOVA with 
Bonferroni multiple comparisons post-hoc test (*p<0.05, ***p<0.001 vs repeated saline treatment group, 
^^^p<0.001 vs single gemcitabine treatment group) 
  
209 
 
SPONTANEOUS CONTRACTIONS  
During bladder distension, spontaneous phasic contractions were observed in both saline and 
gemcitabine treated bladders, as shown in Figure 5.13 A&B. Furthermore, the contractions 
persisted during bladder accommodation to 25mmHg pressure. Single and repeated intravesical 
instillations of gemcitabine (40mg/mL) did not have any effect on the frequency and amplitude 
of the spontaneous contractions during both filling and accommodation (Figure 5.14 A&B)  
 
 
A 
B 
Figure 5.13: Representative traces showing full distension (to 40mmHg) of isolated bladders from mice undergoing 
single intravesical treatments with saline (A) and gemcitabine (40mg/mL) (B). Note the spontaneous phasic contractions 
during filling.  
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Figure 5.14: Frequency (A) and amplitude (B) of spontaneous contractions from bladders from single and 
repeated intravesical treatments w ith saline and gemcitabine (40mg/mL) during filling to 40mmHg and 
accommodation to 25mmHg pressure. Data measured from the 100s directly after intraluminal pressure 
reached 20mmHg, represented as mean ± SEM (n≥4), analysed by one-way ANOVA with Bonferroni multiple 
comparisons post-hoc test.  
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BLADDER COMPLIANCE AND FILLING 
Isolated bladders from mice were infused with isotonic saline to an intraluminal pressure of 
40mmHg to investigate changes in muscle compliance. Intravesical pre -treatment with 
gemcitabine increased the compliance in murine bladders, significantly (p<0.05) in the repeated 
treatment groups (Figure 5.15 A&B). The volume of bladders at 40mmHg intravesical pressure 
was greater in gemcitabine pre-treated groups with comparison to the matched saline controls. 
Single and repeated instillations of gemcitabine enhanced the filling volume by 20% and 109% 
respectively, the latter significantly increased (p<0.05) (Figure 5.15 C&D).  
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Figure 5.15: Volume-pressure curves (A&B) and filling volume at 40mmHg of bladders from single (A&C) and 
repeated (B&D) intravesical treatments w ith saline and gemcitabine (40mg/mL). Data represented as mean ± 
SEM (n≥4), analysed by two-way ANOVA with Bonferroni multiple comparisons post-hoc test (#p<0.05 
gemcitabine treated curve vs saline treated curve, *p<0.05 and **p<0.01 vs saline treated at respective 
pressures) and an unpaired student t-test (^p<0.05 vs repeated saline group). 
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RESPONSES TO PHARMACOLOGICAL AGENTS 
Bladders were distended by filling with isotonic solution to an intravesical pressure of 25mmHg, 
and left for approximately 1 hour to accommodate the volume and muscle tension to stabilise. 
Pharmacological agents were added to the serosal fluid to measure changes in receptor-
mediated contraction/relaxation. Single and repeated intravesical instillations of gemcitabine 
(40mg/mL) had no effect on subsequent in vitro contraction to carbachol, nor did the inhibition of 
NOS by L-NNA potentiate the contraction to carbachol between any of the treatment groups 
(Figure 5.16A). Similarly, there was no difference between contraction to P2X receptor 
stimulation (with α,β-mATP) between the treatment groups (Figure 5.16B). Finally, muscle 
contraction induced by the addition of KCl was also unchanged between treatment groups in 
murine bladders.  
The addition of the β-adrenoceptor agonist isoprenaline to the serosal fluid caused relaxation. 
Bladders treated with gemcitabine exhibited greater relaxation responses than the matched 
saline groups (>20% increase in single treatment group, >42% increase in repeated treatment 
group), but these were not statistically significant differences (Figure 5.17 A&B). Furthermore, 
the pIC50 values for each group were unchanged (saline vs gemcitabine pre-treatment, 8.0±0.9 
vs 8.0±1.7 and 8±1.1 vs 7.1±0.3 in single and repeated groups respectively). 
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Figure 5.16: Effect of single and repeated intravesical instillations of saline (0.9%) or gemcitabine (40mg/mL) on 
the contraction of the bladder to carbachol w ithout and in the presence of L-NNA (A), α,β-mATP (B) and KCl (C). 
Data represented as mean ± SEM (n≥4), analysed by one -way ANOVA with Bonferroni multiple comparisons 
post-hoc test.  
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Figure 5.17: Effect of single (A) and repeated (B) intravesical instillations of saline (0.9%) or gemcitabine 
(40mg/mL) on the relaxations of the bladder to isoprenaline. Data represented as mean ± SEM (n≥5), analysed 
by a two-way ANOVA with Bonferroni multiple comparisons post-hoc test. 
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CONTRACTION TO ELECTRICAL FIELD STIMULATION 
Electrical field stimulation (EFS) was used to investigate the effect of single and repeated 
instillations of gemcitabine (40mg/mL) on the efferent nerve-mediated contraction in mouse 
bladders. Pre-treatment with single or repeated instillations of intravesical gemcitabine 
depressed the contraction to EFS, although this was only significant in the repeated treatments 
group (p<0.05) (Figure 5.18 A&B). At the 20Hz frequency, gemcitabine depressed the 
contraction by 18% and 52% with com parison to saline-instilled bladders in the single and 
repeated treatment groups respectively (Figure 5.18 A&B).  
The addition of the pharmacological agents L-NNA, atropine and α,β-mATP were added to the 
serosal fluid to investigate the respective contributions of nitric oxide, muscarinic and P2X 
receptors to nerve-mediated responses. In the single and repeated saline pre-t reated bladders, 
the addition of L-NNA had no effect on contraction to EFS (Figure 5.19 A&B). The addition of 
atropine significantly inhibited (p<0.05) contractions at low frequencies (1Hz) by 45% and 41% 
in the single and repeated groups respectively. Finally, the inhibition of the P2X receptors by the 
addition of α,β-mATP significantly attenuated (p<0.01) the contraction to EFS by >75% across 
all frequencies measured. 
In bladders pre-treated with intravesical gemcitabine (40mg/mL), the addition of the NOS 
inhibitor L-NNA augmented contractions to EFS (Figure 5.19 C&D). In the single gemcitabine 
treatment group, contractions were significantly (p<0.05) enhanced by 1.4- and 1.5-fold at 5Hz 
and 10Hz respectively (Figure 5.19C). Contractions to high frequency stimulation (>5Hz) in the 
repeated gemcitabine treatment group were increased by >1.5-fold (Figure 5.19D). Similar to 
the saline-treated bladders, the addition of atropine attenuated the contraction to low 
frequencies in the single gemcitabine-treated group, although no change was observed across 
any of the frequencies in the repeated gemcitabine-treatment group. Finally, the desensitization 
of P2X receptors with α,β-mATP significantly (p<0.01) reduced the contraction by a factor of 4 
across all frequencies in both gemcitabine treatment groups.  
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Figure 5.18: Effect of single (A) and repeated (B) intravesical instillations of saline (0.9%) or gemcitabine 
(40mg/mL) on the nerve-mediated contractions to EFS at 1, 5, 10 and 20Hz in isolated mouse bladders. Data 
represented as mean ± SEM (n≥5), analysed by a two-way ANOVA with Bonferroni multiple comparisons post-
hoc test (*p<0.05 vs saline treated bladder at respective frequencies.  
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Figure 5.19: Effect of single and repeated intravesical instillations of saline (A&B respectively) (0.9%) or 
gemcitabine (C&D respectively) (40mg/mL) on the nerve-mediated contractions to EFS at 1, 5, 10 and 20Hz in 
isolated mouse bladders in the presence of L-NNA, atropine and α,β-mATP. Data represented as mean ± SEM 
(n≥4), analysed by a one -way ANOVA with Dunnett multiple comparisons post-hoc test, ( p^<0.05, ^^p<0.01 L-
NNA vs basal EFS response, #p<0.05, ##p<0.01 atropine vs basal EFS response, *p<0.05, **p<0.01 α,β-mATP vs 
basal EFS response at respective frequencies. 
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5.5 DISCUSSION 
Micturition is mediated by a complex coordination of afferent and efferent  nerve activity, release 
of urothelial mediators and detrusor muscle tone. While the previous chapter investigated the 
changes in porcine bladder directly after luminal gemcitabine treatment, the present study 
aimed to investigate the physiological and functional effect of single and repeated intravesical 
gemcitabine instillations in vivo. Treatment parameters for the mouse groups mimicked the 
clinical setting, with instillations of 40mg/mL gemcitabine or the vehicle 0.9% saline given on a 
weekly schedule. 
 
GENERAL EFFECT OF TREATMENT ON ANIMALS 
Single and repeated instillations of gemcitabine appeared to have no effect on the general well -
being of mice. Animals were inspected daily for signs of distress, with no observable differences 
in behaviour or appearance, and there was no difference in water consumption during the VPA 
period between the saline and gemcitabine group. Neither saline nor gemcitabine treated 
animals underwent any significant weight loss over the treatment period, and there was no 
change in bladder weight between any of the treatment groups.  
Intravesical instillations of gemcitabine into the bladder of animals have reported good 
tolerability. In studies of beagle dogs and pigs treated with repeated intravesical instillations of 
up to 350mg gemcitabine for four and six weeks respectively, no change in behaviour or overall 
well-being was reported during the treatment period (Cozzi et al., 1999, Witjes et al., 2003). The 
tolerability of int ravesical gemcitabine found in the present study align with those found by Delto 
et al (2013), who reported no significant weight loss or signs of distress from mice treated with 
intravesical gemcitabine (25mg/mL).  
 
EFFECT OF GEMCITABINE ON VOIDING BEHAVIOURS 
Voiding patterns of mice were measured pre - and post- intravesical gemcitabine or saline 
treatment. The voiding patterns and fluid intake of mice  before treatment align with that 
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previously reported (Sugino et al., 2008, Boudes et al., 2011, Everaerts et al., 2010). The 
urodynamic parameters measured in mice treated with single and repeated instillations of 
gemcitabine significantly increased from pre- to post-treatment, indicative of change to a 
dysfunctional bladder phenotype. As increased frequency of urination is often reported in 
human patients undergoing intravesical gemcitabine treatment for bladder cancer, this result 
was not suprising (Dalbagni et al., 2006, Addeo et al., 2010, De Berardinis et al., 2004, Gontero 
et al., 2004). To the best of my knowledge, no studies have investigated the micturi tion 
behaviours in mice using similar voiding pattern analysis after intravesical chemotherapy. 
However, the development of cystitis-induced detrusor overactivity in mice is well documented, 
with reported increases in urination frequency as measured by voiding behaviours analysed 
with filter paper (Everaerts et al., 2010).  
 
UROTHELIAL EFFECTS OF INTRAVESICAL GEMCITABINE 
Damage to the urothelial layer by intravesical gemcitabine was assessed by histological 
examination. While the luminal surface of the urothelium appeared intact, thickening of this 
epithelial layer was apparent in mouse bladders treated with single and repeated instillations of 
gemcitabine. Additionally, macroscopic signs of bladder inflammation including more prominent 
vasculature and areas of haemorrhage were noted in the gemcitabine treated mice bladders 
with comparison to the saline treated mice bladders (both single and repeated treatment 
groups). This has been similarly reported by Witjes et al (2003) in pigs after repeated 
instillations of intravesical gemcitabine. Furthermore, they noted mild signs of inflammation in 
the treated bladders, including subepithelial leukocyte infiltration and cellular and nuclear 
enlargement.  
The toxicology of repeated intravesical instillations of mitomycin C in mice bladders has 
previously been assessed (Matsushima et al., 2011). Mitomycin C is the first-line chemotherapy 
option for NMIBC (Malmstrom et al., 2009, Hendricksen and Witjes, 2007), and is associated 
with significantly more side effects in patients with comparison to gemcitabine (72.2% compared 
to 38.8% respectively) (Addeo et al., 2010). Mice treated with intravesical mitomycin C at the 
clinical dose used in human patients (2mg/mL) succumbed during the experimental period due 
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to the severity of adverse effects associated with treatment (Matsushima et al., 2011). 
Pathological findings of the murine bladder showed acute inflammation, submucosal oedema 
and detachment of the urothelium from the underlying bladder wall.   
It is well-reported that intravesical chemotherapy causes significant histological changes to the 
bladder wall. Installations of cytotoxic drugs into the bladder induce extensive denudation of the 
apical layer of the urothelium, followed by a period of rapid proliferation resulting in urothelial 
hyperplasia. The appearance of the remaining cells have been reported as atypical, including 
increase in cell size, multi-nucleated and vacuolated cells but with a normal nuclear/cytoplasmic 
ratio (Maruśić et al., 2009, Choe et al., 1995, Drago et al., 1989, Castillo et al., 2012). 
Urothelial thickening is characteristic of inflammatory conditions of the bladder (Wong-You–
Cheong et al., 2006). Inflammation of the epithelial layer of the bladder has a direct effect on 
bladder function, including causing augmented release of urothelial mediators (ATP), increased 
sensitivity of the afferent nerves and altered muscle contraction (Birder et al., 2003, Grover et 
al., 2011). Mast cell activation by mediators released from damaged urothelium including 
substance P and nerve growth factor (NGF) induce a cascade release of inflammatory, 
vasoactive and nocieceptive molecules, such as cytokines, nitric oxide, prostaglandins and 
vascular endothelial growth factor (Cao et al., 2005, Dubner and Ruda, 1992, Theoharides et al., 
2001, Grover et al., 2011).  
In addition to the histological changes induced by intravesical gemcitabine, the release of 
urothelial mediators ATP, acetylcholine and prostaglandin E2 from the bladder was assessed. 
Release of mediators from mice bladders into the lumen and through the serosal wall was 
measurable and repeatable. When normalised to the volume of solution, the total release of 
each mediator was significantly greater from the serosal than the luminal side. This aligns with 
the findings of Ferguson et al (1997), who first reported the release of ATP from both the 
luminal and serosal surfaces in the rabbit bladder. Using an Ussing’s chamber, they 
demonstrated that release of ATP is derived from the urothelium not detrusor, and bladder 
stretch induced an increase in release from the serosal but not luminal side. This was similarly 
observed by Dunning-Davies et al (2013), who also measured ATP release from the serosal 
side in response to stretch, mediated by the rise in intracellular [Ca
2+
]. As the apical layer of the 
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urothelium acts as a barrier to solutions and solutes and the targets of urothelial mediators lie in 
the sub-layers of the bladder, this mono-directional flow is not unexpected.   
While there was no change in serosal release of ATP between t reatment groups, the release of 
luminal ATP was significantly enhanced with repeated intravesical instillations of gemcitabine. It 
is well documented that ATP release from the urothelium plays an important role in the sensory 
response to bladder distension. Luminal applications of ATP have been found to induce bladder 
contraction in unanaesthetized rats, and acts as a signalling molecule of mechanosensation on 
the afferent nerves (Burnstock, 2007, Pandita and Andersson, 2002, Vlaskovska et al., 2001). 
Additionally, enhanced ATP has been measured from cultured urothelial cells from patients with 
interstitial cystitis, a disorder characterised by bladder inflammation, dysuria and increased 
frequency of urination (Sun et al., 2001). Similar to the findings of this study, enhanced ATP 
measured in the lumen of the bladder has been reported in rats with cyclophosphamide-induced 
cystitis, with no change in serosal  release (Smith et al., 2005). Furthermore, increased luminal 
ATP release has been measured from an aged-mouse model with confirmed geriat ric-bladder 
overactivity (Daly et al., 2014). The implications of these findings indicate that urothelial ATP 
release is enhanced, or that the ATP breakdown mechanisms are depressed after repeated 
instillations of gemcitabine. Enhanced urothelial ATP may act upon the underlying afferent 
nerves and muscle, particularly the nociceptive C-fibres (Kullmann et al., 2008), increasing 
sensory stimulation arising from the bladder. This may play a role in the side effects of 
intravesical gemcitabine for NMIBC reported by patients.  
Acetylcholine release from both sides of the bladder was unchanged between treatment groups, 
while prostaglandin E2 release through the luminal and serosal surfaces was significantly 
enhanced in bladders treated with repeated instillations of gemcitabine. As discussed in 
previous chapters, prostaglandin E2 is released from the bladder with stretch, potentiated in the 
presence of the urothelium (Masunaga et al., 2006), and has been shown to be released from 
rat urothelial tissue in response to bladder distension (Tanaka et al., 2011). Furthermore, a 
study investigating prostaglandin E2 release from the urothelium/lamina propria of the guinea pig 
bladder indicated that ATP can activate prostaglandin E2 production mediated via COX-1 (Nile 
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and Gillespie, 2012). This corresponds with the enhanced ATP release observed from mouse 
bladders treated with repeated instillations of intravesical gemcitabine in this study.  
Instillations of prostaglandin E2 in the bladder has been shown to stimulate the nociceptive C-
fibres but not Aδ-fibres of the afferent nerves, and induces phasic contractions and increases 
muscle tone mediated via L-type calcium channels in rodent bladders (Aizawa et al., 2010, 
Kobayter et al., 2012). Additonally, elevated urinary levels of prostaglandin E 2 and tissue COX-2 
expression have been measured in patients with overactive blad der symptoms and mouse 
models of inflamed bladders (Kim et al., 2006, Kim et al., 2005, Hu et al., 2003). This indicates 
that the enhanced release of prostaglandin E2 measured in this study may play a role in the 
symptoms of overactive bladder seen within the mouse models treated with intravesical 
gemcitabine.  
Damage to the urothelium and consequent increased permeability could be an argument for the 
increased luminal concentrations of urothelial mediators as measured in the present study. 
However, Smith et al. (2014) found enhanced luminal levels of both ATP and acetylcholine from 
porcine bladders treated with luminal DMSO. They concluded that the high levels reflected 
leakage of these mediators from the urothelium due to physical damage. As luminal 
acetylcholine concentrations were unchanged between control and gemcitabine treated mice, it 
is more likely that the enhanced ATP and prostaglandin E2 concentrations are a result of 
increased release or depressed breakdown mechanisms.  
Taken together, the altered voiding behaviours and histological appearance of mice treated with 
intravesical gemcitabine are indicative of inflammation of the urothelial lining of the bladder. 
Furthermore, enhanced release of ATP and prostaglandin E2 are associated with inflammatory 
conditions of the bladder, and may play a role in altering the contractions of the detrusor and 
sensitizing afferent nerves. 
 
BLADDER MUSCLE EFFECTS OF INTRAVESICAL GEMCITABINE 
It is well documented that the detrusor muscle exhibits spontaneous action potentials, 
underlying the myogenic phasic contractile activity of the bladder (Levin et al., 1986). Strips of 
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bladder tissue from patients with idiopathic detrusor instability (increased frequency and 
urgency) develop a greater spontaneous tone, but are less responsive to efferent nerve 
stimulation with EFS (Mills et al., 2000). Spontaneous contractile activity during bladder filling 
and accommodation has been shown in rodent isolated bladders, and is enhanced in models of 
cystitis-induced inflamed bladders and overactive detrusor after spinal cord transection (Yu and 
de Groat, 2008, McCarthy et al., 2009). Phasic activity was observed in all bladders tested in 
the current study, and there was no difference between the frequency and amplitude of 
contractions between mice treated with intravesical saline of gemcitabine. While intravesical 
gemcitabine treatment in mice induced an overactive bladder phenotype as measured by a 
change in voiding behaviour, it appears that the myogenic phasic contractions of the detrusor 
are not involved in this pathophysiology. This has been similarly reported by Daly et al (2014), 
who could find no changes in spontaneous frequency and amplitude of spontaneous 
contractions in mouse whole-bladder preparations from an aged-model of bladder overactivity.  
Interestingly, mouse bladders treated with repeated instillations of intravesical gemcitabine 
displayed significantly increased compliance during filling, resulting in enhanced filling volume. 
This was an unexpected result, as patients suffering from inflamed bladders and detrusor 
overactivity are commonly characterised by reduced bladder compliance and bladder filling 
volumes to a fixed pressure (van de Merwe et al., 2008, Abrams et al., 2002). However, one of 
the sub-classifications of neurogenic bladder is characterised by over-distension due to bladder 
flaccidity, arising from detrusor muscle areflexia (Dorsher and McIntosh, 2012). Detrusor muscle 
areflexia can result from damage to the bladder efferent or afferent neural pathways, 
lumbosacral spinal cord damage or myogenic failure (Miyazato et al., 2013). From the results of 
the current study, it could be hypothesized that intravesical gemcitabine causes changes to the 
efferent and afferent nerves of the bladder, resulting in detrusor areflexia. Evidence for this will 
be explored further in this discussion.  
To the best of my knowledge, this study is the first to investigate the functional effects of 
intravesical chemotherapy on the contractility and relaxation of the isolated whole bladder. 
Intravesical gemcitabine instillation caused no change between contractions mediated by the 
muscarinic or P2X purinergic receptors of the bladder. The addition of the NOS inhibitor L-NNA 
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had no effect on muscarinic contraction.  Previous investigations of the contractility of 
cyclophosphamide-induced cystitis in mouse bladders suggested that the alteration of 
cholinergic detrusor responses is in part affected by enhanced nitric oxide production (Vesela et 
al., 2012). While this effect was not observed within this study, this may be due to the 
application of only one concentration (10µM) of carbachol. Furthermore, there was no difference 
in contraction to KCl between treatment groups, indicative that intravesical gemcitabine does 
not affect the intrinsic myogenic detrusor contraction. Finally, the relaxation of the whole bladder 
mediated by the β-adrenoceptors to isoprenaline was unchanged. These results are not entirely 
unexpected. As described previously, the penetrative effect of gemcitabine through the bladder 
wall is unknown, however the concentration of doxorubicin and mitomycin C are reduced by a 
32- and 35-fold respectively (Wientjes et al., 1996, Wientjes et al., 1993). It could be assumed 
from the results of this study that the concentration of gemcitabine that reaches the detrusor 
muscle cells is not cytotoxic. Therefore, the enhanced voiding behaviours and increased 
compliance of mouse bladders observed after intravesical gemcitabine treatment are not 
myogenic in origin.  
Physiological contraction of the bladder is initiated by parasympathetic nerves. Preliminary 
experiments found EFS of isolated mouse bladders produced repeatable, frequency dependent 
and TTX-sensitive contractions. Repeated, but not single, instillations of intravesical 
gemcitabine in mice significantly attenuated efferent nerve-mediated contraction to EFS.  
The contribution of nitric oxide, muscarinic and P2X purinergic receptors to EFS mediated 
contraction was also investigated. In the control bladders, the addition of the nitric oxide 
synthase inhibitor L-NNA had no effect on contraction to any frequencies of stimulation. 
Antagonism of the muscarinic receptors with atropine significantly reduced contractions at low 
(1Hz) frequencies, with no effect at higher frequencies. Finally, the desensitization of P2X 
receptors reduced EFS mediated contractions by >70% at all frequencies This is suggestive 
that the purinergic component makes up the majority of normal mouse bladder nerve-mediated 
contractions, while acetylcholine contributes at lower frequencies and NO has little to no effect.  
Previous reports in the literature of EFS induced contraction in whole mouse bladders are 
inconsistent. The addition of the NOS inhibitor L-NOARG has been reported to have no effect 
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on bladder cont ractions induced by EFS (Fujiwara et al., 2000). However, Liu and Lin-Shiau 
(1997) found the addition of L-NOARG decreased neurogenic contraction in mouse detrusor 
strips, and this was reversed with the addition of L -arginine. Fabiyi and Brading (2006) 
measured almost identically sized responses of whole bladder and bladder strips to EFS, where 
the cholinergic and purinergic component of contraction made up approximately 50% 
respectively at all frequencies tested (1 – 35Hz). Similar to the present study,  Lamarre et al 
(2014) reported an approximate 60% reduction in EFS mediated contraction with the addition of  
α,β-mATP, while atropine affected only the low frequency-induced contractions. Furthermore, 
previous investigations (unreported) within our laboratory using whole mouse bladders align 
with the results of this study.  
Repeated instillations of gemcitabine in mouse bladders significantly attenuated the contractile 
response to EFS. Aronsson et al. (2015) similarly measured depressed EFS response in 
cyclophosphamide t reated rats, although also found that the reflex-evoked response is enlarged 
in these animals, possibly involving sensitization of sensory pathways. Interestingly, single and 
repeated instillations of int ravesical gemcitabine in mouse bladders had no effect on t he relative 
contribution of acetylcholine or ATP to EFS-mediated contraction with comparison to controls. 
However, the addition of L-NNA significantly enhanced the contraction to EFS at 
frequencies >5Hz. The role of nitric oxide in nerve -mediated contractions of the bladder is 
complex, as it has been reported to indirectly have both excitatory and inhibitory effects on the 
detrusor muscle (Andersson and Persson, 1994). As previously described in Chapter 1, nitric 
oxide has been implicated in a range of bladder pathophysiologies. Nitric oxide deficiency 
causes detrusor overactivity in rats through sensitization of muscarinic receptors and reducing 
β3 adrenoceptor mediated relaxation (Monica et al., 2008), while chronic irritation/inflammation 
of the rodent bladder causes increased neuronal and endothelial NOS expression (Kang et al., 
2004, Vizzard et al., 1996). Furthermore, NOS inhibition has similarly been shown to increased 
EFS-mediated detrusor contractions in CPO-inflamed bladders of rats (Vesela et al., 2012). 
Models of chronic inflammation in rats show reduced contraction to EFS, and it has been 
suggested that this may be a result of enhanced NO acting prejunctionally on bladder nerves to 
inhibit acetylcholine release (Persson et al., 1993, Vesela et al., 2012).  
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It appears from the results of this study that nitric oxide plays a significant role in the reduction 
of efferent nerve mediated contraction after int ravesical gemcitabine treatment. NO relaxation of 
the bladder is mediated through increased cGMP formation, with subsequent activation of 
cGMP-dependent protein kinase causing hyperpolarization of the detrusor muscle cell (James 
et al., 1993, Corcos et al., 2015). Furthermore, endogenously generated NO from CPO-inflamed 
rat bladders depresses the excitability of afferent nerves (Yu and de Groat, 2013). Aizawa et al 
(2011) found that NO has a direct inhibitory effect on the mechanosensitive Aδ- and particularly 
the nociceptive C-fibres of the afferent nerves in anesthetized rats, which significantly en hanced 
bladder capacity during filling. The enhanced bladder capacity measured within the repeated 
gemcitabine treated mouse group in this study may be a result of this effect.  
In summary, it appears that single and repeated instillation of intravesical gemcitabine to the 
mouse bladder does not directly affect the detrusor muscle ability in contraction and relaxation. 
However, it has an inhibitory effect on the efferent nerves and consequently may cause detrusor 
hyporeflexia, mediated most likely through enhanced nitric oxide release. In turn, this enhanced 
NO release may desensitizes mechanosensitive afferent nerves, which may result in enhanced 
bladder capacity. 
 
CONCLUSIONS 
Single and repeated instillations of intravesical gemcitabine treatments in the mouse bladder 
resulted in altered voiding behaviours, namely an increase in small voids. The histological and 
macroscopic appearance of the urothelium showed signs of inflammation, releasing enhanced 
ATP and prostaglandin E2. Furthermore, efferent nerve mediated contractions were significantly 
depressed in gemcitabine treated bladders, likely due to enhanced NO release. The results of 
this study indicate that intravesical gemcitabine causes an overactive bladder phenotype, 
potentially mediated by enhanced urothelial release of ATP and prostaglandin E2 acting on the 
C-afferents, and depressed efferent nerve mediated contractions. While this conclusion seems 
counterintuitive, there is significant evidence of the role of decreased motor innervation in 
detrusor instability, which will be discussed in the subsequent chapter.  
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The aim of the present study was to investigate the mechanisms behind the reported side 
effects experienced by bladder cancer patients treated with intravesical gemcitabine. 
Consequently, this thesis has elucidated the effects of gemcitabine on the urothelium, nerves 
and detrusor muscle of the bladder. A variety of techniques and models were used during this 
investigation to measure changes in bladder function after gemcitabine treatment. Additionally, 
this thesis investigated cytotoxicity of gemcitabine with comparison to the current standard 
chemotherapy used for NMIBC, mitomycin C, and investigated the combination of gemcitabine 
and hyperthermia as an adjunct treatment. This final discussion will review the experimental 
models used within this thesis, gemcitabine use in patients, and specifically examine the 
changes within each tissue type after intravesical gemcitabine treatment and the consequent 
interactions and contribution to overall bladder functioning.  
COMPARISON OF EXPERIMENTAL MODELS 
Multiple experimental models were used for the present studies, each with advantages and 
limitations. In vitro urothelial cell culture models have been used previously to assess cell-
specific responses to various stimuli (McDermott et al., 2012, Kang et al., 2013a, Kang et al., 
2015, Mansfield and Hughes, 2014a, Mansfield and Hughes, 2014b).  Similarly, this model was 
used in the present study to examine the cytotoxicity of gemcitabine on malignant and non-
malignant urothelial cells derived from human tissue.  The functional effect of gemcitabine 
treatment on the non-malignant UROtsa urothelial cell line was also examined, which exhibit 
structural and functional properties analogous with in vivo models (Rossi et al., 2001). 
Furthermore, cell culturing provides a cost effective, controlled environment in which 
experiments investigating both the effects immediately after t reatment and subsequent recovery 
periods are easily performed. However, the barrier integrity of the bladder organ, the cell -to-cell 
interactions and systemic input is not well represented in this model,  which must be kept in mind 
when drawing conclusions that relate to the clinical setting.  
As previously discussed in Chapter 4, porcine tissue is comparable to human in both structure 
and function. This tissue was used in the present study to examine the effect of gemcitabine on 
a full-thickness bladder wall model in which all cell types of the bladder  (urothelial/lamina 
propria, myofibroblasts, nerves and smooth muscle) and a complete barrier (GAG layer and 
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uroplakins) were present. Furthermore, the drug administration in this model mimicked the 
conditions of intravesical treatment, where gemcitabine (40mg/mL) was applied only to the 
urothelial side for 60 minutes at 37
o
C. However, like the cell culture method, the systemic 
influences associated with organ blood flow are not represented in this model. Thus, penetration 
of gemcitabine through the bladder wall may be greater than in patients in this model and the 
immune responses will also be absent. Furthermore, tissue viability in this model is limited, 
which prevents the examination of recovery and multiple treatments.  
Finally, in vivo effects of gemcitabine treatment were examined in mice. This model represents 
true intravesical treatments to an intact bladder system with the associated systemic blood flow 
and inflammatory/immune response. Furthermore, the treatment schedule in mice mirrored that 
of the clinical setting, where repeated treatments were given after intermittent recovery periods. 
Voiding pattern analysis complemented ex vivo isolated bladder studies, which elucidated both 
the physiological and functional effects of true int ravesical treatment with gemcitabine. However,  
there are significant differences between the physiology of mouse and human bladder tissue as 
discussed in Chapter 5, which must be considered when interpreting the results of these studies.  
 
GEMCITABINE USE IN PATIENTS  
At presentation, up to 80% of all bladder cancers are diagnosed as superficial or NMIBC. 
Intravesical gemcitabine is only a relatively new treatment for NMIBC, with proven cytotoxicity 
against tumours and excellent tolerability in Phase I, II and III trials in human patients (Jones et 
al., 2012, Shelley et al., 2011a, Witjes et al., 2004, Gontero et al., 2004, Dalbagni et al., 2006, 
De Berardinis et al., 2004, Bartoletti et al., 2005, Addeo et al., 2010). However, the current first-
line and most commonly used intravesical chemotherapeutic agent is mitomycin C, which is 
associated with a significantly greater rate of side effects in patients than gemcitabine, including 
dysuria, increased frequency and urgency and chemical cystitis (Griffiths, 2012, Addeo et al., 
2010).  
This thesis compared the cytotoxicity of gemcitabine and mitomycin C on cultured normal 
urothelial cells in addition to bladder cancer cell lines. It was discovered that while both drugs 
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had similar potency on the cancer cells, gemcitabine was significantly less cytotoxic than 
mitomycin C on the normal urothelial cells. As damage to the urothelial cells by chemotherapies 
is hypothesized to be one of the mechanisms underlying the reported side effects of treatment, 
it would be a judicious change for gemcitabine to be given to patients as the first line 
chemotherapy agent instead of mitomycin C.  
An adjunct regime investigated for bladder cancer treatment is localised hyperthermia, used in 
combination with chemotherapy. The efficacy and toxicity profile of combined gemcitabine and 
hyperthermia treatment in bladder cancer patients has not been reported in the literature. This 
thesis provides a basic investigation of the cytotoxic and consequent tissue changes with 
combined hyperthermia and gemcitabine. Firstly, there was no synergistic cytotoxic effect of the 
combined therapy on bladder cancer cell lines, while normal urothelial cells appeared to be 
more sensitive to this regime. Secondly, the tissue effects of luminal gemcitabine t reated at 
hyperthermic conditions further depressed myogenic and efferent nerve-mediated responses 
compared to gemcitabine alone. Furthermore, the sloughing of the apical urothelial cells was 
more pronounced in the combined treatment. It appears from these preliminary observatio ns 
that there is limited benefit in a combined hyperthermia and gemcitabine t reatment regime for 
bladder cancer patients. However, the cytotoxic effects of hyperthermia for cancer treatment are 
also mediated by vascular damage and the induction of an immun e response, and these 
parameters were not tested within this study (Rampersaud et al., 2010). Further investigation in 
vivo is needed to elucidate whether combined gemcitabine and hyperthermia treatment has a 
therapeutic benefit in the treatment of bladder cancer in humans. 
 
SOURCES OF BLADDER DAMAGE AND INFLAMMATION BY GEMCITABINE 
Inflammation of the bladder is the first response to urothelial damage or exposure of the bladder 
to noxious stimuli. It is suggested that the cascade of mediators stimulated by chronic 
inflammation may sensitize bladder afferent nerves and is thought to contribute to bladder 
overactivity and pain (Dang et al., 2008, Hayashi et al., 2009). It has been shown in animal 
models of chronic inflammation with interstitial cystitis induced by cyclophosphamide that 
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expression of nitric oxide synthase, neuropeptides, growth proteins, COX-2 and prostaglandins 
in bladder afferent neurons are up-regulated (Vizzard et al., 1996, Vizzard and Boyle, 1999, 
Vizzard, 2001, Yoshimura et al., 2014). In particular, hyperactivity and enhanced 
mechanosensation of the C-fibre afferents in response to distensions of the inflamed bladder 
have been suggested to be causative of the pain and overactivity experienced by patients with 
interstitial cystitis (Yoshimura et al., 2014, Yoshimura et al., 2002). The side effects reported by 
patients undergoing intravesical gemcitabine are similar to that of interstitial cystitis, including 
increased frequency and urgency of urination, dysuria and haematuria. Furthermore, it has 
been previously reported that doxorubicin and mitomycin C induce enhanced and prolonged 
release of inflammatory mediators including nitric oxide, prostaglandin E 2 and cytokines IL-8 
and Il -1β, suggested to be responsible for the urological side effects reported by patients 
undergoing intravesical treatment with these agents  (Kang et al., 2013a, Kang et al., 2015). 
The results presented in this thesis, supported by previous findings, indicate the induction of 
bladder inflammation by gemcitabine as a possible mechanism of bladder dysfunction. 
Consequently, the following discussion will address the tissue specific changes of the bladder 
after gemcitabine treatment, and the possible role of inflammation in the etiology of reported 
symptoms of bladder overactivity and pain. 
 
EFFECT OF GEMCITABINE ON DETRUSOR MUSCLE 
While luminal gemcitabine depressed myogenic activity of the detrusor muscle immediately after 
treatment, this effect appeared to recover after a 24 hour period as measured ex vivo in mice. 
Furthermore, the results presented in the present studies did not show any effect of gemcitabine 
on the spontaneous activity of the bladder. Previous studies have shown alterations of the 
phasic contractions in rodents with detrusor overactivity and inflamed bladders (McCarthy et al., 
2009), however this may be a long term effect of chronic irritation or inflammation of the bladder.   
These results suggest that either luminal gemcitabine does not penetrate the bladder wall 
through to the muscle layer, or that it is not directly cytotoxic to the muscle cells. To the best of 
my knowledge, no studies have investigated the direct effect of gemcitabine on smooth muscle 
tissue. An in vivo orthotopic pancreatic cancer rat model treated with repeated doses of 
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gemcitabine (100mg/kg) over 120 days found expression of α-smooth muscle actin (α-SMA) to 
be significantly reduced in myofibroblast-like cells (Yamao et al., 2013). While tenuous, this 
evidence may indicate that long-term treatment with gemcitabine may influence musc le 
contractility, either directly through depressed actin expression in muscle or via reduced 
myofibroblast activity.  
 
EFFECT ON UROTHELIAL LAYER 
The principle function of the urothelium is to act as distensible barrier to water, solutes and ions, 
protecting the underlying nerves and detrusor muscle of the bladder. This barrier function is 
regulated by a variety of factors, including hormones, neurotransmitters, proteases, cytokines 
and exposure to noxious chemicals (Lewis et al., 1995, Lavelle et al., 2002). The permeability 
barrier of the urothelium is compromised in various urinary bladder disorders including interstitial 
cystitis (painful bladder syndrome) and overactive bladder (Parsons, 2007, Lavelle et al., 2000, 
Parsons et al., 1991, Teichman and Moldwin, 2007, Parsons, 2011). This has been shown in 
patients with interstitial cystitis, where 25% of a solution of concentrated urea was absorbed 
through the bladder wall, in comparison to only 4.3% in normal healthy subjects (Parsons et al., 
1991). It is thought that the passing of noxious substances through the bladder wall, acting upon 
the underlying muscle and nerves results in the symptoms of overactivity and pain.  
Inflammation of the urothelial layer has also been reported to occur with these disorders with 
disrupted permeability (Grover et al., 2011, Steers, 2002), however it is currently unclear 
whether urothelial damage directly causes inflammation, or if it develops as a secondary effect. 
In a rat-model of urothelial injury using intravesical instillations of protamine sulphate (PS), 
bladder inflammation occurred in PS treated mice, but not nephrectomised PS treated mice 
(Soler et al., 2008). This indicates that disruption of the permeability layer does not directly 
cause inflammation, but instead allows transport of noxious substances through the bladder wall 
which in turn stimulates the inflammatory process. Furthermore, Lavelle et al (2002) measured 
the transepithelial resistance following PS-induced injury in rats, observing significant increas es 
in permeability of the bladder wall up to 2 days post-injury, with gradual declines to control 
levels 3-5 days after PS exposure. Interestingly, the severity of inflammation measured by light 
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microscopy over 10 days post-PS instillation correlated with the permeability pattern of the 
bladder (Lavelle et al., 2002).  
Conclusive evidence of the cytotoxic and damaging effect of gemcitabine on urothelial cells was 
obtained in all three results chapters of this thesis. Specifically, urothelial sloughing of the 
umbrella cells and disruption to the apical integrity of the urothelium was observed immediately 
after luminal application of gemcitabine on porcine bladder tissue. However, a 24-hour recovery 
period after intravesical gemcitabine t reatment in mice showed thickening of the urothelium with 
comparison to control bladders, indicative of induction of a cellular recovery/proliferation 
process.  
The cells of the normal urothelium have a low cellular turnover rate and display very little mitotic 
activity (Martin, 1972). However, this turnover is rapidly increased after exposure to cytotoxic 
agents, bacteria and bladder damage (Simeonova et al., 2000, Uchida et al., 1989, Romih et al., 
1998). The molecular mechanisms that stimulate tissue repair are not entirely u nderstood, 
however growth factors, namely epidermal growth factor (EGF) and the corresponding 
epidermal growth factor receptor (EGFR), have been confirmed to be involved in urothelial 
regeneration (Daher et al., 2003). EGFR expression is limited to the basal cells of the 
urothelium, with only scattered representations in the intermediate cell layer (Messing, 1990). 
The presence of the protective GAG-layer and lack of EGFR on the umbrella cell layer prevents 
EGF present within urine from inducing urothelial proli feration (Cheng et al., 2002). However, 
exposure of the underlying urothelial layers to EGF after bladder injury stimulates the 
regenerative process, leading to cellular proli feration, hyperplasia and eventual differentiation 
(Romih et al., 2001, Varley and Southgate, 2008). This supports the findings of this thesis.  
 
UROTHELIAL RELEASE OF INFLAMMATORY MEDIATORS 
The release of ATP and prostaglandin E2, but not acetylcholine from urothelial cells is altered 
after gemcitabine treatment. In human urothelial cells and mouse bladder, the release of ATP 
from the urothelium was enhanced after luminal treatment of gemcitabine. It is well reported that 
ATP is released from the bladder in response to inflammation (Kumar et al., 2007, Sun et al., 
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2001, Smith et al., 2005). However, there is some debate as to the mechanism of this enhanced 
ATP release. A recent study by Mansfield and Hughes (2014a) found that the release of 
inflammatory mediators bradykinin, histamine and serotonin were unlikely to be responsible for 
increased ATP release in human urothelial cells. As ATP is released from urothelial cells with 
mechanical stimulation via exocytosis mediated by the soluble N-ethylmaleimide sensitive factor 
receptor (SNARE) complex, it has been suggested that these SNARE mechanisms may be up 
regulated after bladder inflammation (Khera et al., 2004, van der Wijk et al., 2003). Furthermore, 
botulinum toxin A acting via the inhibition of SNARE-dependent exocytotic processes in 
urothelial cells has been shown as a successful treatment for the symptoms of overactive 
bladder and acts via a reduction in stretch-induced release of urothelial ATP (Khera et al., 2004, 
Schmid et al., 2006, Apostolidis et al., 2006, Hanna-Mitchell et al., 2015).  
Enhanced release of urothelial ATP has numerous targets and consequent alterations in 
sensory and mechanical stimulation within the bladder. It has been shown that urothelial ATP 
acts upon the purinergic receptors on the Aδ- and C-fibres of the mechanosensitive and 
nociceptive afferent nerves (Burnstock, 2009). Furthermore, urothelial ATP may influence the 
underlying myofibroblasts and detrusor muscle, and can act in an autocrine manner on the 
urothelial cells itself (Wang et al., 2005, Birder and Andersson, 2013). Stimulation of the 
urothelial P2Y receptors by enhanced ATP release after UROtsa cell infection with UPEC 
(Escherichia coli bacteria) has been shown to cause increased release of the inflammatory 
cytokine interleukin-8 (Save and Persson, 2010). As found in this study, cytokines including IL-
1β, IL-6 and IL-8 have been found to be released from urothelial cells in response to both 
infection and damage induced by cytotoxic drugs (Kang et al., 2013a, Funfstuck et al., 2001). 
These pro-inflammatory mediators have a multitude of targets within the bladder, including the 
process of pathological pain, recruitment of inflammatory cells (T-cells, mast cells and 
neutrophils), cellular proli feration and enhanced release of prostaglandin E 2 and substance P 
(Zhang and An, 2007, Schweizer et al., 1988).  
This inflammatory response has also been shown to induce production of reactive oxygen 
species (Mulvey et al., 2000). Upregulated ROS production has recently been linked to afferent 
nerve sensitivity. Ruan et al. (2014) recently demonstrated the sensitizing effect of ROS on 
238 
 
vagal lung afferent C-fibres, likely mediated through the activation of the TRPV1, TRPA1 and 
P2X receptors. They found that the sensitized afferents resulted in an increased electrical 
excitability and consequent exaggerated reflex responses in rat airways (Ruan et al., 2014). 
While this effect was measured in the lung, this may be a further mechanism of afferent 
sensitivity in the bladder. In the present thesis, gemcitabine induced ROS production in 
urothelial cells, which may therefore play a role in sensitizing afferent nerves, causing 
symptoms of bladder overactivity and pain reported by patients after intravesical treatment with 
this agent.  
Masuda et al. (2008) reported that intravesical instillation of hydrogen peroxide into the bladders 
of anaesthetized rats induced the micturition reflex, and they suggested this effect was 
mediated through the afferent fibres by either direct activation of the C-fibre neurons or 
indirectly by stimulating the release of mediators. Interest ingly, they noted that prostaglandin E2 
and F1α content was enhanced in hydrogen peroxide stimulated bladders, and the addition of 
nonselective COX inhibitors indomethacin and ketoprofen supressed the excitatory effects of 
hydrogen peroxide (Masuda et al., 2008).  Taken together, this indicates that the excitatory 
afferent response due to ROS may be mediated by stimulation of the COX pathway. 
Additionally, enhanced ROS formation in lung tissue is known to increase the release of 
arachidonate metabolites (Matyas et al., 2002), although this effect in bladder tissue has not 
been reported. Interestingly, Eblin et al (2007) also noted that the transformation of normal 
human urothelial cells to a proliferative phenotype was correlated with enhanced ROS 
production and COX-2 expression after acid-induced damage.  
Urothelial COX-2 expression is up-regulated in conditions of bladder obstruction, interstitial 
cystitis, inflammation and overactive bladder (Hu et al., 2003, Park et al., 1999, Jang et al., 
2006). Correspondingly, prostaglandin E2 release is enhanced in response to urothelial damage 
and urinary concentrations are increased in patients with interstitial cystitis (Wheeler et al., 2002,  
Shioyama et al., 2008). In the present studies, the release of prostaglandin E2 from the 
urothelium of pig and mouse bladders was found to be enhanced after luminal gemcitabine 
treatment. 
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Like ATP, prostaglandin E2 is released by the urothelium and has multiple targets within the 
bladder (Poggesi et al., 1980). As discussed previously, prostaglandin E2 has a role in directly 
increasing bladder tone and stimulating nociceptive C-fibers on the afferent nerves. However, 
Schroder et al (2004) reported that the role of EP1 receptors (prostaglandin E2 receptor 1) do 
not appear to be essential for normal micturition, but do play a role in the development of 
detrusor overactivity. It has also been suggested that prostaglandin E2 given intravesically to the 
rat bladder may indirectly facilitate detrusor contraction by the release of tachy kinins from 
bladder nerves, initiating a micturition reflex through the stimulation of the NK-1 and NK-2 
receptors (Ishizuka et al., 1995, Andersson, 2002). Furthermore, prostaglandin E2 plays a 
complex role in the inflammatory response of tissues. It is generally recognised as a mediator of 
active inflammation, attracting neutrophils, macrophages and mast cells and inducing 
production of inflammatory cytokines including IL-6 and IL-8 (Yu and Chadee, 1998, Kozawa et 
al., 1998, Nakayama et al., 2006, Weller et al., 2007).  
Gemcitabine treatment on the bladder and urothelial cells enhanced urothelial release of ATP, 
prostaglandin E2, inflammatory cytokines IL-1 β, Il-6 and IL-8 and stimulated ROS production. 
Taken together, these observations suggest that the physical damage to the apical urothelial 
cells and consequent release of mediators by gemcitabine treatment may sensitize underlying 
afferent nerves, inducing an inflammatory response that may sensitize the afferent nerves and 
alter the normal functioning of the efferent bladder nerves. The following sections will further 
elucidate the reasoning for this hypothesis. 
 
EFFECT OF GEMCITABINE ON AFFERENT NERVES 
While this study did not investigate the direct effect of intravesical gemcitabine on the afferent 
nerves of the bladder, there is some evidence that indicates that sensitization of these nerves 
may play a role in the symptoms of pain and overactivity of the bladder reported by patients.  
As covered previously, the two main types of afferent nerves within the bladder as the 
myelinated Aδ-fibres and the more common C-fibres, which sense mechanical, thermal and 
chemical stimuli and relay information regarding storage and micturition to the central nervous 
system (Kanai and Andersson, 2010). These distension sensitive bladder afferents are further 
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distinguished by their low (<15mmHg) and high (>15mmHg) intravesical mechanical thresholds 
of stimulation, which are conducted by the Aδ- and C-fibre ranges respectively (Shea et al., 
2000). While Aδ-fibres are located primarily in the detrusor smooth muscle layer and respond to 
detrusor stretch during bladder filling, C-fibres are found within the detrusor and the sub-
urothelium/lamina propria regions, and are postulated to play a role in volume, chemical and 
thermal sensations (Wakabayashi et al., 1993, Xu and Gebhart, 2008).  
Afferent nerve sensitisation (lowered thresholds) has been postulated to play a role in the 
symptoms of painful and overactive bladder, particularly the C-fibre afferents. In patients with 
detrusor overactivity caused by bladder outlet obstruction  but not in normal subjects, selective 
C-fibre stimulation by ice-water induced the micturition reflex, suggesting up-regulation of these 
afferents (Hirayama et al., 2003). Intravesical instillation of the C-fibre specific neurotoxins 
resiniferatoxin (RTX) and capsaicin have also been used clinically for patients of bladder 
overactivity, delaying involuntary detrusor contractions during filling cystometry and reducing the 
sub-urothelial afferent nerve densities respectively (Silva et al., 2002, Dasgupta et al., 2000). 
Furthermore, enhanced release of urothelial mediators including ATP and prostaglandin E 2 are 
well documented to play a role in the sensitization of afferent nerves, particularly the C-fibre 
afferents (Burnstock, 2009, Lin et al., 2006).   
 
NEUROGENIC INFLAMMATION  
The peripheral terminals of sensory neurons within tissues release a number of bioactive 
mediators in response to local depolarization, axonal or dorsal  root reflexes. In turn, these 
substances act on target cells in the periphery including mast cells, immune cells and vascular 
smooth muscle inducing inflammation characterised by redness, swelling and neuronal 
hypersensitivity. Collectively, these symptoms resulting from the release of substances from 
sensory nerve terminal are termed neurogenic inflammation (Richardson and Vasko, 2002). In 
the bladder, the inflammatory neuropeptides released from sensory nerve terminals in response 
to noxious stimuli include substance P, calcitonin gene -related peptide (CGRP) and neurokinin 
A (Geppetti et al., 2008). These neuropeptides acting via their respective receptors induce 
tissue oedema and neutrophil accumulation, are implicated in the production of reactive oxygen 
241 
 
species and promote bladder contraction through stimulation of receptors present on the 
bladder nerves.  
The ability of capsacin and other irritants to produce sensations of pain is mediated by the TRP 
vanilloid 1 channel (TRPV1), which is present in the primary afferents and urothelial cells of the 
bladder (Avelino et al., 2002, Birder et al., 2001). Furthermore, increased expression of TRPV1 
channels and nerve growth factor (NGF) has recently been shown in vivo in conditions of 
bladder inflammation and hyperactivity (Liu et al., 2009, Dornelles et al., 2014). NGF is 
produced by the urothelium and detrusor muscle, stimulating several intracellular signalling 
cascades that regulate neuronal responses with roles in pain-signalling systems (Pezet and 
McMahon, 2006, Steers and Tuttle, 2006). Using in vitro approaches, Stein et al (2006) and 
Coelho (2015) observed that NGF regulated the expression and function of TRPV1 channels on 
neuronal and urothelial cells respectively. This enhanced receptor expression was correlated 
with increased sensitivity to noxious stimuli, which supports the role of TRPV1 and NGF in the 
induction of neurogenic inflammation.  
Commonly known as the wasabi receptor, TRPA1 (transient receptor potential cation channel, 
subfamily A, member 1) is co-expressed with TRPV1 in sensory nerves of the bladder (Story et 
al., 2003). These receptors are activated by cold stimuli and the products of tissue injury 
including oxidative stress and environmental irritants, and promote neural pain, neuropeptide 
release and neuronal inflammation (Trevisani et al., 2007, Bautista et al., 2006).  
Mast cells have also been implicated in neurogenic inflammation. Chemical, immune and 
mechanical irritation of the bladder, in addition to conditions characterised by overactive and 
painful bladders are associated with morphological changes in sensory and motor neurons and 
the number and distribution of mast cells (Dupont et al., 2001, Sant and Theoharides, 1994). 
These cells are induced to sites of inflammation by numerous trigger mediators, including 
cytokines, free radicals, NGF, substance P, acetylcholine, noxious chemicals and 
neuropeptides (Theoharides et al., 2001). Furthermore, substance P released by the afferent 
nerves in the bladder stimulates the degranulation of mast cells (Ercan et al., 2006), which 
release cytokines/chemokines, growth factors, peptides and proteoglycans (Theoharides et al., 
2001). These mediators in turn attract leukocytes to the site of inflammation, through chemokine 
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receptors present on leukocytes sensing increasing chemotactic concentration gradients and 
facilitating cellular infiltration towards them (Rutkowski and DeLeo, 2002).  
Subpubic pain, dysuria and increased frequency and urgency are common complaints from 
bladder cancer patients undergoing intravesical chemotherapy. There is limited evidence as to 
an explanation for these symptoms; however it appears likely that neurogenic inflammation is in 
part responsible. With repeated instillations of intravesical gemcitabine into pig bladders, signs 
of the inflammatory response were evident (Witjes et al., 2003). Specifically, leukocyte 
infiltration to the epithelial layer was noted, which is associated with cascades of inflammatory 
mediators, including cytokines, histamines, kinins, nitric oxide and proteases (Grover et al., 
2011). Furthermore, in vivo investigations into the inflammatory response after intravesical 
mitomycin C following transurethral resection has been performed in mice. Chronic inflammation 
was caused by repeated instillations of mitomycin C, associated with enhanced lymphocyte and 
eosinophil migration to the bladder, oedema and fibrosis. It has previously been shown that 
leukocytic adhesion is mediated by NK1 receptors after stimulation with the inflammatory 
neuropeptides substance P, where release is enhanced during periods of bladder neurogenic 
inflammation (Baluk et al., 1995).  
EFFECT OF GEMCITABINE ON EFFERENT NERVES 
Intravesical instillation of gemcitabine depressed the efferent nerve-mediated contractions 
induced by EFS both immediately and after 24-hours recovery on porcine and mouse bladder 
respectively. The synaptic release of the neurotransmitters acetylcholine and ATP are the main 
drivers of detrusor contraction; however numerous substances including monoamines, purines, 
amino acids, peptides and NO have also been implicated as NANC neurotransmitters and play 
a role in bladder contraction (Zhou and Ling, 1999). Parasympathetic nerves terminating in the 
detrusor muscle of the human bladder stain positively for acetylcholinesterase and for vesicular 
acetylcholine transferase, indicating that the release of acetylcholine is vesicular (Ek et al., 1977,  
Dixon et al., 1983). ATP is co-released with acetylcholine by efferent nerves of the bladder 
similarly by exocytosis, although there is some debate as to the exact release mechanism 
(Burnstock et al., 1978, Bodin and Burnstock, 2001).  
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Depressed nerve-mediated contraction of the bladder could be a result of numerous alterations 
in efferent activity. These include direct damage to the efferent nerves, impairment of or 
alterations to neurotransmitter release or depressed myogenic mechanisms. After immediate 
luminal treatment of gemcitabine on porcine bladder, it appeared that the depressed efferent-
nerve mediated contractions were due to direct muscle damage, due to loss of int rinsic 
contractility with KCl, muscarinic and purinergic stimulation. However, in mice bladders 24 -hours 
post repeated intravesical gemcitabine (ie. recovery); neurogenic responses to EFS were 
significantly depressed without any change in muscle contractility. The addition of a nitric oxide 
synthase inhibitor L-NNA significantly enhanced contraction amplitude with no changes to the 
contribution of acetylcholine or ATP, indicative of enhanced neurally released NO after 
gemcitabine treatment. It would be my hypothesis that the depressed contraction of gemcitabine 
pre-treated porcine bladder to EFS is mediated in part by enhanced NO release, however this 
effect was not examined. 
In the guinea-pig and human bladder, NOS-immunoreactive nerve fibres and intrinsic neurons 
are distributed throughout the bladder body (Smet et al., 1996). NO is released from 
parasympathetic nerves with acetylcholine, and exerts an inhibitory effect on contractions 
(Dokita et al., 1991).  In the urinary bladder of mice with cyclophosphamide-induced cystitis, but 
not control mice, a NO-dependent reduction in muscarinic contraction has been reported in 
addition to a decrease in EFS-induced contractions (Giglio et al., 2005, Giglio et al., 2007). 
Vesela et al. (2012) tentatively suggested that the reduction in contractility of inflamed mouse 
bladders to EFS is the result of an enhanced production of NO and consequent relaxation. 
Furthermore, NO is thought to play a role in inflammation progression, as elevated levels of NO 
have been reported in inflammatory diseases including bacterial and interstitial cystitis and after 
BCG treatment for bladder cancer (Ehren et al., 1999a, Logadottir et al., 2004, Lundberg et al., 
1996). Additionally, urothelial cells treated with mitomycin C released more nitric oxide than 
control cells persistently over a prolonged period (Kang et al., 2015).  It would be an interesting 
avenue of future research to investigate the effect of gemcitabine on nitric oxide release from 
the bladder, and its consequent effects on the detrusor muscle.  
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Although somewhat counter-intuitive, the physiological implications of depressed efferent nerve 
induced contractions of the bladder after intravesical gemcitabine may contribute to the 
symptoms of overactivity reported by patients. Detrusor underactivity is a common lower urinary 
tract dysfunction that is poorly understood, but is characterised by impaired bladde r emptying 
that is distinct from bladder outlet obstruction (Abrams et al., 2002). Furthermore, the impaired 
detrusor contractility may arise from either a reduction in contractile strength and/or duration 
resulting in prolonged or incomplete emptying, which in turn can lead to increased voiding 
habits (Osman et al., 2014). Some of the causes of detrusor underactivity include neurogenic 
and myogenic origins, aging or medication side effects (Miyazato et al., 2013). Disruption to, or 
decline in, the efferent nerve activity can result in detrusor underactivity and is typically seen in 
diseases involving neuronal injury, in aged human bladders and in patients with bladder outlet 
obstruction (Gilpin et al., 1986, Gosling et al., 1986).  
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FUTURE INVESTIGATIONS 
The culmination of this thesis has generated a number of questions and avenues for future 
investigation. Gemcitabine cytotoxicity on urothelial cells is associated with enhanced reactive 
oxygen species production, and induces augmented release of mediators ATP and 
prostaglandin E2 and cytokines. Taken together, these findings indicate that gemcitabine plays a 
role in initiating a inflammatory response in the bladder. As previously discussed, afferent nerve 
sensitization is associated with inflammatory condit ions of the bladder and the symptoms of 
overactivity and pain. Consequently, it would be an interesting avenue of research to investigate 
the effect of intravesical gemcitabine, in addition to other commonly used chemotherapeutics for 
bladder cancer, on total afferent nerve activity and more specifically individual nerve fibres.  
From a clinical perspective, this thesis provides evidence that the symptoms of bladder 
overactivity and pain experienced by patients undergoing intravesical therapy with gemcitabi ne 
are most likely linked to the induction of inflammation within the bladder. It would appear from 
this that anticholinergic medications that are currently used as the first line treatment for bladder 
overactivity would thus be ineffective in relieving patient symptoms. Furthermore, it has recently 
been shown that patients undergoing int ravesical BCG with oral oxybutynin (anticholinergic 
medication) had a greater increase in urinary frequency and pain than the placebo group 
(Johnson et al., 2013). Thus, there may be therapeutic benefits of anti-inflammatory medication 
over the standard anticholinergics to address the symptoms of bladder overactivity reported by 
patients undergoing intravesical gemcitabine, warranting further investigation.  
The penetrative ability of gemcitabine through the urothelium is currently unknown. Accordingly, 
this would be beneficial for future studies elucidating the direct effects of this chemotherapeutic 
on the bladder efferent nerves and detrusor muscle. This thesis focused on t he effects 
immediately post-gemcitabine treatment and after short -term recovery periods. Further research 
into the effects of repeated intravesical gemcitabine treatment and long-term recovery in animal 
models would further elucidate the sustained tissue damage and consequent cellular changes. 
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CONCLUDING REMARKS 
The results presented here indicate that intravesical instillations of gemcitabine cause 
symptoms of bladder overactivity, as assessed by increased voiding behaviours in a mouse 
model. The cytotoxicity of gemcitabine is significantly more potent on malignant human 
urothelial cells with comparison to non-malignant urothelial cells. Furthermore, it is likely that 
enhanced release of urothelial mediators and inflammatory cytokines, and depressed efferent 
nerve activity after gemcitabine treatment play a role in the pathogenesis of bladder overactivity 
and pain reported by patients, through sensitization of bladder afferent nerves and reduced 
detrusor muscle contractility. It also appears from the results of this thesis that gemcitabine may 
be a superior treatment option for patients with non-muscle invasive bladder cancer than the 
current first-line agent mitomycin C, due to its enhanced cytotoxicity on malignant cells and 
improved toxicity profile.  
In conclusion, gemcitabine is less cytotoxic to normal urothelial cells than malignant cells, but 
still has a substantial impact on normal bladder function which can explain the symptoms of 
bladder overactivity and pain observed in patients.   
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